{"meta":{"query_hash":"48e507805529","filters":{"venue":"Neurology and Therapy"},"cohort_total":99,"direct_labels_cover":0,"predictions_cover":99,"exported":99,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/48e507805529","api":"https://metacan.xera.ac/api/v1/cohort?venue=Neurology+and+Therapy"},"results":[{"id":"W1993130299","doi":"10.1007/s40120-013-0012-3","title":"Perampanel: What is its Place in the Management of Partial Onset Epilepsy?","year":2013,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Perampanel; Epilepsy; Medicine; AMPA receptor; Adjunctive treatment; Dosing; Context (archaeology); Pharmacology; Neuroscience; Anesthesia; Glutamate receptor; Psychiatry; Psychology; Internal medicine; Receptor; Biology","score_opus":0.07848670123672485,"score_gpt":0.3740838144762321,"score_spread":0.29559711323950727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993130299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015489445,0.9800279,2.5746255e-7,0.0021434545,0.00010077819,0.0019295134,0.000012681566,0.000009336544,0.00028660524],"genre_scores_gemma":[0.002384354,0.99506456,0.000010253465,0.0017130316,0.000055742275,0.00044384078,0.000041560514,0.000022382772,0.00026425257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835694,0.00046497962,0.00032044208,0.00035062633,0.00020087592,0.00030614148],"domain_scores_gemma":[0.9991625,0.0002247682,0.00010492068,0.00040786617,0.000023375796,0.000076556134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029065483,0.0002594246,0.0009091467,0.000114791226,0.000044868644,0.000024340228,0.00017131935,0.0002334995,0.00032640513],"category_scores_gemma":[0.000003826658,0.00013675234,0.00017716954,0.00014411754,0.00012515315,0.00005593802,0.000040224644,0.00052289234,0.00007786267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003270102,0.00034245636,0.0004956296,0.0024532592,0.00048657536,0.00045727895,0.0002286824,5.2202598e-8,1.8427744e-7,0.00016230412,0.00050261914,0.99454397],"study_design_scores_gemma":[0.001587946,0.001857852,0.0013110278,0.0012305873,0.00023574407,0.0003271126,0.000037389043,0.0000041045955,0.0000037641678,0.00006594465,0.9932418,0.00009676017],"about_ca_topic_score_codex":0.00001299408,"about_ca_topic_score_gemma":0.0000015122226,"teacher_disagreement_score":0.9944472,"about_ca_system_score_codex":0.0000075041253,"about_ca_system_score_gemma":0.00005581881,"threshold_uncertainty_score":0.55765986},"labels":[],"label_agreement":null},{"id":"W1999230231","doi":"10.1007/s40120-012-0005-7","title":"Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease","year":2012,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tetrabenazine; Huntington's disease; Neurology; Medicine; Motor function; Neuroscience; Disease; Physical medicine and rehabilitation; Internal medicine; Psychology; Psychiatry","score_opus":0.007995521505863837,"score_gpt":0.22744759279401863,"score_spread":0.2194520712881548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999230231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99928397,0.000061541126,0.0000022688098,0.000067750385,0.00017168606,0.00032630638,0.000008479014,0.000014743238,0.00006324133],"genre_scores_gemma":[0.9984765,0.00003654556,0.0000010231616,0.0014097453,0.000029202767,0.000023758563,0.000002046719,0.000012798793,0.000008363158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897474,0.00039938831,0.000088836285,0.00022809747,0.00012578566,0.00018315719],"domain_scores_gemma":[0.9994936,0.00022467203,0.000050567116,0.00013951046,0.000011024822,0.00008062053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007916061,0.00011564214,0.00012023157,0.00007888388,0.00004108702,0.0000044690323,0.00005833468,0.000029429937,0.000021491822],"category_scores_gemma":[0.00011146823,0.00007926594,0.000020038939,0.0000981445,0.00009384998,0.00006346453,0.000012555012,0.00009770387,0.000004880267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007212185,0.00038701142,0.9519999,0.000008900906,0.0000019884574,8.077458e-7,0.000014405874,0.00002083046,0.03608643,0.0001046793,0.000005304914,0.0041575395],"study_design_scores_gemma":[0.0018006525,0.0056750407,0.82508224,0.000002602632,0.000005692058,1.3435628e-7,1.5382992e-7,0.0000118834,0.16725187,0.000018451483,0.00009946473,0.000051793962],"about_ca_topic_score_codex":0.0000015680406,"about_ca_topic_score_gemma":3.9181288e-7,"teacher_disagreement_score":0.13116544,"about_ca_system_score_codex":0.0000016416631,"about_ca_system_score_gemma":0.0000056512254,"threshold_uncertainty_score":0.32323712},"labels":[],"label_agreement":null},{"id":"W2004034787","doi":"10.1007/s40120-012-0001-y","title":"A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada","year":2012,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto","funders":"GlaxoSmithKline","keywords":"Medicine; Generalized anxiety disorder; Pharmacotherapy; Absenteeism; Discontinuation; Anxiety; Psychiatry; Demography; Pediatrics; Psychology","score_opus":0.03323368080884807,"score_gpt":0.31709635684278187,"score_spread":0.2838626760339338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004034787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97902304,0.013990224,0.0026789384,0.00024222326,0.00044371438,0.00035176423,0.000023038909,0.000008367725,0.0032386773],"genre_scores_gemma":[0.9842481,0.014271612,0.00019353034,0.0010344735,0.00005002572,0.00012195181,0.00000916024,0.00002230535,0.000048847014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985723,0.00040680548,0.00027385494,0.00027778198,0.00013502264,0.00033426032],"domain_scores_gemma":[0.99912125,0.00027754813,0.0002023161,0.0002720392,0.00007197035,0.000054849115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031452463,0.00017401495,0.00030270373,0.00011766095,0.00008389724,0.000005427104,0.00018344651,0.00013125327,0.000092455215],"category_scores_gemma":[0.0000354293,0.00011774506,0.00004114559,0.00039341795,0.0001984548,0.000101832964,0.000036708298,0.00023561459,5.001098e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003738722,0.00043280816,0.79728854,0.000012048755,0.00006963144,7.434487e-7,0.0014213559,0.00008575018,0.00012521056,0.00038191176,0.00023606447,0.19957206],"study_design_scores_gemma":[0.003981379,0.000105483596,0.9800676,0.0000058494456,0.000032577416,0.000035179804,0.0009795334,0.0021671213,0.00034952938,0.0007788757,0.011273216,0.00022364617],"about_ca_topic_score_codex":0.07549125,"about_ca_topic_score_gemma":0.010648579,"teacher_disagreement_score":0.19934842,"about_ca_system_score_codex":0.000012575075,"about_ca_system_score_gemma":0.000117854644,"threshold_uncertainty_score":0.93066514},"labels":[],"label_agreement":null},{"id":"W2073883789","doi":"10.1007/s40120-015-0026-0","title":"Concurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case–Control Study","year":2015,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Older Adults Driving Studies","field":"Health Professions","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Odds ratio; Cohort; Nested case-control study; Confidence interval; Internal medicine; Population; Logistic regression; Cohort study; Psychiatry; Environmental health","score_opus":0.06609463873192555,"score_gpt":0.3676319648305371,"score_spread":0.30153732609861156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073883789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953029,0.0022444425,0.0000065534427,0.00075314095,0.00018978749,0.001458746,0.000027950397,0.000011835925,0.000004650793],"genre_scores_gemma":[0.99719393,0.0022554859,0.0000033049855,0.0004377429,0.000026576488,0.000064822285,2.5134594e-7,0.000009133105,0.000008751031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736655,0.0017990522,0.00034221084,0.00021945992,0.000087889806,0.0001848236],"domain_scores_gemma":[0.9972813,0.0021469013,0.00023795744,0.00017603842,0.00010738792,0.000050420454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064604194,0.00012353144,0.00042623078,0.000072079776,0.00016785451,0.0000046695504,0.000059161634,0.0000861917,0.0000051103384],"category_scores_gemma":[0.00033602977,0.00007592239,0.000020040317,0.00006214374,0.00034892868,0.00009066518,0.00009822689,0.00030865642,3.3247522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000468688,0.00015037293,0.979236,0.000018307841,0.00011222848,0.000040686667,0.017108308,0.0000045858683,0.000043861437,0.000025212823,0.000045763216,0.0027459948],"study_design_scores_gemma":[0.01801734,0.0006809857,0.979053,0.00002391156,0.00005538561,0.000016369542,0.0014855374,0.00043221793,0.0000073882625,0.000113205424,0.000060297323,0.000054361604],"about_ca_topic_score_codex":0.0013884441,"about_ca_topic_score_gemma":0.0020609119,"teacher_disagreement_score":0.017548652,"about_ca_system_score_codex":0.0000026960374,"about_ca_system_score_gemma":0.00002351029,"threshold_uncertainty_score":0.3096025},"labels":[],"label_agreement":null},{"id":"W2168919398","doi":"10.1007/s40120-015-0033-1","title":"Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience","year":2015,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Pregnancy and Medication Impact","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; McGill University","funders":"","keywords":"Medicine; Dimethyl fumarate; Pregnancy; Postmarketing surveillance; Clinical trial; Neurology; Reproductive medicine; Pharmacology; Obstetrics; Anesthesia; Internal medicine; Adverse effect; Psychiatry; Multiple sclerosis","score_opus":0.3501967812369235,"score_gpt":0.5069049779139999,"score_spread":0.15670819667707642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168919398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74152154,0.25440073,0.00002628425,0.0031150617,0.00032213633,0.00048326314,0.000010565282,0.00004122143,0.00007918011],"genre_scores_gemma":[0.8811269,0.11505073,0.00025474402,0.0033166248,0.000074171934,0.00004714229,0.0000052357605,0.000016588641,0.00010786425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967363,0.0014514179,0.00078758405,0.00060535665,0.00015446152,0.00026490868],"domain_scores_gemma":[0.99412847,0.004722433,0.00029345922,0.00028866422,0.000083035666,0.0004839199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019092661,0.00024465224,0.0010484158,0.000057416524,0.00012737932,0.000021494538,0.000065543085,0.0002926658,0.000018384078],"category_scores_gemma":[0.006942696,0.00016439676,0.00006738849,0.000057843215,0.0008439402,0.0001529294,0.000101185484,0.00043251083,0.0000017397001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018962757,0.00013139172,0.6350114,0.000031922136,0.00031705317,0.000056286,0.003055143,5.9720286e-8,0.00016477912,0.000042161966,0.00007674348,0.35921678],"study_design_scores_gemma":[0.015488684,0.00428727,0.9738336,0.000879279,0.00025131655,0.000079680554,0.00037731574,0.00012928712,0.00018579238,0.0027489087,0.0014841937,0.00025468005],"about_ca_topic_score_codex":0.00002658973,"about_ca_topic_score_gemma":0.0000069500475,"teacher_disagreement_score":0.3589621,"about_ca_system_score_codex":0.00000327997,"about_ca_system_score_gemma":0.00008285099,"threshold_uncertainty_score":0.8311557},"labels":[],"label_agreement":null},{"id":"W2173983813","doi":"10.1007/s40120-015-0037-x","title":"Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study","year":2015,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Biogen","keywords":"Dimethyl fumarate; Medicine; Adverse effect; Tolerability; Multiple sclerosis; Delphi method; Internal medicine; Psychiatry","score_opus":0.07491696866877938,"score_gpt":0.3312264611467177,"score_spread":0.2563094924779383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173983813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778825,0.00035266942,0.000017991768,0.0007335438,0.000027065746,0.0007395342,0.0000066804064,0.00002891976,0.0003053704],"genre_scores_gemma":[0.99916345,0.00021823979,0.00017864697,0.00026793987,0.000013907696,0.000043143937,0.0000049605837,0.000013659069,0.000096036885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988012,0.00026407567,0.00017786532,0.00024080968,0.0002759141,0.00024015874],"domain_scores_gemma":[0.9992376,0.00016529599,0.00008394116,0.00017857431,0.00019191955,0.00014265072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038714684,0.00013226431,0.0002911147,0.00007058459,0.000057184756,0.0000030706449,0.00006045374,0.000031609296,0.0000148638555],"category_scores_gemma":[0.000108297805,0.000091957474,0.000025482126,0.00013865983,0.00019206681,0.000014455527,0.0000553941,0.00020354919,0.0000033424203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015651975,0.0020013324,0.9730516,0.000017042335,0.0009131005,0.00064229063,0.00045998846,0.000022966615,0.00094284036,0.000015642625,0.00036322692,0.0059180097],"study_design_scores_gemma":[0.013702521,0.016610295,0.9686134,0.00003623347,0.00006642196,0.00009300725,0.0003633128,0.00023230494,0.000072244125,0.000044999644,0.000094916686,0.0000703538],"about_ca_topic_score_codex":0.0000836978,"about_ca_topic_score_gemma":0.00004255504,"teacher_disagreement_score":0.014608962,"about_ca_system_score_codex":0.000009693664,"about_ca_system_score_gemma":0.000038712074,"threshold_uncertainty_score":0.3749917},"labels":[],"label_agreement":null},{"id":"W2411351210","doi":"10.1007/s40120-016-0045-5","title":"Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada","year":2016,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; MedDRA; Drug reaction; Mefloquine; Family medicine; Drug; Adverse drug reaction; Patient safety; Psychiatry; Pharmacovigilance; Malaria; Pathology; Health care; Chloroquine","score_opus":0.060984874766783125,"score_gpt":0.3718949081555471,"score_spread":0.310910033388764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411351210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077654,0.0011189991,0.000006011765,0.006867319,0.00047949713,0.0006066215,0.000044516626,0.000011254801,0.00008925945],"genre_scores_gemma":[0.99298704,0.0019138588,0.000011415756,0.004764059,0.000043964377,0.00003877256,0.000001791399,0.0000088051875,0.00023031332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844134,0.0005155266,0.00041359136,0.00026843412,0.0000987587,0.00026232324],"domain_scores_gemma":[0.9987894,0.00071090896,0.00016664903,0.00015579394,0.000025400252,0.00015180628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025043308,0.00016997207,0.00031604114,0.00009127711,0.00016353547,0.0000056396552,0.00011899678,0.00011416214,0.000047546022],"category_scores_gemma":[0.000048992264,0.00010658018,0.000027312237,0.00013364463,0.00010445732,0.00007205666,0.000031566957,0.00037917864,0.0000027319938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021937327,0.00022007553,0.9550236,0.0002608405,0.00014157397,0.000056763653,0.0023188055,0.0004412927,0.02201807,0.00051111693,0.011535334,0.0052788164],"study_design_scores_gemma":[0.008687827,0.0012916642,0.5775379,0.0002751274,0.00023574989,0.00042671146,0.00031855336,0.00032976604,0.002460063,0.00039324095,0.40755844,0.00048493926],"about_ca_topic_score_codex":0.02386509,"about_ca_topic_score_gemma":0.02999697,"teacher_disagreement_score":0.3960231,"about_ca_system_score_codex":0.000012847486,"about_ca_system_score_gemma":0.00007072812,"threshold_uncertainty_score":0.9877031},"labels":[],"label_agreement":null},{"id":"W2535734852","doi":"10.1007/s40120-016-0053-5","title":"Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial","year":2016,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto","funders":"","keywords":"Placebo; Medicine; Narcolepsy; SF-36; Quality of life (healthcare); Post-hoc analysis; Population; Randomized controlled trial; Internal medicine; Physical therapy; Neurology; Health related quality of life; Psychiatry; Alternative medicine","score_opus":0.336758150808247,"score_gpt":0.4327083332960083,"score_spread":0.09595018248776127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535734852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850816,0.0000150651,0.0000034916804,0.0003480927,0.000053374213,0.0010244838,0.000038052025,0.0000033449146,0.000005938698],"genre_scores_gemma":[0.9995297,0.00010258744,0.0000012885165,0.00032162116,0.0000068745935,0.000025990392,0.0000017306544,0.000007670009,0.0000025058257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920243,0.0062984894,0.0006313484,0.00028781602,0.000571748,0.00018629433],"domain_scores_gemma":[0.996967,0.0022169403,0.00028895997,0.00029262333,0.00018720338,0.000047260735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004547003,0.00009273335,0.0003928884,0.00010302607,0.000030159303,0.0000034458765,0.00015594136,0.00009866395,0.0000104557585],"category_scores_gemma":[0.0018189031,0.00004340467,0.000030595427,0.00036409087,0.0005043794,0.00008948668,0.0000286078,0.00017899717,1.4089059e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12077859,0.0007054147,0.85734093,0.0000045245943,0.000009243141,2.782935e-7,0.000077347824,0.0000045731385,0.00026417573,0.000020223015,0.0000023633772,0.020792307],"study_design_scores_gemma":[0.04082942,0.005301886,0.9518263,0.000013382767,0.0000028816644,2.3560698e-7,0.0000016941857,0.00006471311,0.0018598168,0.00005419937,0.0000030762521,0.000042435],"about_ca_topic_score_codex":0.0009483685,"about_ca_topic_score_gemma":0.0029155735,"teacher_disagreement_score":0.0944853,"about_ca_system_score_codex":0.0000095416135,"about_ca_system_score_gemma":0.0002679902,"threshold_uncertainty_score":0.21775283},"labels":[],"label_agreement":null},{"id":"W2734970544","doi":"10.1007/s40120-017-0076-6","title":"Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis","year":2017,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Toronto","funders":"Jazz Pharmaceuticals","keywords":"Medicine; Narcolepsy; Quality of life (healthcare); Post-hoc analysis; Vitality; SF-36; Population; Clinical Global Impression; Clinical trial; Neurology; Post hoc; Physical therapy; Internal medicine; Disease; Health related quality of life; Psychiatry; Alternative medicine","score_opus":0.1515670147074061,"score_gpt":0.4139817489890378,"score_spread":0.26241473428163165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734970544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99912745,0.000021215557,0.0000039042147,0.00011178073,0.000053076204,0.0006345107,0.000029784072,0.00000293235,0.00001533796],"genre_scores_gemma":[0.9997453,0.00004992253,0.0000039736674,0.000106059146,0.000008828804,0.00007509726,0.0000052782775,0.00000535469,2.0287906e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975178,0.0009474775,0.0007285312,0.0003115991,0.00030547395,0.00018909901],"domain_scores_gemma":[0.9979515,0.00035069833,0.0012061619,0.00031710888,0.00013534282,0.000039167604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006055276,0.00010668132,0.00060744584,0.0001994514,0.00003916037,0.0000047695094,0.00014760207,0.00012806582,0.000005718467],"category_scores_gemma":[0.0006185914,0.00007670243,0.00004333275,0.00056031503,0.000363882,0.00011622344,0.000051976916,0.00018556624,4.6346937e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13835754,0.0013363475,0.8430266,0.000016741911,0.0000337134,0.0000053984418,0.00055375235,0.00004110065,0.0016646113,0.000019695519,8.141757e-8,0.01494444],"study_design_scores_gemma":[0.031183481,0.008691027,0.95398647,0.000030421728,0.000018115657,1.2682602e-7,0.000029084062,0.0015585519,0.0044134436,0.00002937671,3.244382e-7,0.000059575555],"about_ca_topic_score_codex":0.0013578598,"about_ca_topic_score_gemma":0.0021569957,"teacher_disagreement_score":0.11095989,"about_ca_system_score_codex":0.0000045846914,"about_ca_system_score_gemma":0.000049750797,"threshold_uncertainty_score":0.31278345},"labels":[],"label_agreement":null},{"id":"W2790537473","doi":"10.1007/s40120-018-0091-2","title":"Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate","year":2018,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baycrest Hospital; University of Toronto","funders":"","keywords":"Substantia nigra; Neuroscience; Pars compacta; Neuroprotection; Parkinson's disease; Neuron; Dopaminergic; Medicine; Degeneration (medical); Disease; Dopamine; Biology; Internal medicine; Pathology","score_opus":0.01559085316679454,"score_gpt":0.2528604754054529,"score_spread":0.23726962223865838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790537473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832023,0.004503763,0.0000094634925,0.005939331,0.00019273696,0.00024780072,0.0000083172245,0.00004541872,0.00073293934],"genre_scores_gemma":[0.9828386,0.0051598656,0.000011460403,0.011383655,0.00022161703,0.000032976997,0.000005532055,0.000018058652,0.00032824927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991838,0.00009149696,0.00009377079,0.00033031282,0.00008831404,0.00021234511],"domain_scores_gemma":[0.9994531,0.000051597843,0.000037772013,0.00024113453,0.000024806399,0.000191543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000070508904,0.0001524279,0.00015716985,0.000040501425,0.00020878544,0.000017598322,0.000050904502,0.000056596728,0.00007299376],"category_scores_gemma":[0.000011181169,0.00009026836,0.000036974998,0.0000616682,0.00029471298,0.000036925834,0.000029727298,0.00012038471,0.000019977975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016048849,0.0009839574,0.73469454,0.00004571592,0.00048290397,0.0018248735,0.00050717854,0.000001336265,0.009914337,0.00613198,0.0019628224,0.22740154],"study_design_scores_gemma":[0.0019999277,0.0013183495,0.71349764,0.0000036212275,0.00005856345,0.00011886251,0.00000272526,0.00030248586,0.00036129376,0.0020689901,0.2801979,0.00006964202],"about_ca_topic_score_codex":0.000014142035,"about_ca_topic_score_gemma":0.0000061297906,"teacher_disagreement_score":0.27823508,"about_ca_system_score_codex":0.0000021349063,"about_ca_system_score_gemma":0.000023012517,"threshold_uncertainty_score":0.36810368},"labels":[],"label_agreement":null},{"id":"W2903056119","doi":"10.1007/s40120-018-0121-0","title":"A Videogame-Based Digital Therapeutic to Improve Processing Speed in People with Multiple Sclerosis: A Feasibility Study","year":2018,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Neurological Disorders and Stroke; Doris Duke Charitable Foundation","keywords":"Medicine; Multiple sclerosis; Physical therapy; Expanded Disability Status Scale; Cognition; Physical medicine and rehabilitation; Psychiatry","score_opus":0.07012734933937709,"score_gpt":0.32466153608279963,"score_spread":0.25453418674342254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903056119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945941,0.00024156217,0.000083111605,0.0024802256,0.00004128425,0.0023846098,0.000007013988,0.00006920418,0.000098907185],"genre_scores_gemma":[0.99666584,0.000040954503,0.000052925538,0.0029610146,0.00008985187,0.00014027994,0.0000019626993,0.000028731818,0.000018452469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831915,0.00013830296,0.00022154055,0.0006272148,0.00026306507,0.00043072752],"domain_scores_gemma":[0.9990609,0.0002127409,0.00005246527,0.00034872658,0.00017269324,0.00015246822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031041403,0.00022048967,0.0004171219,0.00017485724,0.00016083999,0.0000572009,0.000108349406,0.00007723305,0.000020933681],"category_scores_gemma":[0.00018331048,0.00015075869,0.000035308847,0.00040914176,0.00032523525,0.00011555249,0.00005745971,0.00030004416,0.000009690649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013679663,0.0014101136,0.9104573,0.000021149139,0.000051359188,0.000013854293,0.002059108,0.0000031945058,0.019002112,5.7818534e-7,0.0000068892487,0.053294666],"study_design_scores_gemma":[0.011809639,0.015330812,0.9696789,0.0000334416,0.000011951509,0.000006151551,0.00025480194,0.0010426666,0.0015330485,0.000015238493,0.00015200312,0.00013135783],"about_ca_topic_score_codex":0.00012615543,"about_ca_topic_score_gemma":0.0010321541,"teacher_disagreement_score":0.059221573,"about_ca_system_score_codex":0.000023496917,"about_ca_system_score_gemma":0.00011152512,"threshold_uncertainty_score":0.6147761},"labels":[],"label_agreement":null},{"id":"W2909923106","doi":"10.1007/s40120-018-0124-x","title":"Intravenous Milrinone Salvage Therapy in Acute Internal Carotid Artery Occlusion: Case Report","year":2019,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Milrinone; Internal carotid artery; Neurology; Occlusion; Carotid arteries; Cardiology; Internal medicine; Anesthesia; Heart failure","score_opus":0.009646331308357846,"score_gpt":0.2506238095484474,"score_spread":0.24097747824008953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909923106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900147,0.0006361707,0.000032677093,0.003659822,0.0005027975,0.00069696765,0.0000028299557,0.000050760533,0.004403298],"genre_scores_gemma":[0.9845313,0.0026343823,0.00008140256,0.011485172,0.00014549094,0.000020427531,0.000012018272,0.000027525239,0.001062279],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987487,0.000073695745,0.00030141041,0.0004487394,0.00013417745,0.00029323774],"domain_scores_gemma":[0.9992879,0.000061320316,0.00009559399,0.00044621833,0.000027107482,0.00008183947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021347098,0.00019959599,0.00037193147,0.0001503475,0.00004019995,0.000009651638,0.00009115322,0.00015550786,0.000286819],"category_scores_gemma":[0.0000063141615,0.00016095483,0.00006514611,0.00009968282,0.000091955895,0.000050330833,0.00007860763,0.00045885195,0.00003198467],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037693486,0.0003812376,0.37110877,0.000019095878,0.00044751068,0.5576407,0.0010528537,0.0000026318032,0.038358063,0.000041782525,0.0026675018,0.024510503],"study_design_scores_gemma":[0.012237117,0.0057284613,0.24126208,0.000028544673,0.00004874432,0.68829805,0.00008514924,0.0001322393,0.008773044,0.0000837031,0.04300849,0.00031435819],"about_ca_topic_score_codex":0.00008875811,"about_ca_topic_score_gemma":0.000011080202,"teacher_disagreement_score":0.13065737,"about_ca_system_score_codex":0.0000134541015,"about_ca_system_score_gemma":0.00002720574,"threshold_uncertainty_score":0.6563548},"labels":[],"label_agreement":null},{"id":"W2913440059","doi":"10.1007/s40120-019-0126-3","title":"Neurology and Therapy: Looking Back on 2018 and Forward to 2019","year":2019,"lang":"en","type":"letter","venue":"Neurology and Therapy","topic":"Neurology and Historical Studies","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universidade Federal do Rio de Janeiro; Ottawa Hospital Research Institute","keywords":"Neurology; Medicine; Clinical neurology; Physical medicine and rehabilitation; Neuroscience; Psychology; Psychiatry","score_opus":0.03199121748331405,"score_gpt":0.25315100876839547,"score_spread":0.22115979128508143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913440059","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30410433,0.004316476,0.000004143959,0.6870151,0.0020867735,0.00080381316,0.000032042208,0.00008462871,0.0015527039],"genre_scores_gemma":[0.020001577,0.030704169,0.0000051640477,0.9463169,0.0010432818,0.000045194905,0.0000047738026,0.00008570426,0.0017932426],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616677,0.00075589836,0.00032961174,0.0017383395,0.00021647367,0.00079290196],"domain_scores_gemma":[0.99718165,0.0019776537,0.00018747107,0.0005162712,0.00002531765,0.0001116517],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00016604758,0.00064549304,0.00086762983,0.00028150628,0.0004837859,0.000052510553,0.0003596309,0.0012623393,0.000097701835],"category_scores_gemma":[0.00008976316,0.0005280858,0.00009048347,0.00014583058,0.0008328408,0.00008383016,0.00022044263,0.002747084,0.00024639445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035451339,0.00008435054,0.0031737029,0.00003443077,0.00006128849,0.0006661936,0.00026764206,0.0000032810392,0.0047788466,0.00033083613,0.9727425,0.014311795],"study_design_scores_gemma":[0.0014425637,0.007280074,0.0037404122,0.0000050643857,0.00001423286,0.00030825334,3.7983634e-7,0.00000990292,0.00041059125,0.0012956158,0.98509324,0.00039965106],"about_ca_topic_score_codex":0.000031278225,"about_ca_topic_score_gemma":0.0000066141015,"teacher_disagreement_score":0.28410274,"about_ca_system_score_codex":0.0000053567633,"about_ca_system_score_gemma":0.000022047778,"threshold_uncertainty_score":0.99971706},"labels":[],"label_agreement":null},{"id":"W2960106648","doi":"10.1007/s40120-019-0145-0","title":"Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?","year":2019,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Biopharmaceutical; Multiple sclerosis; Pharmacy; Intensive care medicine; Family medicine; Internal medicine; Psychiatry; Biotechnology","score_opus":0.037013532446487245,"score_gpt":0.2776106795977571,"score_spread":0.24059714715126984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960106648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934867,0.0014509632,0.00013055353,0.0027949307,0.0013747625,0.00040837788,0.00010272927,0.00006500733,0.00018598103],"genre_scores_gemma":[0.988175,0.0016274275,0.000705561,0.0084990105,0.000079967074,0.000034023982,0.000031554922,0.000021184294,0.0008262891],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987055,0.00034642505,0.00020832404,0.00042961506,0.000028883447,0.00028124673],"domain_scores_gemma":[0.9990504,0.00048939773,0.00010169115,0.00027066935,0.000051526677,0.000036349447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044647997,0.0001743201,0.00028140374,0.000090178204,0.00014469746,0.000015712036,0.00022590949,0.00044065405,0.0007538673],"category_scores_gemma":[0.00007012883,0.00012151566,0.000090825306,0.00006990565,0.00025152776,0.00008337277,0.000043995315,0.0002986419,0.000027267146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04190328,0.0009800268,0.19585438,0.000027454777,0.0012312862,0.000005623169,0.0007960505,0.000007783105,0.49895626,0.0038388474,0.0065402607,0.24985875],"study_design_scores_gemma":[0.01856844,0.0069847,0.21170491,0.000019135361,0.00010368168,0.0000762035,0.00018671626,0.0008048499,0.09664088,0.0033662263,0.66090816,0.00063610805],"about_ca_topic_score_codex":0.000014654105,"about_ca_topic_score_gemma":0.00000990489,"teacher_disagreement_score":0.6543679,"about_ca_system_score_codex":0.000004059601,"about_ca_system_score_gemma":0.000021747781,"threshold_uncertainty_score":0.8254319},"labels":[],"label_agreement":null},{"id":"W2963912492","doi":"10.1007/s40120-019-0146-z","title":"Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials","year":2019,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"Novartis Pharma; Javna Agencija za Raziskovalno Dejavnost RS","keywords":"Fingolimod; Medicine; Expanded Disability Status Scale; Multiple sclerosis; Placebo; Relapsing remitting; Internal medicine; Post-hoc analysis; Randomization; Clinical trial; Immunology; Pathology","score_opus":0.03219779123218237,"score_gpt":0.2880480217703848,"score_spread":0.25585023053820244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963912492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579686,0.0013779915,0.000009489762,0.0004910407,0.00029980612,0.001904481,0.00006449307,0.000027556873,0.000028262688],"genre_scores_gemma":[0.9959136,0.0035003629,0.000029475725,0.00015835953,0.00009483058,0.00015403176,0.00010894439,0.000028793063,0.000011590705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970464,0.0010710843,0.00056194427,0.0005440388,0.00036096355,0.0004155353],"domain_scores_gemma":[0.99408084,0.0048240297,0.0003369231,0.0005279085,0.0001386206,0.000091697686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007748486,0.0003269053,0.0013205034,0.00022484755,0.00017134217,0.000015653013,0.00015912503,0.00018091519,0.000046815512],"category_scores_gemma":[0.00089282217,0.0001724763,0.00025878666,0.0004476368,0.00029348218,0.000068833804,0.00008310661,0.00033884912,0.000003809291],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057477247,0.00035181947,0.9188045,0.000011233027,0.0044884463,0.0000055580363,0.0011973202,0.00007384909,0.005179105,0.0000011423235,0.0000068837176,0.012402898],"study_design_scores_gemma":[0.06340917,0.012800084,0.92003834,0.00006745355,0.0010220202,5.699517e-7,0.000028467142,0.0008962283,0.0016125067,0.0000020585658,0.0000033255453,0.000119777695],"about_ca_topic_score_codex":0.0027335244,"about_ca_topic_score_gemma":0.00262099,"teacher_disagreement_score":0.012448265,"about_ca_system_score_codex":0.00003747557,"about_ca_system_score_gemma":0.00003339204,"threshold_uncertainty_score":0.70333797},"labels":[],"label_agreement":null},{"id":"W2973051044","doi":"10.1007/s40120-019-00154-7","title":"Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review","year":2019,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Eisai","keywords":"Dementia with Lewy bodies; Medicine; Dementia; Donepezil; Clinical trial; Randomized controlled trial; Disease; Quality of life (healthcare); Psychological intervention; Psychiatry; Systematic review; MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.03453986119457354,"score_gpt":0.36624187789760326,"score_spread":0.33170201670302973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973051044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008073603,0.99630046,0.0000037245827,0.0002575577,0.00004878583,0.0022014978,0.00003322981,0.000006792942,0.00034057308],"genre_scores_gemma":[0.00027727665,0.99898785,0.000013600016,0.000280682,0.00003304731,0.00012630226,0.000087005734,0.000020970652,0.00017328316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869174,0.00019442674,0.00033445226,0.000369885,0.0002218472,0.00018763257],"domain_scores_gemma":[0.99923176,0.00006647236,0.00021334522,0.00028758857,0.000094963514,0.000105861334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001954698,0.00025888564,0.0011868337,0.00013634824,0.000024195615,0.000007133602,0.00008749327,0.00008069251,0.00007913632],"category_scores_gemma":[0.000005891783,0.00015524702,0.00015008301,0.00013924597,0.00017873921,0.000030503772,0.00007701315,0.00031677276,0.0000025838442],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049883046,0.0001259237,0.00087828323,0.20833507,0.0010508567,0.000069098656,0.00002608468,5.1831064e-9,3.509058e-7,0.000098145865,0.00015370533,0.78876364],"study_design_scores_gemma":[0.0014125094,0.0019593602,0.0017347841,0.08841312,0.0036909524,0.000056842266,0.0000028162972,5.7031997e-7,5.138379e-7,0.00003284023,0.9025805,0.00011517612],"about_ca_topic_score_codex":8.336051e-7,"about_ca_topic_score_gemma":1.03035454e-7,"teacher_disagreement_score":0.9024268,"about_ca_system_score_codex":0.0000023192142,"about_ca_system_score_gemma":0.000068885056,"threshold_uncertainty_score":0.63307893},"labels":[],"label_agreement":null},{"id":"W2975995412","doi":"10.1007/s40120-019-00156-5","title":"Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population","year":2019,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Multiple sclerosis; Dosing; Population; Methylprednisolone; Medical prescription; Pediatrics; Relapse prevention; Internal medicine; Fingolimod; Neurology; Psychiatry","score_opus":0.08588918681136075,"score_gpt":0.33635967359676505,"score_spread":0.2504704867854043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975995412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963468,0.00096538116,0.000017744453,0.0009760732,0.00006860031,0.0015816555,0.000014773154,0.000012240908,0.000016779459],"genre_scores_gemma":[0.99613154,0.003424455,0.000065453765,0.00017891913,0.000019812742,0.00013471761,0.000027402455,0.0000089433715,0.000008727407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992079,0.0002054791,0.00014807018,0.00020049924,0.000068949455,0.00016911424],"domain_scores_gemma":[0.9993759,0.0003838409,0.000055912635,0.00012129991,0.000026283014,0.000036779285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023473726,0.000080059166,0.00030356937,0.000103971004,0.000044865796,0.0000016863527,0.000020046555,0.00006788755,0.000004194186],"category_scores_gemma":[0.00006324943,0.00006053124,0.000039453167,0.00006897492,0.000040157443,0.000025882817,0.000009157718,0.00007309318,9.893878e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008574392,0.00021489957,0.9459282,0.00007784334,0.000035237274,6.786826e-7,0.00021649589,0.00004947257,0.01817141,0.00004527233,0.0000061295527,0.026679924],"study_design_scores_gemma":[0.01045157,0.0066357907,0.9797134,0.00003842332,0.0000031352054,0.0000031173327,0.0000066452817,0.0015814248,0.0011186246,0.000046295194,0.00036741706,0.000034160086],"about_ca_topic_score_codex":0.00095876143,"about_ca_topic_score_gemma":0.00025162662,"teacher_disagreement_score":0.03378515,"about_ca_system_score_codex":0.0000327091,"about_ca_system_score_gemma":0.000022594228,"threshold_uncertainty_score":0.24683924},"labels":[],"label_agreement":null},{"id":"W2978197534","doi":"10.1007/s40120-019-00158-3","title":"Cognitive Fatigability Interventions in Neurological Conditions: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Fibromyalgia and Chronic Fatigue Syndrome Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; Ottawa Hospital","funders":"","keywords":"PsycINFO; Medicine; MEDLINE; Psychological intervention; Cochrane Library; Randomized controlled trial; Systematic review; Data extraction; Cognition; Physical therapy; Physical medicine and rehabilitation; Psychiatry; Internal medicine","score_opus":0.16186607822065543,"score_gpt":0.44346544846650143,"score_spread":0.281599370245846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978197534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005156822,0.99227715,0.000001910663,0.0005354079,0.00008764412,0.0063855913,0.0000377079,0.000033441203,0.00012546203],"genre_scores_gemma":[0.0003779544,0.9976209,0.0000024731673,0.0005271341,0.000010594338,0.0011114463,0.00017388006,0.00002955951,0.00014604817],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962533,0.0017301944,0.00091639935,0.00059368595,0.00018277529,0.00032364347],"domain_scores_gemma":[0.9978617,0.0012879084,0.00025153186,0.00043102767,0.000065331245,0.000102527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066916813,0.00034015466,0.0032693385,0.00023613327,0.00004811203,0.000011352004,0.00015079216,0.00045394205,0.000595933],"category_scores_gemma":[0.0005268605,0.00022291043,0.0006864137,0.00027860526,0.0002915885,0.000038393646,0.00006614455,0.0013000133,0.00020219426],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045101093,0.0002224608,0.00011522526,0.98668915,0.00019737643,0.00016337947,0.000009797847,5.9230323e-9,5.5830625e-8,0.00008465787,0.00006184401,0.012410915],"study_design_scores_gemma":[0.0013698238,0.003094363,0.00075035024,0.98075557,0.0017603419,0.0022441365,0.000003026779,0.000006272561,4.9947726e-8,0.00016667726,0.009623652,0.00022574587],"about_ca_topic_score_codex":0.000003929325,"about_ca_topic_score_gemma":6.8990437e-7,"teacher_disagreement_score":0.012185169,"about_ca_system_score_codex":0.00001356009,"about_ca_system_score_gemma":0.00022573545,"threshold_uncertainty_score":0.90900236},"labels":[],"label_agreement":null},{"id":"W3000343054","doi":"10.1007/s40120-020-00176-6","title":"Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective","year":2020,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"Roche","keywords":"Cronbach's alpha; Item response theory; Medicine; Interquartile range; Classical test theory; Confirmatory factor analysis; Relapsing remitting; Expanded Disability Status Scale; Reliability (semiconductor); Scale (ratio); Physical therapy; Psychometrics; Clinical psychology; Multiple sclerosis; Structural equation modeling; Psychiatry; Statistics; Internal medicine","score_opus":0.0955429705972189,"score_gpt":0.2910573773475456,"score_spread":0.19551440675032672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000343054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082637,0.0019446452,0.0000033665194,0.0062902533,0.000036497153,0.0008736104,0.000004949043,0.0000123576265,0.000007981425],"genre_scores_gemma":[0.99892527,0.0004321254,0.00001534065,0.00056759134,0.000016477587,0.000031161253,0.0000010960451,0.000010632826,3.0408358e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998797,0.0002988598,0.00025917255,0.00024367828,0.0002576163,0.00014369194],"domain_scores_gemma":[0.9993188,0.0001278387,0.0001568313,0.00019639562,0.00016767107,0.00003250699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017760354,0.000108341424,0.00025119336,0.000053780437,0.00013108141,0.000004643301,0.000089402245,0.000057856745,0.0000018753306],"category_scores_gemma":[0.0010340809,0.000051687748,0.000049125832,0.0005277972,0.00048261174,0.000058899514,0.00005584691,0.00028896148,1.1447186e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028570162,0.00023587667,0.98297536,0.000054633172,0.000047672424,6.4631244e-8,0.0049083177,0.00002462927,0.0017333344,0.000017613855,0.0000025205914,0.0071429657],"study_design_scores_gemma":[0.0023659163,0.0009923307,0.99493015,0.0001739825,0.000011742299,3.3479367e-7,0.00035000106,0.00043767362,0.0006724765,0.000014797375,0.0000061489404,0.000044477212],"about_ca_topic_score_codex":0.00062700873,"about_ca_topic_score_gemma":0.00013207071,"teacher_disagreement_score":0.011954764,"about_ca_system_score_codex":0.000017848266,"about_ca_system_score_gemma":0.000015867417,"threshold_uncertainty_score":0.21077652},"labels":[],"label_agreement":null},{"id":"W3011755412","doi":"10.1007/s40120-020-00181-9","title":"Current Directions in Deep Brain Stimulation for Parkinson’s Disease—Directing Current to Maximize Clinical Benefit","year":2020,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke","keywords":"Deep brain stimulation; Computer science; Neuroimaging; Neuroscience; Essential tremor; Medicine; Biomedical engineering; Parkinson's disease; Physical medicine and rehabilitation; Psychology; Disease; Pathology","score_opus":0.12966503099995536,"score_gpt":0.4329764095297719,"score_spread":0.30331137852981654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011755412","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004032393,0.989241,0.00009227135,0.0028170815,0.0009756303,0.0027038057,0.000049789152,0.0000705901,0.000017438986],"genre_scores_gemma":[0.001148311,0.9946573,0.000042503223,0.0029624663,0.0003091877,0.0007011615,0.0001243927,0.000046197034,0.000008500185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781877,0.00029436479,0.00062787085,0.0008497479,0.000102822945,0.00030641438],"domain_scores_gemma":[0.99815893,0.0011018827,0.00017274058,0.0002153162,0.000029028984,0.0003220917],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017712783,0.00036929734,0.0013852769,0.00016058885,0.00010540936,0.0000149952075,0.000086682725,0.00022230444,0.000024134262],"category_scores_gemma":[0.0003505728,0.00027414507,0.00043612116,0.00024124542,0.000049448663,0.000024430656,0.00004723987,0.0006924081,0.000013400249],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011674906,0.00062292337,0.013982338,0.00058477063,0.00007363601,0.000036878202,0.000017097243,0.0000022310255,3.7105863e-8,0.000055976012,0.00015173106,0.9833049],"study_design_scores_gemma":[0.0023018487,0.0015353855,0.033121865,0.00038636645,0.00028653987,0.000007274515,3.772234e-7,0.00014333632,2.435307e-8,0.0012221773,0.96082336,0.0001714329],"about_ca_topic_score_codex":0.0000031330567,"about_ca_topic_score_gemma":0.000013919498,"teacher_disagreement_score":0.98313344,"about_ca_system_score_codex":0.000016219281,"about_ca_system_score_gemma":0.000070854665,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W3016131637","doi":"10.1007/s40120-020-00186-4","title":"A Case Report of Myoclonus-Dystonia with Isolated Myoclonus Phenotype and Novel Mutation Successfully Treated with Deep Brain Stimulation","year":2020,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Glycogen Storage Diseases and Myoclonus","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"","keywords":"Myoclonus; Dystonia; Myoclonic Jerk; Deep brain stimulation; Medicine; Globus pallidus; Movement disorders; Neuroscience; Psychology; Internal medicine; Anesthesia; Psychiatry; Basal ganglia; Parkinson's disease; Disease; Central nervous system","score_opus":0.014332266108547884,"score_gpt":0.2460717604870046,"score_spread":0.23173949437845673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016131637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317765,0.0006177176,0.0032659846,0.0022620067,0.000018763543,0.0005223139,0.0000123639265,0.000063541665,0.00005967779],"genre_scores_gemma":[0.99614835,0.000049030252,0.00028973984,0.003338723,0.000043283428,0.000014329008,0.00006751309,0.000030922925,0.000018106206],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9990219,0.00005148004,0.00024052702,0.0003915923,0.00012348837,0.000171032],"domain_scores_gemma":[0.9992422,0.0000818447,0.00018457223,0.00016450074,0.00014558432,0.00018131688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006579308,0.00019296966,0.00033992514,0.000067735135,0.00008890405,0.000011422747,0.000028077273,0.00012104806,0.000028548404],"category_scores_gemma":[0.00003474483,0.00013712818,0.000028579101,0.00022613569,0.0001552927,0.00008161902,0.000011096477,0.00016214498,6.600154e-7],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07887897,0.0006476178,0.13348053,0.000219998,0.000843357,0.72794014,0.00283835,0.0007093474,0.031984866,0.00027026795,0.0000532909,0.022133287],"study_design_scores_gemma":[0.03377196,0.038637742,0.14186361,0.00005442259,0.00089725666,0.7409884,0.00019935795,0.039031744,0.0023981896,0.00008716702,0.0014488293,0.0006213383],"about_ca_topic_score_codex":0.00018942133,"about_ca_topic_score_gemma":0.000044519253,"teacher_disagreement_score":0.045107014,"about_ca_system_score_codex":0.000003992798,"about_ca_system_score_gemma":0.00006070566,"threshold_uncertainty_score":0.5591925},"labels":[],"label_agreement":null},{"id":"W3024180170","doi":"10.1007/s40120-020-00191-7","title":"Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies","year":2020,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Sanofi","keywords":"Medicine; Expanded Disability Status Scale; Alemtuzumab; Multiple sclerosis; Thyroid; Adverse effect; Quality of life (healthcare); Internal medicine; Post-hoc analysis; Visual analogue scale; Health related quality of life; Physical therapy; Immunology; Disease","score_opus":0.05676913280950129,"score_gpt":0.3111541731663431,"score_spread":0.2543850403568418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024180170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963847,0.0020941223,0.0000027255687,0.0007072896,0.000032021664,0.0007067541,0.000042624688,0.000017730525,0.000012077947],"genre_scores_gemma":[0.99642235,0.0022149866,0.00012215321,0.0011594105,0.000014693851,0.000029320247,0.000009735095,0.000021123811,0.0000062150352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981364,0.000349142,0.00046284232,0.00038561033,0.0004162117,0.00024981634],"domain_scores_gemma":[0.9984494,0.00047589443,0.00035291954,0.00033839722,0.00031006726,0.000073363524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002447306,0.0001996648,0.0009318157,0.00015011609,0.00009535562,0.0000024812402,0.00014252435,0.00008323069,0.000012288065],"category_scores_gemma":[0.0007398876,0.00010586121,0.00011640049,0.00076038396,0.00053449575,0.00007508483,0.00013179,0.00032366483,2.2558807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024844436,0.00020021596,0.9522173,0.00009329938,0.0019832405,0.0000015244774,0.008405064,0.00008259506,0.009366267,0.0000015334707,0.000005572286,0.0027989626],"study_design_scores_gemma":[0.011893581,0.0042441543,0.98172337,0.000083015235,0.00018579775,2.4537724e-7,0.0012517394,0.00026694004,0.00022519229,8.1548365e-7,0.00002533777,0.00009982956],"about_ca_topic_score_codex":0.0004494473,"about_ca_topic_score_gemma":0.00083269086,"teacher_disagreement_score":0.029506063,"about_ca_system_score_codex":0.00001987839,"about_ca_system_score_gemma":0.000097827164,"threshold_uncertainty_score":0.43168947},"labels":[],"label_agreement":null},{"id":"W3106029492","doi":"10.1007/s40120-020-00219-y","title":"Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis","year":2020,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Propensity score matching; Medical prescription; Internal medicine; Multiple sclerosis; Retrospective cohort study; Family medicine; Health care; Psychiatry","score_opus":0.06549670668876888,"score_gpt":0.295872571729544,"score_spread":0.23037586504077512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106029492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767905,0.00044415524,0.000085408814,0.00076943584,0.00008848783,0.000825267,0.000060241768,0.000019370244,0.000028605094],"genre_scores_gemma":[0.99655205,0.002770946,0.00015520383,0.0003622869,0.000037344962,0.000096488606,0.000008760995,0.000009144875,0.000007784953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991432,0.00010802369,0.00029056068,0.00020231244,0.00013069721,0.00012522526],"domain_scores_gemma":[0.9991352,0.00029342453,0.00016459356,0.00010652045,0.00023889256,0.00006139759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042005795,0.00008640556,0.00031105467,0.000047154932,0.00008820794,0.0000036122565,0.000052536492,0.00007477687,0.000005377899],"category_scores_gemma":[0.00037480964,0.000071164606,0.000058185375,0.00009927684,0.0005234775,0.00005892768,0.000022985889,0.00009843401,2.0134154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021657413,0.000089073976,0.63821656,0.000036743568,0.00014271738,5.510433e-7,0.0004132124,0.00000927613,0.35580608,0.000006382237,0.000078049816,0.0030356257],"study_design_scores_gemma":[0.0031241386,0.0035544473,0.8448072,0.00001807661,0.000027762067,0.0000013501261,0.000014034898,0.00021739656,0.1481052,0.000015847425,0.000075303964,0.00003920113],"about_ca_topic_score_codex":0.00008684097,"about_ca_topic_score_gemma":0.000009749169,"teacher_disagreement_score":0.20770088,"about_ca_system_score_codex":0.0000033936776,"about_ca_system_score_gemma":0.000030228242,"threshold_uncertainty_score":0.29020083},"labels":[],"label_agreement":null},{"id":"W3124790920","doi":"10.1007/s40120-021-00230-x","title":"Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale","year":2021,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche España","keywords":"Item response theory; Disease; Scale (ratio); Psychology; Depression (economics); Clinical psychology; Medicine; Psychometrics; Internal medicine","score_opus":0.09553282751054976,"score_gpt":0.36469278569025354,"score_spread":0.2691599581797038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124790920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9193405,0.07872982,0.0000041874637,0.0010587585,0.00013530973,0.0003790132,0.000022706605,0.000007705038,0.0003219811],"genre_scores_gemma":[0.9970807,0.0024084367,0.0000034801535,0.0003241021,0.000031000145,0.000026206728,0.000007812583,0.000013473192,0.0001047893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998322,0.0006291812,0.00031164382,0.0003051648,0.00022866453,0.00020332007],"domain_scores_gemma":[0.9986918,0.000089030524,0.0001373058,0.000571614,0.00036571067,0.00014454803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000288991,0.00013850148,0.00040848163,0.0002942057,0.000118210235,0.0000070688857,0.0002000684,0.000058707872,0.00014172676],"category_scores_gemma":[0.00008942112,0.00007464262,0.000317006,0.0017411865,0.00059194525,0.000051284158,0.00011518523,0.00018924635,0.0000012407011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013273882,0.0016248382,0.9596206,0.000070055954,0.0015162106,0.000002650814,0.00045026705,0.0000035933933,0.015096063,0.00011784505,0.000027412167,0.020143073],"study_design_scores_gemma":[0.0011032053,0.0003273108,0.9627899,0.000042636533,0.0027717045,0.0000025666436,0.000067322406,0.0006225346,0.031520776,0.00004841483,0.0006409331,0.0000627067],"about_ca_topic_score_codex":0.000017497534,"about_ca_topic_score_gemma":0.00004323177,"teacher_disagreement_score":0.077740185,"about_ca_system_score_codex":0.0000024289764,"about_ca_system_score_gemma":0.00024518702,"threshold_uncertainty_score":0.30438378},"labels":[],"label_agreement":null},{"id":"W3138642635","doi":"10.1007/s40120-021-00238-3","title":"Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach","year":2021,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"Biogen","keywords":"Medicine; Discontinuation; Delphi method; Tolerability; Delphi; Internal medicine; Adverse effect","score_opus":0.11435784276983815,"score_gpt":0.37110336991867643,"score_spread":0.25674552714883825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138642635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95165926,0.0031046895,0.00015483494,0.020862116,0.0001623519,0.0006165976,0.00001151843,0.000059373582,0.023369255],"genre_scores_gemma":[0.9881461,0.006553681,0.00085947197,0.0038247325,0.00012463333,0.00010496453,0.000017205455,0.000014612681,0.00035457773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998301,0.00029755617,0.00021119195,0.00059198006,0.00024588456,0.0003523625],"domain_scores_gemma":[0.99904096,0.00015367518,0.00010413392,0.00044948564,0.00012056216,0.00013115573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027783777,0.00018282665,0.00036876532,0.000040034214,0.000142546,0.000029593095,0.00010406514,0.00011867995,0.0001269167],"category_scores_gemma":[0.000110590714,0.0001454278,0.00008331515,0.00018356666,0.00026532242,0.00007618647,0.00009016197,0.0003015746,0.000016539],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016506322,0.0066427886,0.47350472,0.0005550989,0.0023083882,0.0009988506,0.0026693698,0.000027956567,0.00275979,0.0026887818,0.0036785486,0.48765936],"study_design_scores_gemma":[0.0104851825,0.0040051993,0.79766554,0.000033349057,0.00017598043,0.00038193073,0.000804748,0.0008525309,0.00036411246,0.00032559503,0.18460506,0.00030079458],"about_ca_topic_score_codex":0.000054941396,"about_ca_topic_score_gemma":0.000037541155,"teacher_disagreement_score":0.48735857,"about_ca_system_score_codex":0.000022446451,"about_ca_system_score_gemma":0.000043440632,"threshold_uncertainty_score":0.59303737},"labels":[],"label_agreement":null},{"id":"W3183672670","doi":"10.1007/s40120-021-00264-1","title":"How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma","keywords":"Medicine; Systematic review; MEDLINE; Reimbursement; Health technology; Family medicine; Cohort study; Health care; Pathology; Political science","score_opus":0.11775590514556157,"score_gpt":0.37728595010986177,"score_spread":0.2595300449643002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183672670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012430013,0.9936577,0.0000014925369,0.0015719952,0.00015857416,0.0043315124,0.00005431534,0.000033084634,0.00006704335],"genre_scores_gemma":[0.000054851196,0.9968619,0.000050537245,0.0011176266,0.00014579637,0.0010736432,0.00018661356,0.0000664645,0.00044259222],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959646,0.0018809226,0.0007417106,0.0007664087,0.00024528176,0.0004011171],"domain_scores_gemma":[0.9971823,0.0015193635,0.0003545697,0.0006997874,0.000119274366,0.00012470469],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000989977,0.0005044726,0.003745865,0.0003560169,0.0001311165,0.00009605945,0.00016439719,0.00048807834,0.0001314906],"category_scores_gemma":[0.0012200545,0.0003596281,0.0005137714,0.00030273484,0.0001433483,0.00010734273,0.000110377914,0.0011308339,0.00002959457],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009111923,0.00018546564,0.0004028116,0.58521944,0.0011210603,0.00016655684,0.00022506608,5.2569777e-7,0.000034036846,0.000015199,0.0032030072,0.4093357],"study_design_scores_gemma":[0.0021340877,0.00030838477,0.0006638905,0.72023976,0.00080964173,0.0002371076,0.000004933739,0.00032981462,8.6010056e-7,0.000006470395,0.2749455,0.00031956774],"about_ca_topic_score_codex":0.0000060704688,"about_ca_topic_score_gemma":0.000024034824,"teacher_disagreement_score":0.40901613,"about_ca_system_score_codex":0.00009039934,"about_ca_system_score_gemma":0.00024305779,"threshold_uncertainty_score":0.99988556},"labels":[],"label_agreement":null},{"id":"W3201511800","doi":"10.1007/s40120-021-00274-z","title":"Systematic Review of Exercise Studies in Persons with Multiple Sclerosis: Exploring the Quality of Interventions According to the Principles of Exercise Training","year":2021,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; CINAHL; Physical therapy; MEDLINE; Psychological intervention; Aerobic exercise; Exercise prescription; Randomized controlled trial; Sports medicine; Medical prescription; Intervention (counseling); Clinical trial; Physical medicine and rehabilitation; Alternative medicine; Systematic review; Internal medicine; Pathology","score_opus":0.6117735547135543,"score_gpt":0.46962414539215125,"score_spread":0.14214940932140308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201511800","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011219967,0.9836674,0.0000053103654,0.00041984784,0.0000793891,0.0045559118,0.000033324417,0.000009460848,0.000009434062],"genre_scores_gemma":[0.016758746,0.98026353,0.000058221347,0.00006463268,0.000017845321,0.0027864517,0.000005036993,0.000029086239,0.000016437156],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959455,0.0014350965,0.001605274,0.00037628034,0.0003770724,0.00026074715],"domain_scores_gemma":[0.99513274,0.0028948612,0.000895634,0.000735396,0.00028944644,0.000051901687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031709499,0.0003203754,0.004690773,0.00021847135,0.000118938726,0.0000060664242,0.000331975,0.00007896768,0.00000532923],"category_scores_gemma":[0.0027021708,0.00014707538,0.0006339708,0.000634153,0.0004925846,0.000047508798,0.00024438836,0.00050268037,3.8446532e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013105305,0.00014200524,0.0005318546,0.9074513,0.0010075441,0.000004362002,0.0054926733,0.0000020710447,0.000009436152,0.00002786454,0.000009208069,0.08519067],"study_design_scores_gemma":[0.0006293524,0.00038793506,0.0014350429,0.98948586,0.0012017955,0.000013432806,0.00583047,0.0000026493724,0.000012657377,0.0000010600306,0.0008902758,0.00010947124],"about_ca_topic_score_codex":0.00004483125,"about_ca_topic_score_gemma":0.000059491555,"teacher_disagreement_score":0.0850812,"about_ca_system_score_codex":0.000017049708,"about_ca_system_score_gemma":0.000114985625,"threshold_uncertainty_score":0.599756},"labels":[],"label_agreement":null},{"id":"W3209567033","doi":"10.1007/s40120-021-00293-w","title":"Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework","year":2021,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ontario Centre of Innovation; Ontario Centres of Excellence","keywords":"Cannabis; Observational study; Medicine; Action (physics); Test (biology); Electroencephalography; Neurology; Psychiatry; Internal medicine; Biology","score_opus":0.17927169245526403,"score_gpt":0.3831984949532664,"score_spread":0.20392680249800238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209567033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956004,0.00016197158,0.000015386704,0.00349612,0.00003655166,0.00066648744,0.000013797551,0.0000059259883,0.0000033765066],"genre_scores_gemma":[0.99861103,0.00009223763,0.000023170107,0.0011737588,0.000012891241,0.00004966041,0.0000034438738,0.000012306036,0.000021510197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998755,0.00042928974,0.00017815847,0.00027191846,0.00021927437,0.00014636028],"domain_scores_gemma":[0.99793774,0.0014763152,0.00014163274,0.00023866311,0.00016476867,0.000040903393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041486887,0.00013803487,0.00024773003,0.000054011853,0.00017900462,0.000030679985,0.00007886251,0.00009930336,0.00000704251],"category_scores_gemma":[0.00055919157,0.00006830451,0.000031423653,0.00025161935,0.00044403286,0.000105040024,0.00003500095,0.00052706705,4.697447e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009306457,0.00048765555,0.97961587,0.00002187735,0.000073688156,0.0000061859955,0.007407707,0.000043598953,0.009051564,0.00006193436,0.000009098839,0.0022902014],"study_design_scores_gemma":[0.0015846246,0.0015198195,0.9867106,0.000034325294,0.00003642033,0.000017374601,0.0013174016,0.0020329088,0.0065781972,0.0000785551,0.000031856638,0.00005792257],"about_ca_topic_score_codex":0.0003763791,"about_ca_topic_score_gemma":0.00031505173,"teacher_disagreement_score":0.0070947516,"about_ca_system_score_codex":0.0000069412263,"about_ca_system_score_gemma":0.00013010524,"threshold_uncertainty_score":0.27853772},"labels":[],"label_agreement":null},{"id":"W4210816119","doi":"10.1007/s40120-022-00326-y","title":"Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute on Aging; University of Southampton","keywords":"Receiver operating characteristic; Cutoff; Medicine; Dementia; Internal medicine; Clinical Dementia Rating; Neurology; Disease; Population; Alzheimer's disease; Psychiatry","score_opus":0.07268052579107506,"score_gpt":0.3558980312520183,"score_spread":0.28321750546094326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210816119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989494,0.0031754167,0.00021000455,0.00624653,0.00006753085,0.00048077333,0.0002135017,0.00003078502,0.000081413564],"genre_scores_gemma":[0.99219877,0.00042419301,0.000015680493,0.006986308,0.000059372494,0.00003632447,0.00022579041,0.000012991707,0.00004057716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982978,0.00047551637,0.00012565222,0.0004914254,0.0003470728,0.00026251844],"domain_scores_gemma":[0.99896616,0.000079404956,0.000054762637,0.000639449,0.00005098758,0.00020923317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040744906,0.0001258648,0.00021401388,0.00013939904,0.0008073052,0.000031279535,0.00024192744,0.000016851332,0.00051778497],"category_scores_gemma":[0.000020912625,0.000091976945,0.00008633854,0.000466262,0.00022978112,0.000086827524,0.00045138027,0.00042950505,0.0000012365912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003914545,0.00026946396,0.9912652,0.000004481885,0.000959834,0.00029000727,0.000102395985,0.000029127032,0.00019618719,0.00006969649,0.00008568412,0.0028133981],"study_design_scores_gemma":[0.0011508161,0.00029453693,0.9773695,0.0000018835921,0.0013141255,0.000016156995,0.000036342502,0.01751577,0.000014600246,0.00045481615,0.0017497503,0.000081701706],"about_ca_topic_score_codex":0.000068406385,"about_ca_topic_score_gemma":0.0000040372665,"teacher_disagreement_score":0.017486641,"about_ca_system_score_codex":0.00001225893,"about_ca_system_score_gemma":0.00010098497,"threshold_uncertainty_score":0.620922},"labels":[],"label_agreement":null},{"id":"W4213217769","doi":"10.1007/s40120-022-00335-x","title":"The Humanistic and Economic Burden of Alzheimer's Disease","year":2022,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Quality of life (healthcare); Dementia; Medicine; Caregiver burden; Disease; Gerontology; Cognition; Disease burden; Activities of daily living; Comorbidity; Clinical psychology; Psychiatry; Internal medicine","score_opus":0.05961626731245458,"score_gpt":0.3671856582136772,"score_spread":0.30756939090122265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213217769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002751423,0.99538225,1.9508978e-7,0.00045550126,0.00009494781,0.00064357236,0.00001917292,0.0000074728205,0.00064547296],"genre_scores_gemma":[0.0024333561,0.99691176,4.7076466e-7,0.00022145643,0.00009245352,0.00012696312,0.00002667872,0.000018058543,0.00016879343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990827,0.00025212986,0.00019655684,0.00023312791,0.00008066331,0.00015482646],"domain_scores_gemma":[0.9992755,0.00035417435,0.00009390114,0.0001810525,0.000009054183,0.00008632827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022188685,0.00013997233,0.00049377844,0.00006459231,0.00017970063,0.00001197474,0.00007921038,0.000056756966,0.0005217659],"category_scores_gemma":[0.000015033509,0.00008535581,0.00010708731,0.000028261404,0.00029491418,0.000011212516,0.000079238445,0.0003049198,0.0000059670924],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002525284,0.000027901502,0.00038884918,0.00041002576,0.00035370287,0.00004426839,0.000014430115,1.9287487e-8,2.4482958e-7,0.00049479824,0.00012105499,0.9978922],"study_design_scores_gemma":[0.0004906451,0.0009304624,0.0018794512,0.00006146644,0.000563349,0.00006794438,0.00000382226,0.0000047722037,2.3472913e-7,0.0002848742,0.99565494,0.000058034217],"about_ca_topic_score_codex":0.000011762463,"about_ca_topic_score_gemma":8.006425e-7,"teacher_disagreement_score":0.99783415,"about_ca_system_score_codex":0.0000035862763,"about_ca_system_score_gemma":0.00014080867,"threshold_uncertainty_score":0.57129705},"labels":[],"label_agreement":null},{"id":"W4220742828","doi":"10.1007/s40120-022-00341-z","title":"COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Sanofi Genzyme; Greenwich Biosciences; EMD Serono; National Institutes of Health; Genentech; Multiple Sclerosis Society; International Progressive MS Alliance; Race to Erase MS; TG Therapeutics; Bristol-Myers Squibb; University of Miami; Biogen; Celgene; Alexion Pharmaceuticals; U.S. Department of Defense; Conrad N. Hilton Foundation; Sanofi; National Multiple Sclerosis Society; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries","keywords":"Medicine; Vaccination; Ofatumumab; Coronavirus disease 2019 (COVID-19); Multiple sclerosis; Internal medicine; Pandemic; Pediatrics; Disease; Immunology; Rituximab","score_opus":0.05366258251714152,"score_gpt":0.3011824989109759,"score_spread":0.24751991639383442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220742828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894118,0.00071396027,0.000016160042,0.009100503,0.00001783007,0.0005786452,0.000007918982,0.000045945402,0.000107258966],"genre_scores_gemma":[0.9937291,0.0022363854,0.00006404223,0.0036905648,0.000008912034,0.00017353785,0.000012290878,0.000018570101,0.000066605586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989036,0.00022938102,0.000121324294,0.0003270206,0.00019442063,0.00022429724],"domain_scores_gemma":[0.9992148,0.00043609418,0.000050041817,0.00014526371,0.000030358096,0.00012341866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022814266,0.00013470244,0.0002950433,0.00019300486,0.00033816672,0.000010884483,0.000043594002,0.000043041826,0.00011775686],"category_scores_gemma":[0.00015546627,0.00009117575,0.000016244489,0.00025987072,0.00009465084,0.000055730783,0.000057649806,0.0003396073,3.8828787e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005895737,0.0001631285,0.9834507,0.00001912572,0.00006847023,0.000037613878,0.0012320718,0.00005855069,0.0014519806,0.000012773662,0.00006778776,0.007542024],"study_design_scores_gemma":[0.013939824,0.0028746093,0.98082024,0.0000056591925,0.0000122644215,0.00007899446,0.00018304726,0.0007119575,0.00009046743,0.000016126043,0.0011812589,0.00008552651],"about_ca_topic_score_codex":0.000511809,"about_ca_topic_score_gemma":0.0010325115,"teacher_disagreement_score":0.008044087,"about_ca_system_score_codex":0.00004329311,"about_ca_system_score_gemma":0.000076389566,"threshold_uncertainty_score":0.37180394},"labels":[],"label_agreement":null},{"id":"W4220907749","doi":"10.1007/s40120-022-00340-0","title":"Correction to: Staging Disease Severity Using the Alzheimer’s Disease Composite Score (ADCOMS): A Retrospective Data Analysis","year":2022,"lang":"en","type":"erratum","venue":"Neurology and Therapy","topic":"Healthcare Systems and Public Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"University of Southampton","keywords":"Medicine; Neurology; Disease; Internal medicine; Retrospective cohort study; Psychiatry","score_opus":0.09003641099511255,"score_gpt":0.3756017194699634,"score_spread":0.28556530847485084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220907749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5452045,0.09151725,0.0019624222,0.18447065,0.15347463,0.010790344,0.008541058,0.00072964374,0.0033094892],"genre_scores_gemma":[0.8923839,0.010709342,0.00004387435,0.0763887,0.005464897,0.00019429173,0.008075028,0.00018745026,0.0065525617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590445,0.0013677557,0.00047758233,0.0012021394,0.00051794056,0.0005301499],"domain_scores_gemma":[0.99657816,0.00020122582,0.00029889776,0.0018477925,0.00015150169,0.0009224324],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011190643,0.0003836745,0.0009134898,0.00041046398,0.0010757844,0.00006390674,0.00040472293,0.00021218785,0.0003011463],"category_scores_gemma":[0.00018125368,0.0002878373,0.0001886362,0.0010282275,0.00014675072,0.000105673644,0.00032512652,0.0023279432,0.000002364801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004462338,0.0002796146,0.56475526,0.00019310764,0.0023469354,0.0005847351,0.0008408039,0.00006182105,0.0000046976074,0.000076800636,0.41357353,0.012820357],"study_design_scores_gemma":[0.00039088848,0.00032899636,0.6108412,0.000045452976,0.0010935657,0.000039226084,0.00002678774,0.0123547325,1.0067177e-7,0.00003923838,0.37465435,0.00018543363],"about_ca_topic_score_codex":0.006325155,"about_ca_topic_score_gemma":0.0004546454,"teacher_disagreement_score":0.34717935,"about_ca_system_score_codex":0.00009453911,"about_ca_system_score_gemma":0.0019332899,"threshold_uncertainty_score":0.9999737},"labels":[],"label_agreement":null},{"id":"W4221041873","doi":"10.1007/s40120-022-00338-8","title":"Alzheimer’s Disease: Epidemiology and Clinical Progression","year":2022,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Dementia; Medicine; Epidemiology; Cognitive decline; Disease; Neurodegeneration; Neurology; Alzheimer's disease; Biomarker; Gerontology; Internal medicine; Psychiatry; Biology","score_opus":0.2497319148056762,"score_gpt":0.5273113714621325,"score_spread":0.2775794566564563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221041873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016455188,0.9949421,0.0000013550866,0.0014779782,0.00023271459,0.0012327353,0.000011604142,0.000034366898,0.0004215762],"genre_scores_gemma":[0.000115158466,0.9953244,0.000015539481,0.0037638799,0.00021330055,0.00027608976,0.00012459705,0.000031625896,0.00013544936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99614614,0.0022464192,0.0004965661,0.0006387182,0.00012573469,0.00034639245],"domain_scores_gemma":[0.99754757,0.0016940037,0.00017379694,0.0002449299,0.000018896875,0.00032078035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013414267,0.00025432959,0.0013844811,0.00012655299,0.0001567,0.0000060065095,0.00008901438,0.00028202037,0.0008999914],"category_scores_gemma":[0.0002545318,0.00016752991,0.00024168265,0.00009097193,0.0004808501,0.000020823582,0.00016482883,0.001109031,0.000013707405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062802475,0.00021153012,0.05358667,0.0004949376,0.00034698288,0.00020842707,0.0000026390442,6.19842e-10,2.1042645e-8,0.000099944635,0.0003902351,0.9440306],"study_design_scores_gemma":[0.0009767269,0.003190347,0.040222596,0.00019986209,0.00082316657,0.000291979,7.0947823e-7,0.0000026357545,3.3190705e-8,0.00026700695,0.953915,0.00010995928],"about_ca_topic_score_codex":0.0000015893911,"about_ca_topic_score_gemma":2.0574436e-7,"teacher_disagreement_score":0.95352477,"about_ca_system_score_codex":0.000003253063,"about_ca_system_score_gemma":0.00017613961,"threshold_uncertainty_score":0.9854275},"labels":[],"label_agreement":null},{"id":"W4224223845","doi":"10.1007/s40120-022-00351-x","title":"Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson’s Disease-Related Pill Burden Reduction in Advanced Parkinson’s Disease: A Retrospective Real-World Cohort Study","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; University of Toronto","funders":"AbbVie","keywords":"Medicine; Pill; Deep brain stimulation; Parkinson's disease; Retrospective cohort study; Cohort; Enteral administration; Internal medicine; Pediatrics; Disease; Parenteral nutrition; Pharmacology","score_opus":0.014683356933362493,"score_gpt":0.2930636290510469,"score_spread":0.2783802721176844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224223845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995486,0.0008450509,0.0000011113705,0.00068928784,0.0001649693,0.00263148,0.000019762392,0.00003765324,0.0001246474],"genre_scores_gemma":[0.9986567,0.00057722256,0.0000024531682,0.0002975943,0.000018085513,0.00032271433,0.00007043033,0.000019448207,0.000035388304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735856,0.0012594528,0.00026272863,0.00068044517,0.00023728739,0.00020151878],"domain_scores_gemma":[0.9991882,0.00029364962,0.00013622854,0.00021643072,0.000039266277,0.00012622337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027192733,0.0002280198,0.0005582491,0.00020775682,0.00017477486,0.0000060663,0.000047279387,0.00004216732,0.00004940752],"category_scores_gemma":[0.00003425686,0.0001931989,0.000057791105,0.00027465555,0.00013046946,0.000059163383,0.00005177931,0.0003732974,6.467462e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04746953,0.001657629,0.9459861,0.0000151161385,0.0001238068,0.00032693686,0.00055192877,0.0016630621,0.001033366,0.000109267836,0.000007256246,0.0010559863],"study_design_scores_gemma":[0.009683067,0.00888594,0.9761246,0.00001736468,0.00008095056,0.000008896476,0.000061214756,0.0016899401,0.00003707961,0.0031851646,0.00010354729,0.00012224066],"about_ca_topic_score_codex":0.00016697377,"about_ca_topic_score_gemma":0.000057919024,"teacher_disagreement_score":0.03778646,"about_ca_system_score_codex":0.000058735517,"about_ca_system_score_gemma":0.000024633038,"threshold_uncertainty_score":0.7878423},"labels":[],"label_agreement":null},{"id":"W4224862282","doi":"10.1007/s40120-022-00350-y","title":"Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Medicine; Dementia; Disease; Neurology; Internal medicine; Alzheimer's disease; Quality of life (healthcare); Cognitive decline; Oncology; Pediatrics; Psychiatry","score_opus":0.05726727534140876,"score_gpt":0.3496279505558316,"score_spread":0.2923606752144229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224862282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454594,0.0044822814,0.000029404056,0.00033498483,0.000023005083,0.00054950215,0.000020415442,0.0000107596725,0.0000037334987],"genre_scores_gemma":[0.9991206,0.0000897661,0.000012928034,0.000690811,0.00000668588,0.0000184269,0.00004509712,0.000014858016,8.4140964e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910706,0.00013902954,0.00014868479,0.00019497391,0.00021622793,0.00019401486],"domain_scores_gemma":[0.9995852,0.000038550443,0.000060012306,0.00013852124,0.000032501703,0.0001451962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006643586,0.0000953533,0.00021933489,0.00012040585,0.000114443144,0.0000031696686,0.000033860342,0.000019595476,0.00002924259],"category_scores_gemma":[0.0000039896763,0.000073784475,0.000030725598,0.00009708796,0.00004495707,0.000050667226,0.000025828744,0.00014226479,3.370318e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071435883,0.00071734586,0.9779514,0.000008113783,0.0006026616,0.000051013685,0.00009448996,0.010821412,7.4721606e-7,0.0000069422267,2.8775102e-7,0.0026019744],"study_design_scores_gemma":[0.0057426114,0.0021257908,0.9755598,0.000005596081,0.000066155706,0.0000014854334,0.0000025429688,0.01639628,0.0000012999757,0.000050649218,9.854064e-7,0.000046801302],"about_ca_topic_score_codex":0.000111250134,"about_ca_topic_score_gemma":0.000004368063,"teacher_disagreement_score":0.0055748685,"about_ca_system_score_codex":0.000013282556,"about_ca_system_score_gemma":0.0001345178,"threshold_uncertainty_score":0.30088434},"labels":[],"label_agreement":null},{"id":"W4225326898","doi":"10.1007/s40120-022-00346-8","title":"Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab","year":2022,"lang":"en","type":"erratum","venue":"Neurology and Therapy","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Multiple sclerosis; Coronavirus disease 2019 (COVID-19); Ofatumumab; Neurology; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccination; MEDLINE; Natalizumab; Pandemic; Virology; Family medicine; Internal medicine; Immunology; Psychiatry","score_opus":0.038334396382768955,"score_gpt":0.3130202134119375,"score_spread":0.2746858170291685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225326898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99090075,0.0013753395,0.000040128056,0.0031193297,0.0019191536,0.0011042942,0.00001174705,0.000098402634,0.0014308675],"genre_scores_gemma":[0.8716142,0.0013714234,0.000025505518,0.12248088,0.0001772083,0.00042194512,0.000107570544,0.00011598587,0.00368525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825627,0.00026578817,0.00020383373,0.00065575587,0.0002977963,0.00032058076],"domain_scores_gemma":[0.99896806,0.0005075208,0.00010545165,0.00027250874,0.00006467648,0.00008178186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025770164,0.00029939573,0.00057397445,0.00058544026,0.0002459897,0.000032644402,0.000086195854,0.00029825768,0.00005360335],"category_scores_gemma":[0.00022199335,0.0002192953,0.0000380678,0.0005454337,0.00007199146,0.00006659891,0.00004932864,0.0013148604,0.0000019074819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0132872965,0.00020597741,0.95309156,0.0000769277,0.00011538535,0.00015882158,0.0009654999,0.000006006037,0.000495839,0.000004084622,0.0218746,0.009717981],"study_design_scores_gemma":[0.009491338,0.0063979896,0.75884336,0.000055550358,0.00005087123,0.00029917096,0.0000884122,0.0005943959,0.00016823955,0.000017066925,0.22375022,0.00024338595],"about_ca_topic_score_codex":0.0020670947,"about_ca_topic_score_gemma":0.0055977,"teacher_disagreement_score":0.20187561,"about_ca_system_score_codex":0.000114048446,"about_ca_system_score_gemma":0.00042085047,"threshold_uncertainty_score":0.8942603},"labels":[],"label_agreement":null},{"id":"W4226000077","doi":"10.1007/s40120-022-00343-x","title":"Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Pharmacokinetics; Medicine; Neurology; Pharmacology; Phase (matter); Internal medicine; Chemistry; Psychiatry","score_opus":0.08842120990572219,"score_gpt":0.40617810077464206,"score_spread":0.3177568908689199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226000077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945795,0.0020700456,0.000063702784,0.0025751337,0.00013279937,0.00039139314,0.00004362642,0.0000083042105,0.00013551617],"genre_scores_gemma":[0.9940649,0.0040336624,0.000020663412,0.0017446174,0.00007817055,0.000025607053,0.000013370428,0.0000055973132,0.000013413374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994555,0.000075905984,0.00017852477,0.0001118782,0.00009422592,0.00008393996],"domain_scores_gemma":[0.99942553,0.00032849095,0.00012533489,0.000050906783,0.000032578908,0.000037136157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014028342,0.000063591106,0.00018657865,0.00006204514,0.00009662441,0.0000018331918,0.000023261382,0.00003150761,0.00024022629],"category_scores_gemma":[0.000026675021,0.000053458898,0.000028015342,0.00012415755,0.00006294532,0.00003491145,0.000030769865,0.00017291018,1.3645672e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6803805,0.007343655,0.023865983,0.00022105816,0.00084756553,0.000035374334,0.0010989617,0.000118994714,0.2526602,0.004451388,0.00085954415,0.02811677],"study_design_scores_gemma":[0.76261026,0.053494677,0.08270554,0.0000055489077,0.0012849122,0.0003202626,0.00023102993,0.010016561,0.006917053,0.0029551282,0.079121545,0.0003374749],"about_ca_topic_score_codex":0.0000079867905,"about_ca_topic_score_gemma":4.4363534e-7,"teacher_disagreement_score":0.24574316,"about_ca_system_score_codex":0.000001922126,"about_ca_system_score_gemma":0.00001738487,"threshold_uncertainty_score":0.26303095},"labels":[],"label_agreement":null},{"id":"W4229062821","doi":"10.1007/s40120-022-00352-w","title":"Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute on Aging","keywords":"Dementia; Clinical Dementia Rating; Medicine; Clinical trial; Neuroimaging; Disease; Neurology; Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; Rating scale; Receiver operating characteristic; Internal medicine; Psychology; Psychiatry; Developmental psychology","score_opus":0.09013134555555159,"score_gpt":0.40435803474261006,"score_spread":0.3142266891870585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229062821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869442,0.0012764307,0.000015556785,0.010572263,0.0002451169,0.00041858747,0.0000043144014,0.000012230083,0.0005113063],"genre_scores_gemma":[0.98884004,0.00018713412,0.0000035244082,0.010785336,0.00006694889,0.000051437728,0.0000042898173,0.00000928763,0.00005198746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834394,0.0008601387,0.00018945006,0.000187572,0.00026067343,0.0001582492],"domain_scores_gemma":[0.99926186,0.0003195807,0.00007574635,0.000245093,0.000044037002,0.000053694832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069472747,0.0000774578,0.00015586996,0.000027510061,0.0005015194,0.000017165963,0.0001645524,0.000026464983,0.00027367182],"category_scores_gemma":[0.000035712794,0.000041256168,0.000102119004,0.00012226042,0.00038056695,0.000039539984,0.00018018669,0.000506495,0.0000013069443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011781307,0.00028464687,0.9497328,0.0000047049034,0.00010917858,0.000031179516,0.000072591225,0.0000028432107,0.0005404573,0.00035701078,0.0001849199,0.047501586],"study_design_scores_gemma":[0.0015619044,0.0007254637,0.98833394,0.0000048531406,0.000094399606,0.000047005273,0.000041472038,0.00017612551,0.00036292765,0.00065729755,0.00795468,0.000039958246],"about_ca_topic_score_codex":0.0000059166887,"about_ca_topic_score_gemma":4.64441e-7,"teacher_disagreement_score":0.047461625,"about_ca_system_score_codex":0.0000019871857,"about_ca_system_score_gemma":0.00009045656,"threshold_uncertainty_score":0.38573328},"labels":[],"label_agreement":null},{"id":"W4247759492","doi":"10.1007/s40120-020-00178-4","title":"Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials","year":2020,"lang":"en","type":"erratum","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Fingolimod; Relapsing remitting; Multiple sclerosis; Medicine; Neurology; Term (time); Internal medicine; Pediatrics; Oncology; Immunology; Psychiatry","score_opus":0.03766881059752894,"score_gpt":0.2968666545273557,"score_spread":0.2591978439298268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247759492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98306113,0.003335602,0.000029404237,0.0009678061,0.009395215,0.0028818084,0.00019592614,0.000051576873,0.00008153579],"genre_scores_gemma":[0.98133343,0.015631815,0.00002419436,0.0003799178,0.00089074817,0.0004533729,0.0010199364,0.00007495886,0.00019160661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99507,0.001984016,0.0008835199,0.00095783186,0.0005860154,0.0005186203],"domain_scores_gemma":[0.9916056,0.006670531,0.00066394283,0.0006052037,0.0002620914,0.00019264534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074851804,0.00063629315,0.0024952758,0.00043011789,0.00023129027,0.000035185058,0.00024113664,0.0004994884,0.00002788078],"category_scores_gemma":[0.004149568,0.00036435135,0.00046389486,0.00088621565,0.00032448082,0.000054378903,0.000112270405,0.0012635041,0.0000039045713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09643284,0.00033017664,0.8562078,0.000034398137,0.01007726,0.000020432675,0.0014622621,0.00006121206,0.0005471087,1.4333592e-7,0.0063137,0.028512653],"study_design_scores_gemma":[0.037784934,0.017784925,0.93904275,0.00030826783,0.003295976,9.708226e-7,0.00002686441,0.0011817528,0.00023946741,6.3421686e-7,0.00009829297,0.00023517858],"about_ca_topic_score_codex":0.006675182,"about_ca_topic_score_gemma":0.014563583,"teacher_disagreement_score":0.08283492,"about_ca_system_score_codex":0.00009942014,"about_ca_system_score_gemma":0.000110671805,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W4281644083","doi":"10.1007/s40120-022-00366-4","title":"Therapeutic Decision-Making Under Uncertainty in the Management of Spinal Muscular Atrophy: Results From DECISIONS-SMA Study","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; St. Michael's Hospital","funders":"Roche","keywords":"Spinal muscular atrophy; SMA*; Medicine; Neurology; Physical medicine and rehabilitation; Neuroscience; Physical therapy; Pathology; Psychology; Computer science; Disease; Psychiatry","score_opus":0.04258665417488318,"score_gpt":0.34644262919573465,"score_spread":0.3038559750208515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281644083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931735,0.0038814805,0.00018945105,0.0015356367,0.000091053065,0.000985398,0.000007330225,0.000008688887,0.00012747891],"genre_scores_gemma":[0.9948765,0.0019207239,0.000084278145,0.0029885946,0.000018539718,0.000085953274,0.0000056157096,0.000014360882,0.0000054375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979883,0.0006118566,0.00028527217,0.0003981025,0.0005060775,0.0002103995],"domain_scores_gemma":[0.9988747,0.0004920165,0.00005881619,0.0005196135,0.000023181701,0.000031675132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006593143,0.00012439306,0.00023154702,0.00013478691,0.00019241366,0.000008742313,0.00026245517,0.000035232533,0.00010557637],"category_scores_gemma":[0.00001848951,0.00008329072,0.000083424864,0.00031620025,0.00010446609,0.000013106605,0.00014503994,0.00040285467,0.0000018145631],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051631212,0.0036930034,0.046461854,0.000013674444,0.00085198623,0.002243637,0.0027674611,0.0067048864,0.0016580877,0.0009772273,0.000061792896,0.88293517],"study_design_scores_gemma":[0.0105699375,0.005586835,0.9687136,0.000020097708,0.000076181386,0.00007120035,0.0024932243,0.0005377377,0.000008872192,0.008056623,0.0037639898,0.000101691825],"about_ca_topic_score_codex":0.00008600479,"about_ca_topic_score_gemma":0.000022345966,"teacher_disagreement_score":0.92225176,"about_ca_system_score_codex":0.000008052905,"about_ca_system_score_gemma":0.000028271093,"threshold_uncertainty_score":0.33964968},"labels":[],"label_agreement":null},{"id":"W4282975754","doi":"10.1007/s40120-022-00372-6","title":"Outcomes of Endovascular Therapy in Young Patients with Acute Basilar Artery Occlusion: A Substudy of BASILAR Registry Study","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Laboratoires d'excellence Nanostructures en Interaction avec leur Environnement","keywords":"Medicine; Basilar artery; Neurology; Occlusion; Internal medicine; Cardiology; Psychiatry","score_opus":0.008850043664875747,"score_gpt":0.23489500199660193,"score_spread":0.2260449583317262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282975754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972095,0.0004938052,0.0000070862416,0.0004989241,0.00011527579,0.001376786,0.000014950324,0.000017895232,0.00026577234],"genre_scores_gemma":[0.9980332,0.0004508624,0.00003689494,0.0012819556,0.0000103408565,0.000088360444,0.000014235848,0.000024062241,0.00006004035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843067,0.00024090392,0.00034325203,0.00037042692,0.0004157211,0.0001990438],"domain_scores_gemma":[0.99910814,0.000072501,0.00018963394,0.00053954305,0.00005153179,0.000038680202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030572797,0.00019335379,0.0005792863,0.00018453742,0.00007362139,0.0000023603998,0.00017364405,0.000051958184,0.000115208364],"category_scores_gemma":[0.000009646655,0.00014321282,0.00007966308,0.00023404912,0.0001149774,0.0000313474,0.00013485282,0.00032361786,3.295084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048411526,0.0022234826,0.98777187,0.000008831325,0.00097647955,0.00040981383,0.0013607698,0.000005852713,0.00074930146,0.000007380231,0.000120954704,0.0015241044],"study_design_scores_gemma":[0.016657159,0.008764725,0.9729826,0.000003895126,0.00009037218,0.00006019037,0.0003419555,0.000009887256,0.00042581363,0.000010820203,0.0005638549,0.00008875843],"about_ca_topic_score_codex":0.000053229443,"about_ca_topic_score_gemma":0.000010122209,"teacher_disagreement_score":0.0147893075,"about_ca_system_score_codex":0.000010919978,"about_ca_system_score_gemma":0.000028035229,"threshold_uncertainty_score":0.5840049},"labels":[],"label_agreement":null},{"id":"W4283159318","doi":"10.1007/s40120-022-00373-5","title":"The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Willingness to pay; Medicine; Disease; Quality of life (healthcare); Health care; Quality-adjusted life year; Neurology; Gerontology; Psychiatry; Internal medicine; Cost effectiveness; Economics; Nursing","score_opus":0.01945440523287799,"score_gpt":0.28915242062595764,"score_spread":0.26969801539307964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283159318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99889517,0.00033629904,0.00010485008,0.00026612484,0.00004333324,0.0003251621,0.000003882434,0.0000038468306,0.000021324546],"genre_scores_gemma":[0.99963874,0.000047063066,0.000004636346,0.00026559387,0.000013568268,0.000012505431,0.0000065912923,0.000007266348,0.000004058619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942183,0.00012740924,0.000098935154,0.00012130707,0.00011212053,0.00011840119],"domain_scores_gemma":[0.99979943,0.00003741402,0.00003218176,0.00007488018,0.000022725413,0.000033343662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012350432,0.00004982027,0.000079584315,0.00005538408,0.00014434014,0.000005450533,0.000034991062,0.000013430944,0.00003547416],"category_scores_gemma":[0.0000029713883,0.000035218527,0.000018541812,0.000038114507,0.000051813277,0.000033447,0.000027578717,0.00012500846,3.0522258e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009548123,0.00013634145,0.8425597,0.0000018115363,0.000048070677,0.000008234951,0.00005344382,0.14173843,0.000053801137,0.000054548378,4.7886505e-7,0.0057970467],"study_design_scores_gemma":[0.002753322,0.0012238459,0.6638583,0.0000013749237,0.000024699913,0.0000011844644,0.000007937977,0.3318421,0.000011227495,0.00022232611,0.000027534708,0.00002616006],"about_ca_topic_score_codex":0.000052038646,"about_ca_topic_score_gemma":0.0000016795806,"teacher_disagreement_score":0.19010368,"about_ca_system_score_codex":0.0000063200014,"about_ca_system_score_gemma":0.000055648055,"threshold_uncertainty_score":0.14361697},"labels":[],"label_agreement":null},{"id":"W4283764603","doi":"10.1007/s40120-022-00379-z","title":"Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Eisai Incorporated; National Institute on Aging; National Institutes of Health; Eisai; U.S. Department of Veterans Affairs","keywords":"Concordance; Medicine; Veterans Affairs; Neurology; Health care; Disease; Healthcare system; Gerontology; Family medicine; Psychiatry; Pathology; Internal medicine","score_opus":0.04860978337695539,"score_gpt":0.40361071278878835,"score_spread":0.355000929411833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283764603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932913,0.004091993,0.000010231236,0.001435737,0.00008313508,0.0006820655,0.000025902847,0.0000061109467,0.0003735299],"genre_scores_gemma":[0.9980475,0.0008773007,0.000006611023,0.0009341945,0.000018386292,0.00009863585,0.00000565105,0.000006627417,0.0000051426423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797595,0.0011871831,0.00024542146,0.00022491835,0.00021839161,0.00014816305],"domain_scores_gemma":[0.9993105,0.0003441881,0.00010480235,0.00012587353,0.00006167422,0.00005295598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008562411,0.00007634291,0.0002685627,0.00008053486,0.00008336693,0.0000030650083,0.00006321591,0.000027317177,0.000015508824],"category_scores_gemma":[0.00001731471,0.000055811808,0.00004269131,0.00012507377,0.00022471801,0.000029117533,0.000052883017,0.00036002384,1.1230221e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043423814,0.00024578377,0.98119336,0.000060035545,0.00010102476,0.00008324404,0.00067107065,5.5539493e-7,0.00015013016,0.00050531176,0.0000069888224,0.012640081],"study_design_scores_gemma":[0.002929761,0.0051124347,0.9886199,0.000020467223,0.000035755445,0.000032784654,0.00271904,0.00011120364,0.000091736765,0.00017443266,0.00011632702,0.00003615691],"about_ca_topic_score_codex":0.000083259525,"about_ca_topic_score_gemma":0.000005608969,"teacher_disagreement_score":0.012603925,"about_ca_system_score_codex":0.0000074469913,"about_ca_system_score_gemma":0.000107985994,"threshold_uncertainty_score":0.22759394},"labels":[],"label_agreement":null},{"id":"W4283770967","doi":"10.1007/s40120-022-00376-2","title":"Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”","year":2022,"lang":"en","type":"letter","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Neuromyelitis optica; Medicine; Food and drug administration; Neurology; Spectrum disorder; Aquaporin 4; Drug; Antibody; Immunology; Pharmacology; Psychiatry; Internal medicine","score_opus":0.04097943961968167,"score_gpt":0.29064898686716745,"score_spread":0.24966954724748577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283770967","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036079768,0.0053492314,0.00014412362,0.95357287,0.000402672,0.003388168,0.0009821153,0.000027034053,0.000054017535],"genre_scores_gemma":[0.3458813,0.017317837,0.0010531229,0.60539347,0.01835315,0.008709425,0.0018627344,0.00019293548,0.0012360084],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975377,0.00050464104,0.00038599176,0.0007715018,0.00034817765,0.00045202908],"domain_scores_gemma":[0.9972796,0.0017428182,0.00021967539,0.0005711529,0.00011270402,0.00007408473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027927262,0.00042040803,0.0014577298,0.00021715053,0.0004639031,0.00003721845,0.00015800018,0.00018279004,0.00011008356],"category_scores_gemma":[0.000060886698,0.00023804992,0.0005627297,0.00035969893,0.00027660446,0.00003525661,0.000084278094,0.00077508774,5.0973017e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023110874,0.0005274044,0.0013031814,0.00016014928,0.34385607,0.00020497435,0.0032457786,0.00062925735,0.00008482189,0.00016655921,0.6235647,0.0031461797],"study_design_scores_gemma":[0.0031246988,0.019620834,0.0053124316,0.0000092220025,0.033591032,0.000030529533,0.00005909734,0.00016649973,0.00007419823,0.000038846996,0.93771285,0.00025973588],"about_ca_topic_score_codex":0.000112219706,"about_ca_topic_score_gemma":0.00041995817,"teacher_disagreement_score":0.3481794,"about_ca_system_score_codex":0.000020805788,"about_ca_system_score_gemma":0.00006634243,"threshold_uncertainty_score":0.9707394},"labels":[],"label_agreement":null},{"id":"W4291146664","doi":"10.1007/s40120-022-00393-1","title":"A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Medicine; Disease; Dementia; Alzheimer's disease; Epidemiology; Disease burden; Neurology; Gerontology; Caregiver burden; Indirect costs; Psychiatry; Environmental health; Internal medicine","score_opus":0.05488187758269159,"score_gpt":0.39359092334242146,"score_spread":0.3387090457597299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291146664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728507,0.0004596247,0.000060235066,0.001333231,0.000025102452,0.00075461704,0.00003496378,0.0000049928726,0.0000421917],"genre_scores_gemma":[0.9992006,0.000104075756,0.0000017142464,0.00052634394,0.000015946942,0.00010488655,0.000016642012,0.000009086849,0.000020719155],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.999022,0.0002548753,0.00013189568,0.00017530077,0.00026874206,0.00014718295],"domain_scores_gemma":[0.99958163,0.00009567247,0.000033816188,0.00014923602,0.000042484877,0.0000971833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020060074,0.000085372056,0.00014602412,0.0001301456,0.00009092149,0.0000029567975,0.00006063926,0.00001549347,0.00012296459],"category_scores_gemma":[0.000024237865,0.000055023538,0.00007934104,0.00012232791,0.000055371915,0.000023385897,0.000045266763,0.0001164969,8.2378324e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050112315,0.00087979576,0.16744724,0.000009498453,0.00028217406,0.00005834637,0.0008325105,0.7400594,0.0032443916,0.00004518557,0.000009631777,0.037019566],"study_design_scores_gemma":[0.003713498,0.003379941,0.65236646,0.0000056586623,0.000116741765,0.0000012759564,0.000028651091,0.3394011,0.00009571312,0.0008339208,0.000012784318,0.000044252723],"about_ca_topic_score_codex":0.000059493712,"about_ca_topic_score_gemma":4.504015e-7,"teacher_disagreement_score":0.48491922,"about_ca_system_score_codex":0.000010861251,"about_ca_system_score_gemma":0.000094193536,"threshold_uncertainty_score":0.22437948},"labels":[],"label_agreement":null},{"id":"W4307947172","doi":"10.1007/s40120-022-00408-x","title":"Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient’s Perspective: A Qualitative Study","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Alexion Pharmaceuticals; AstraZeneca","keywords":"Myasthenia gravis; Medicine; Perspective (graphical); Neurology; Qualitative research; Family medicine; Intensive care medicine; Physical therapy; Internal medicine; Psychiatry; Sociology; Artificial intelligence; Social science","score_opus":0.06029704980408308,"score_gpt":0.349289097090994,"score_spread":0.2889920472869109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307947172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036497,0.0020021116,0.0000151210315,0.0067276973,0.00006528456,0.00061457674,0.000048383703,0.000012901779,0.00014898131],"genre_scores_gemma":[0.9987632,0.00016801193,0.000002731529,0.0009328888,0.000058819438,0.000038805123,0.000004067759,0.000015072031,0.000016396143],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9983232,0.00092313724,0.00016242515,0.00025111536,0.00018832798,0.00015179001],"domain_scores_gemma":[0.9988636,0.00070595945,0.000106540545,0.00024633866,0.000035231486,0.000042381278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036923387,0.00013598613,0.0002549802,0.00004544107,0.00042753902,0.00001301213,0.000101817226,0.00003249785,0.0001883121],"category_scores_gemma":[0.000024531457,0.00006788578,0.00007976312,0.00013807816,0.00028110642,0.000023084805,0.00008561098,0.00036998617,4.8520053e-7],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006862393,0.00040844467,0.15698288,0.0000027523918,0.0011111657,0.000064915206,0.81902224,0.00001542285,0.0013084423,0.010201691,0.00029895117,0.0037206814],"study_design_scores_gemma":[0.0069148224,0.024365367,0.48846018,0.000006828646,0.00016823223,0.00022016146,0.4202727,0.00019253223,0.000019479354,0.05804435,0.001154491,0.00018084738],"about_ca_topic_score_codex":0.0013999911,"about_ca_topic_score_gemma":0.000024009789,"teacher_disagreement_score":0.39874953,"about_ca_system_score_codex":0.00002522363,"about_ca_system_score_gemma":0.000038607686,"threshold_uncertainty_score":0.32883278},"labels":[],"label_agreement":null},{"id":"W4309923835","doi":"10.1007/s40120-022-00423-y","title":"Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors","year":2022,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Eisai Incorporated; University of California, San Francisco","keywords":"Neurology; Medicine; Preference; Disease; Neuroscience; Physical medicine and rehabilitation; Psychiatry; Psychology; Internal medicine","score_opus":0.04672954928704472,"score_gpt":0.32257178770880507,"score_spread":0.27584223842176037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309923835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377227,0.0028659818,0.0001964192,0.0022438304,0.00003119865,0.00076764775,0.000062129686,0.000021167547,0.000039359318],"genre_scores_gemma":[0.99613744,0.0020711517,0.00008460681,0.0011839996,0.000015459493,0.00036370978,0.00006487221,0.00000962141,0.000069130445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990819,0.00012765097,0.00008551261,0.00037349644,0.00013423286,0.00019722583],"domain_scores_gemma":[0.99946386,0.00018507025,0.000031335174,0.00014956325,0.00004066467,0.00012948376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007842516,0.00012044835,0.00021142878,0.00014211373,0.00023895122,0.000014469865,0.000044260738,0.00002552932,0.00015558775],"category_scores_gemma":[0.000010255068,0.000081461934,0.000055995577,0.0001520689,0.00013348431,0.000027944378,0.000041940955,0.00009754812,3.7937474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027113345,0.00035552037,0.8795962,0.000005699941,0.0008053461,0.00017997934,0.00021383024,0.0000103278235,0.00022425427,0.00005344346,0.00004711705,0.09139494],"study_design_scores_gemma":[0.0066391183,0.016053662,0.9533843,0.0000011461832,0.0009718775,0.000059584505,0.00004027173,0.0012178897,0.00007498189,0.00013960345,0.021332497,0.00008506697],"about_ca_topic_score_codex":0.000042049007,"about_ca_topic_score_gemma":0.000014360169,"teacher_disagreement_score":0.09130987,"about_ca_system_score_codex":0.000005496619,"about_ca_system_score_gemma":0.000039918697,"threshold_uncertainty_score":0.33219212},"labels":[],"label_agreement":null},{"id":"W4313680745","doi":"10.1007/s40120-022-00436-7","title":"Clinical Burden of Angiographic Vasospasm and Its Complications After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Idorsia Pharmaceuticals","keywords":"Medicine; Subarachnoid hemorrhage; Vasospasm; Neurology; Cardiology; Radiology; Internal medicine; Intensive care medicine","score_opus":0.059842483018534155,"score_gpt":0.3549191436832379,"score_spread":0.2950766606647037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313680745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002350019,0.99239874,0.0000023082757,0.0014084677,0.00008406111,0.0035358192,0.0000622311,0.00009029766,0.00006808483],"genre_scores_gemma":[0.010194541,0.98674864,0.00002430668,0.0013860253,0.00011147618,0.0011985692,0.00009984698,0.00005561155,0.00018100916],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99752396,0.00045937698,0.0010812673,0.00056913,0.00013574795,0.00023051962],"domain_scores_gemma":[0.99818987,0.00048778212,0.00046501958,0.000611912,0.00011317656,0.00013226584],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003311551,0.0003858126,0.0025779936,0.00023117222,0.0000973659,0.000010259697,0.00016897448,0.0003731908,0.000029418783],"category_scores_gemma":[0.000071963885,0.00026940592,0.0005470471,0.00047520455,0.00021590746,0.00003022123,0.00005759456,0.0005173721,0.0000603626],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008567164,0.00024441376,0.00020098647,0.9479424,0.00029415902,0.0002620892,0.000025985686,1.2830277e-8,0.0000017253984,0.00061082764,0.000021593116,0.050310154],"study_design_scores_gemma":[0.014040697,0.02228659,0.026095565,0.5077563,0.1430519,0.076818846,0.000034035067,0.0005167106,0.000004202366,0.003149845,0.20110813,0.005137179],"about_ca_topic_score_codex":0.000005976753,"about_ca_topic_score_gemma":0.0000015808241,"teacher_disagreement_score":0.44018608,"about_ca_system_score_codex":0.0000033991103,"about_ca_system_score_gemma":0.00006185957,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W4317209673","doi":"10.1007/s40120-022-00433-w","title":"Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Pill; Medicine; Parkinson's disease; Deep brain stimulation; Enteral administration; Carbidopa; Polypharmacy; Levodopa; Internal medicine; Disease; Parenteral nutrition; Pharmacology","score_opus":0.015604509761700606,"score_gpt":0.2826522068468737,"score_spread":0.2670476970851731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317209673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800485,0.00028776826,0.000012909915,0.0004925817,0.00009751671,0.0010379492,0.000026570835,0.000025616762,0.000014217575],"genre_scores_gemma":[0.9991197,0.00020854609,0.000017662685,0.00028491084,0.000023698365,0.00009645709,0.0002313378,0.00001410952,0.0000035715498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909717,0.00019308356,0.00011733069,0.00032213324,0.00012724206,0.00014302706],"domain_scores_gemma":[0.9994248,0.000224326,0.00006631561,0.0001123598,0.00007158906,0.00010060773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103759456,0.00014043962,0.00028601562,0.00012931452,0.00005767703,0.0000033903327,0.000023778046,0.0000546181,0.00000394324],"category_scores_gemma":[0.00002081837,0.00010632149,0.000022712684,0.00015072635,0.000047950245,0.00005385173,0.000012114783,0.000083370884,8.9845054e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.102914795,0.0007064109,0.8671395,0.00023759149,0.00017373559,0.00008832159,0.0014599554,0.0013600258,0.005697285,0.00014149406,0.000010693804,0.02007017],"study_design_scores_gemma":[0.013234126,0.0034021828,0.97936076,0.00010059667,0.000039187205,0.0000031161826,0.0000391699,0.002339851,0.0006020617,0.00051612355,0.00028557557,0.000077232944],"about_ca_topic_score_codex":0.000029971307,"about_ca_topic_score_gemma":0.000016863927,"teacher_disagreement_score":0.11222125,"about_ca_system_score_codex":0.000013707631,"about_ca_system_score_gemma":0.000021694364,"threshold_uncertainty_score":0.43356642},"labels":[],"label_agreement":null},{"id":"W4319827031","doi":"10.1007/s40120-023-00445-0","title":"Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"H. Lundbeck A/S; Otsuka Pharmaceutical; Biogen","keywords":"Medicine; Neurology; Disease; Alzheimer's disease; Neuroscience; Gerontology; Psychology; Pathology; Psychiatry","score_opus":0.041159801294563855,"score_gpt":0.3859470541010277,"score_spread":0.34478725280646383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319827031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598342,0.0016749528,0.00020648398,0.037738662,0.000065622036,0.0003429715,0.00000641017,0.0000751318,0.000055522254],"genre_scores_gemma":[0.9803061,0.0020757301,0.000019928459,0.01727357,0.000016695043,0.00006958195,0.00009963882,0.000013349876,0.00012539294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894893,0.00020109666,0.00009608884,0.00030561248,0.00017537356,0.00027287347],"domain_scores_gemma":[0.9994165,0.00018065191,0.000024183033,0.00012783834,0.00005264061,0.00019819377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019217514,0.00010598592,0.00022323293,0.0003252443,0.000109456145,0.00009773546,0.000047551373,0.000041097857,0.00024090761],"category_scores_gemma":[0.000025618012,0.000086904765,0.00007341239,0.0010128277,0.000062695566,0.00018886349,0.000031669526,0.00012846812,0.00007488751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025994047,0.00038459027,0.8977718,0.000020105128,0.002404147,0.00024409937,0.00086186157,0.000009399695,0.023338597,0.00006601509,0.00923872,0.06306126],"study_design_scores_gemma":[0.00095657125,0.0008575253,0.9935765,0.0000078844305,0.0003548041,0.0000037189866,0.00019563061,0.00065607834,0.0004157161,0.00006766937,0.0028306353,0.00007722264],"about_ca_topic_score_codex":0.000021002232,"about_ca_topic_score_gemma":0.000010063792,"teacher_disagreement_score":0.09580474,"about_ca_system_score_codex":0.000002525309,"about_ca_system_score_gemma":0.000024352461,"threshold_uncertainty_score":0.35438734},"labels":[],"label_agreement":null},{"id":"W4320856890","doi":"10.1007/s40120-023-00443-2","title":"Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Clinical Dementia Rating; Dementia; Rating scale; Disease; Psychology; Cognition; Gerontology; Medicine; Alzheimer's disease; Activities of daily living; Neurology; Clinical psychology; Neuroscience; Psychiatry; Internal medicine; Developmental psychology","score_opus":0.09589878507492791,"score_gpt":0.5055491533534149,"score_spread":0.409650368278487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320856890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97928566,0.008660916,0.0000061158935,0.010842734,0.00010678428,0.000558984,0.0000135264945,0.000022136874,0.000503128],"genre_scores_gemma":[0.9217713,0.070059374,0.0000069707517,0.007949123,0.00002933656,0.00003806445,0.000010197855,0.000007113369,0.00012855347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987823,0.00028155668,0.00038151533,0.00016946442,0.00021217152,0.000172987],"domain_scores_gemma":[0.99905246,0.00043533507,0.00010803915,0.00022778363,0.00009481618,0.00008157788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012595529,0.00007514523,0.0003931211,0.000026215477,0.000040758354,0.000002413875,0.00009075658,0.00005673279,0.000108992186],"category_scores_gemma":[0.00022677513,0.000041180963,0.00015782494,0.00014465145,0.0004246679,0.000019737505,0.00007291803,0.00022925397,0.000007900203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068458746,0.00022343297,0.9541323,0.00014347945,0.00014761068,0.000029121804,0.000006940432,6.530997e-9,0.00019594778,0.0000721862,0.0012757368,0.04308862],"study_design_scores_gemma":[0.0015769638,0.0011101583,0.9888016,0.000109689085,0.00008862877,0.0000059929966,0.0000048387997,0.00000506156,0.00015119225,0.00025028046,0.007866734,0.000028884542],"about_ca_topic_score_codex":0.0000032414157,"about_ca_topic_score_gemma":0.0000010822299,"teacher_disagreement_score":0.061398458,"about_ca_system_score_codex":4.6801418e-7,"about_ca_system_score_gemma":0.000051520114,"threshold_uncertainty_score":0.1679311},"labels":[],"label_agreement":null},{"id":"W4321487680","doi":"10.1007/s40120-023-00449-w","title":"Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Pharmacological Receptor Mechanisms and Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Teva Pharmaceutical Industries","keywords":"Medicine; QT interval; Neurology; Pharmacology; Intensive care medicine; Internal medicine; Psychiatry","score_opus":0.02787311845413496,"score_gpt":0.30724032847438015,"score_spread":0.27936721002024517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321487680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293716,0.0007375845,0.000028679004,0.015042468,0.00062634214,0.0004700312,0.000009563531,0.000041516367,0.00010668628],"genre_scores_gemma":[0.9682435,0.007669641,0.000005365755,0.02295062,0.00031974638,0.00011487852,0.00001578411,0.00002010998,0.0006603926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844456,0.0004876646,0.00021471035,0.0004134631,0.00010534181,0.00033423575],"domain_scores_gemma":[0.999141,0.00036813394,0.000088105386,0.0003106768,0.000028785262,0.000063316744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008358064,0.00017732376,0.00016626697,0.00001759448,0.0003106288,0.000022302569,0.00031759538,0.00020183784,0.00008758384],"category_scores_gemma":[0.00009106078,0.00007395857,0.00011080489,0.00008915936,0.00032248115,0.000003005531,0.0002128104,0.00030313473,0.000043265998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002779094,0.00005184178,0.0011707632,0.0000043067475,0.0000915014,0.000015572985,0.000076694276,0.000012956744,0.95738626,0.00019119713,0.001224173,0.03699563],"study_design_scores_gemma":[0.0031094195,0.008022109,0.047961358,0.0000056626304,0.00005596456,0.00007855378,0.000044941047,0.0006493164,0.6022337,0.0040280316,0.3334107,0.00040020226],"about_ca_topic_score_codex":0.0000036262788,"about_ca_topic_score_gemma":0.000012301208,"teacher_disagreement_score":0.35515255,"about_ca_system_score_codex":0.000002340536,"about_ca_system_score_gemma":0.000021770418,"threshold_uncertainty_score":0.3015943},"labels":[],"label_agreement":null},{"id":"W4327682176","doi":"10.1007/s40120-023-00460-1","title":"Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Medicine; Willingness to pay; CLARITY; Quality of life (healthcare); Disease; Caregiver burden; Quality-adjusted life year; Gerontology; Biomarker; Neurology; Psychiatry; Cost effectiveness; Dementia; Internal medicine","score_opus":0.06002915615347265,"score_gpt":0.356793999213452,"score_spread":0.29676484305997936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327682176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992284,0.000118647746,0.00015621481,0.0001403402,0.0000164734,0.00029804834,0.0000026896373,0.000019614936,0.000019528348],"genre_scores_gemma":[0.99967074,0.00004495741,0.000023070124,0.00021414261,0.000008070313,0.000005166759,0.000020430474,0.000009561531,0.000003865005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994332,0.000054794877,0.00009451094,0.0001363906,0.00013781915,0.00014325399],"domain_scores_gemma":[0.9997694,0.000039120874,0.000022765747,0.00005910896,0.000060800612,0.000048833066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085164545,0.00006107991,0.00010911115,0.00009877309,0.000036513895,0.000003837026,0.000019353934,0.000035261877,0.000013564825],"category_scores_gemma":[0.000010633835,0.000047762933,0.000018325647,0.00016691853,0.000055172113,0.0000480748,0.0000125036895,0.000092420974,0.0000014410952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031055037,0.00013780978,0.96861094,0.000008167231,0.00004402347,0.000015660926,0.000099332705,0.024298938,0.00021117038,0.000011032345,5.941093e-7,0.0034568121],"study_design_scores_gemma":[0.0022836113,0.0006400426,0.6049187,0.000009102311,0.000021175496,3.1587993e-7,0.0000026153618,0.39196283,0.000035158242,0.000101611164,0.0000011358223,0.00002369085],"about_ca_topic_score_codex":0.000025902084,"about_ca_topic_score_gemma":5.37281e-7,"teacher_disagreement_score":0.3676639,"about_ca_system_score_codex":0.000002221837,"about_ca_system_score_gemma":0.000036522757,"threshold_uncertainty_score":0.19477159},"labels":[],"label_agreement":null},{"id":"W4327811413","doi":"10.1007/s40120-023-00462-z","title":"Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer’s Disease","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Medicine; Medicaid; Food and drug administration; Disease; Health care; Drug development; Alzheimer's disease; Healthcare system; Neurology; Psychiatry; Drug; Pathology; Pharmacology; Political science","score_opus":0.6795240567739593,"score_gpt":0.5135187704976755,"score_spread":0.16600528627628386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327811413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90899163,0.053446926,0.000040559742,0.036635317,0.0003430731,0.00049240526,0.000006266085,0.000025927826,0.000017887045],"genre_scores_gemma":[0.9773796,0.016431062,0.000052135612,0.0059100185,0.000043110023,0.00015094574,0.0000017870368,0.000011758387,0.000019573665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997698,0.000578065,0.0008421518,0.00061570946,0.000042388783,0.00022368507],"domain_scores_gemma":[0.9968399,0.0026002272,0.00020079238,0.00019989666,0.000027075159,0.00013212915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011479361,0.00011385799,0.00049629755,0.00023951361,0.00017282883,0.0000315072,0.00008612988,0.000064573425,0.000009609711],"category_scores_gemma":[0.0006654783,0.00011219314,0.000017950144,0.00015925763,0.00022039622,0.00015793693,0.00005526937,0.000116429386,0.00012509669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000497097,0.00006609582,0.96477324,0.00011836201,0.00011741943,0.0000120383465,0.0024022313,0.00019561879,0.000001187153,0.022897428,0.000214075,0.008705187],"study_design_scores_gemma":[0.0007274742,0.0002193881,0.9806044,0.00006157138,0.0000024235148,0.0000014172397,0.00008116559,0.00010077728,0.0000015038307,0.011661327,0.0064199134,0.00011865426],"about_ca_topic_score_codex":0.00001480317,"about_ca_topic_score_gemma":0.00010589353,"teacher_disagreement_score":0.06838797,"about_ca_system_score_codex":0.000016344295,"about_ca_system_score_gemma":0.00007924951,"threshold_uncertainty_score":0.45751035},"labels":[],"label_agreement":null},{"id":"W4360600322","doi":"10.1007/s40120-023-00466-9","title":"Design of a Non-Interventional Study to Assess Neurologists’ Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; St. Michael's Hospital","funders":"Roche","keywords":"Neurology; Medicine; Disease; Alternative medicine; Intensive care medicine; Psychiatry; Pathology","score_opus":0.14083120854365191,"score_gpt":0.4333269126382176,"score_spread":0.2924957040945657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360600322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605316,0.000498567,0.00014840462,0.0019162169,0.00003447689,0.0012958312,0.0000049576697,0.000020821906,0.000027549533],"genre_scores_gemma":[0.9979748,0.0013778363,0.000024164832,0.00035434382,0.000019538771,0.00020539136,0.0000025619786,0.0000075308967,0.000033839246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988406,0.0003487927,0.00014654995,0.00032699094,0.00014136682,0.00019573997],"domain_scores_gemma":[0.9992934,0.00040216668,0.00002354439,0.00008225503,0.000049081627,0.00014956777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002692254,0.000107830805,0.00020911433,0.00023055835,0.000054273285,0.00000949384,0.000048836053,0.000031028903,0.00006752542],"category_scores_gemma":[0.000049277485,0.00007696335,0.000040992043,0.00020970871,0.00012474963,0.00003063845,0.000055191304,0.00012020641,0.000006844717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010172564,0.004211815,0.9695743,0.0000016213346,0.00020623897,0.0007091807,0.0009950148,0.000016770524,0.0025838527,0.000017800137,0.000024376805,0.011486522],"study_design_scores_gemma":[0.0047446336,0.029035097,0.9651176,0.0000043409086,0.00007004649,0.0000111474355,0.00016802855,0.00039677793,0.00019247814,0.00017744831,0.00003438137,0.000048033387],"about_ca_topic_score_codex":0.000022756954,"about_ca_topic_score_gemma":0.0000038140493,"teacher_disagreement_score":0.024823282,"about_ca_system_score_codex":0.0000041948388,"about_ca_system_score_gemma":0.00003681683,"threshold_uncertainty_score":0.31384742},"labels":[],"label_agreement":null},{"id":"W4362507008","doi":"10.1007/s40120-023-00473-w","title":"A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Medicine; Dementia; Disease; Neurology; Alzheimer's disease; Cognitive decline; Quality of life (healthcare); Cognition; Internal medicine; Psychiatry","score_opus":0.06299750840487883,"score_gpt":0.37933115185925004,"score_spread":0.3163336434543712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362507008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816653,0.0040782914,0.0000053782146,0.012190899,0.00016023824,0.0018063931,0.00003923428,0.000036194902,0.000018047369],"genre_scores_gemma":[0.99238265,0.0006220292,0.000008272231,0.006738835,0.00007031758,0.00009941089,0.000049236944,0.000017586492,0.0000116825895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841046,0.000370081,0.000294753,0.00034114058,0.0002183043,0.00036527347],"domain_scores_gemma":[0.99895537,0.0004608324,0.00007705304,0.00026143243,0.00005709259,0.00018821473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003669088,0.00014740173,0.00036787157,0.000104301755,0.00010794498,0.000014871846,0.000113666014,0.00007674157,0.000039862167],"category_scores_gemma":[0.00008650692,0.000099145014,0.0000868801,0.00023296711,0.00010082129,0.0000381057,0.000075373784,0.00033175354,0.0000072035077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027078142,0.00019115327,0.91432923,0.000012578678,0.00020634166,0.00006239885,0.0013322397,9.231819e-7,0.00019498255,0.0000072270636,0.000030230873,0.056554526],"study_design_scores_gemma":[0.023103742,0.0037408804,0.97257197,0.000016562737,0.000070511844,9.1865735e-7,0.000053879787,0.000094515795,0.000072125935,0.00010900884,0.00009594529,0.000069932525],"about_ca_topic_score_codex":0.0006568141,"about_ca_topic_score_gemma":0.00020622766,"teacher_disagreement_score":0.05824272,"about_ca_system_score_codex":0.0000055298265,"about_ca_system_score_gemma":0.00016621583,"threshold_uncertainty_score":0.4043016},"labels":[],"label_agreement":null},{"id":"W4365811132","doi":"10.1007/s40120-023-00472-x","title":"Understanding Barriers Along the Patient Journey in Alzheimer’s Disease Using Social Media Data","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute on Aging; Eisai Incorporated; Eisai","keywords":"Social media; Medicine; Stakeholder; Disease; Anxiety; Health care; Family medicine; Psychiatry; Public relations; World Wide Web; Pathology; Political science","score_opus":0.5508424590705465,"score_gpt":0.4467249856737546,"score_spread":0.10411747339679189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365811132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95378876,0.0009144232,0.000004353265,0.041401174,0.0033858763,0.00039072678,0.000009488458,0.00003898468,0.00006623745],"genre_scores_gemma":[0.9946904,0.0020777073,0.0000036005547,0.0024980402,0.00067144976,0.000038316197,0.000010724423,0.000009411406,3.0437502e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983571,0.0007933938,0.0001446497,0.00020351236,0.00019480503,0.0003065194],"domain_scores_gemma":[0.99749535,0.0021289994,0.00006994335,0.00013922276,0.000019367648,0.00014711448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097057846,0.00006481848,0.00009346865,0.000080526,0.0011267168,0.00003093845,0.00022989234,0.00009632824,0.000048051148],"category_scores_gemma":[0.0015180628,0.00005454849,0.000015127899,0.0004147821,0.00045439752,0.00013560452,0.000048593207,0.00022800389,0.0000033001854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035666642,0.000042221403,0.5792614,0.000005213063,0.00004143612,0.00004590835,0.3545995,0.000028608996,0.000013946323,0.017536573,0.0032647036,0.04480379],"study_design_scores_gemma":[0.0011117293,0.00008893918,0.83732426,0.000014710836,0.00005161613,0.0000020303587,0.048719645,0.0016409026,0.0000034729385,0.04777369,0.06296589,0.00030310734],"about_ca_topic_score_codex":0.0010910629,"about_ca_topic_score_gemma":0.0028699206,"teacher_disagreement_score":0.30587986,"about_ca_system_score_codex":0.000032783926,"about_ca_system_score_gemma":0.00039160516,"threshold_uncertainty_score":0.8665909},"labels":[],"label_agreement":null},{"id":"W4376643230","doi":"10.1007/s40120-023-00492-7","title":"Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Eisai Incorporated","keywords":"Medicine; Willingness to pay; Disease; Dementia; Quality of life (healthcare); Health care; Caregiver burden; Quality-adjusted life year; Gerontology; Neurology; Biomarker; CLARITY; Alzheimer's disease; Psychiatry; Internal medicine; Cost effectiveness; Nursing","score_opus":0.04653057928319896,"score_gpt":0.3357652207862911,"score_spread":0.28923464150309214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376643230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971541,0.00039979076,0.0000034923623,0.0018583299,0.000039594674,0.00042552763,0.0000050658687,0.000013799196,0.00010027332],"genre_scores_gemma":[0.99889064,0.00024099537,0.0000016414065,0.0007769057,0.000020336845,0.00003454648,0.000008477583,0.0000071004447,0.00001938298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924326,0.0001491115,0.00014226144,0.00014499229,0.00014562915,0.00017472095],"domain_scores_gemma":[0.99959195,0.000230467,0.000031665062,0.0000805879,0.000026373104,0.00003896785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022474569,0.00006106198,0.000108082626,0.00010332121,0.000038890947,0.000004263161,0.000036250825,0.000043952674,0.000019376548],"category_scores_gemma":[0.000047351816,0.000042983913,0.00003150522,0.00023620397,0.000098254575,0.000037620393,0.000026355045,0.00018389893,0.0000031607742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011204579,0.000114503804,0.97503144,0.0000074257023,0.000027048809,0.00002945019,0.0013726418,0.00026241533,0.0003748051,0.00004615425,0.000006848285,0.021606812],"study_design_scores_gemma":[0.0018684883,0.0009395009,0.9776974,0.000010914621,0.0000135921755,0.0000017140463,0.00007176143,0.018740335,0.00014618167,0.00041593768,0.00006500288,0.00002917544],"about_ca_topic_score_codex":0.00009440083,"about_ca_topic_score_gemma":0.000011237357,"teacher_disagreement_score":0.021577638,"about_ca_system_score_codex":0.0000023855325,"about_ca_system_score_gemma":0.00004047798,"threshold_uncertainty_score":0.17528331},"labels":[],"label_agreement":null},{"id":"W4378781211","doi":"10.1007/s40120-023-00498-1","title":"Estimating Transition Probabilities Across the Alzheimer’s Disease Continuum Using a Nationally Representative Real-World Database in the United States","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Eisai Incorporated; Eisai","keywords":"Neurology; Medicine; Disease; Alzheimer's disease; Database; Transition (genetics); Data science; Gerontology; Psychiatry; Computer science; Internal medicine; Chemistry","score_opus":0.0767510819299604,"score_gpt":0.40676956382653057,"score_spread":0.3300184818965702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378781211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801382,0.00012578438,0.00007423552,0.01866175,0.000040615658,0.00078809995,0.000056671106,0.000032581025,0.00008208723],"genre_scores_gemma":[0.99356025,0.0004159436,0.000038790145,0.005345657,0.000058124704,0.0001333573,0.00038829594,0.000009232567,0.00005032948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986452,0.0005377178,0.00014864876,0.0002089492,0.00022692622,0.00023258686],"domain_scores_gemma":[0.99897224,0.000709045,0.000037864687,0.00014609969,0.00009433792,0.000040412437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008975495,0.00008876879,0.00010372014,0.000116398056,0.00024997722,0.000034894154,0.000073442214,0.000023081115,0.00003056182],"category_scores_gemma":[0.000080583675,0.00005080599,0.00002953315,0.0005005615,0.00032814607,0.00008463964,0.000026025575,0.00024908912,0.0000020924742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011100028,0.00080060627,0.92059875,0.00011923751,0.00042087372,0.000941508,0.049507122,0.001399341,0.0023174456,0.002177919,0.0015509684,0.009066181],"study_design_scores_gemma":[0.002235508,0.0003723012,0.942854,0.000028639195,0.000047836395,0.00002375939,0.0019049688,0.046841606,0.00017487591,0.0047205086,0.0007239307,0.00007209106],"about_ca_topic_score_codex":0.00043860512,"about_ca_topic_score_gemma":0.00019122839,"teacher_disagreement_score":0.047602154,"about_ca_system_score_codex":0.000003965333,"about_ca_system_score_gemma":0.000049063357,"threshold_uncertainty_score":0.20718081},"labels":[],"label_agreement":null},{"id":"W4378952249","doi":"10.1007/s40120-023-00504-6","title":"A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements","year":2023,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Eisai","keywords":"Medicine; Dementia; Systematic review; Intensive care medicine; Disease; Biomarker; Rivastigmine; Clinical Practice; MEDLINE; Neurocognitive; Neurology; Memantine; Cognition; Pathology; Psychiatry; Donepezil; Physical therapy","score_opus":0.30575132696215385,"score_gpt":0.5798969847401684,"score_spread":0.27414565777801453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378952249","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010507513,0.9865244,0.000075568314,0.0035155572,0.00023118655,0.009487291,0.00010250944,0.000018992208,0.000033959415],"genre_scores_gemma":[7.5117134e-7,0.9874313,0.00030734332,0.009086174,0.000377091,0.0025177347,0.00013486913,0.000038011356,0.000106757274],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748033,0.00043776564,0.0012816426,0.00040704073,0.00018614704,0.0002070862],"domain_scores_gemma":[0.9962863,0.0018768582,0.00062333373,0.0002447616,0.00083408976,0.00013470817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018748804,0.00024822244,0.0022694743,0.000080734935,0.000058150577,0.000013582138,0.00008923375,0.00016826425,0.000010183848],"category_scores_gemma":[0.0028343478,0.00015364366,0.00038849592,0.00009857957,0.000108874316,0.0000741214,0.000035268782,0.00021731872,0.0000020740479],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007045637,0.00010786871,0.000012420616,0.72895026,0.0014224894,0.000015062174,0.0000044853946,2.0013295e-9,3.4500218e-8,0.00028974525,0.0013888575,0.2671042],"study_design_scores_gemma":[0.0014689524,0.0023750367,0.00003257285,0.17420991,0.009523407,0.00004846517,0.000032914777,0.0000053503586,4.806925e-8,0.00031750422,0.8118808,0.00010498304],"about_ca_topic_score_codex":6.834178e-7,"about_ca_topic_score_gemma":3.0552874e-7,"teacher_disagreement_score":0.810492,"about_ca_system_score_codex":0.0000015561275,"about_ca_system_score_gemma":0.0003686529,"threshold_uncertainty_score":0.62654066},"labels":[],"label_agreement":null},{"id":"W4380576930","doi":"10.1007/s40120-023-00505-5","title":"Dietary Patterns and Their Associations with Symptom Levels Among People with Multiple Sclerosis: A Real-World Digital Study","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Multiple Sclerosis Society of Canada","funders":"Innovationsfonden; Scleroseforeningen","keywords":"Multiple sclerosis; Neurology; Medicine; Gerontology; Psychiatry","score_opus":0.07206174104287816,"score_gpt":0.2949780695767183,"score_spread":0.22291632853384014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380576930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996663,0.00008380798,0.0000053303206,0.0018189227,0.000028064858,0.00097272004,0.00011940616,0.00015918301,0.00014960674],"genre_scores_gemma":[0.99743503,0.0017310338,0.000005447359,0.0003486402,0.000059996277,0.00020655115,0.000032968455,0.0000351178,0.00014523864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987209,0.000117165095,0.00015681148,0.00042567577,0.00021186937,0.00036757582],"domain_scores_gemma":[0.99885666,0.0006299179,0.000065785855,0.00024007318,0.00008045102,0.00012710961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017559303,0.00021547965,0.00040441734,0.00017887549,0.0003078546,0.000053606687,0.00006822464,0.00005780173,0.0000113182605],"category_scores_gemma":[0.000054336997,0.00012880212,0.000031001,0.00037135262,0.00021265821,0.00014542574,0.00008466347,0.00030463233,0.0000034985255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007633859,0.00028530252,0.9864278,0.0000117445425,0.00045262874,0.000029158286,0.0037538784,0.000004974221,0.00033716706,0.000001704148,0.00006500607,0.007867276],"study_design_scores_gemma":[0.0048757102,0.0033202022,0.99045134,0.000028923172,0.00002436837,0.000007024365,0.0007611471,0.00027826402,0.00005525485,0.000010938126,0.0000639305,0.00012287285],"about_ca_topic_score_codex":0.0006102738,"about_ca_topic_score_gemma":0.008513128,"teacher_disagreement_score":0.007902854,"about_ca_system_score_codex":0.000008831541,"about_ca_system_score_gemma":0.000028180148,"threshold_uncertainty_score":0.5252398},"labels":[],"label_agreement":null},{"id":"W4381308813","doi":"10.1007/s40120-023-00485-6","title":"Systematic Comparison of Muscle Ultrasound Thickness in Polyneuropathies and Other Neuromuscular Diseases","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Neurology; Neuromuscular disease; Ultrasound; Electromyography; Physical medicine and rehabilitation; Anatomy; Pathology; Radiology","score_opus":0.01864076105009953,"score_gpt":0.2789695339476709,"score_spread":0.26032877289757134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381308813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928255,0.00589799,0.0000029817268,0.00063177897,0.00013148367,0.0003449773,0.0000071645823,0.00006416137,0.00009392468],"genre_scores_gemma":[0.9943854,0.0026181582,0.0000027588223,0.0029014002,0.00001928847,0.000021755339,0.0000023644643,0.000022960927,0.00002588898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998903,0.00026889445,0.00027137532,0.00025381794,0.00011594744,0.00018695947],"domain_scores_gemma":[0.99928683,0.00036100287,0.000074680895,0.00019306212,0.000017383325,0.00006704057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012893429,0.00013859264,0.00046808776,0.00014084528,0.00005588211,0.000009461724,0.00005385067,0.000076746386,0.000014400371],"category_scores_gemma":[0.00014686133,0.00010700608,0.00004788342,0.00024001561,0.00022680529,0.000036306672,0.000025809986,0.00017990317,0.0000026455823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010115657,0.00037065812,0.95317924,0.0038737983,0.0000389011,0.00022546457,0.0017526572,0.000034989058,0.037290722,0.0004024951,0.00014753832,0.0016719485],"study_design_scores_gemma":[0.0023556845,0.001341665,0.9934807,0.00020825645,0.00004592975,0.00011163119,0.0003364531,0.00060793833,0.00022911032,0.00041116562,0.0007382842,0.00013318862],"about_ca_topic_score_codex":0.000043766133,"about_ca_topic_score_gemma":0.0000224931,"teacher_disagreement_score":0.04030143,"about_ca_system_score_codex":0.0000010319806,"about_ca_system_score_gemma":0.0000119294,"threshold_uncertainty_score":0.43635815},"labels":[],"label_agreement":null},{"id":"W4384663785","doi":"10.1007/s40120-023-00519-z","title":"What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Sanofi Genzyme; EMD Serono; Fondation Charcot; Teva Pharmaceutical Industries; Celgene; Merck KGaA; Sanofi; Biogen; Bristol-Myers Squibb","keywords":"Foundation (evidence); Medicine; Multiple sclerosis; Cognitive impairment; Neurology; Gerontology; Cognition; Neuroscience; Psychiatry; Psychology; Political science","score_opus":0.043031321534395504,"score_gpt":0.31949025083241683,"score_spread":0.27645892929802135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384663785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94948,0.0003389073,0.000011393639,0.048583582,0.00006491522,0.0014060896,0.00007929212,0.000017593758,0.000018238406],"genre_scores_gemma":[0.9816168,0.015820311,0.0000036373278,0.00221454,0.00006954646,0.00016255258,0.000047233538,0.000022376573,0.000042997435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886304,0.00031960927,0.00018707491,0.00021816828,0.00017583824,0.00023624368],"domain_scores_gemma":[0.9973838,0.0021177083,0.00011978322,0.00022295494,0.00010197503,0.00005377904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051840977,0.00013583044,0.00025763063,0.000053339405,0.0003706712,0.000016061385,0.00009789522,0.000029475486,0.00006527833],"category_scores_gemma":[0.00009125211,0.00005735269,0.0001232815,0.00019959961,0.00039693213,0.00008325196,0.00014270592,0.00015073465,0.0000032275211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089718625,0.0005894813,0.8663925,0.0001029727,0.0011772603,0.0000034411166,0.035098348,0.000034529636,0.061215617,0.0000063733664,0.006667762,0.01973987],"study_design_scores_gemma":[0.0035055326,0.0043135574,0.9877396,0.00018216608,0.000051634925,0.000007695198,0.0015221061,0.0008567172,0.0015720838,0.000008955633,0.00018455763,0.000055343324],"about_ca_topic_score_codex":0.00011723082,"about_ca_topic_score_gemma":0.00015484811,"teacher_disagreement_score":0.12134717,"about_ca_system_score_codex":0.000012164534,"about_ca_system_score_gemma":0.000021757774,"threshold_uncertainty_score":0.28509405},"labels":[],"label_agreement":null},{"id":"W4386189439","doi":"10.1007/s40120-023-00533-1","title":"Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; Selkirk College","funders":"UCB Pharma; National Institutes of Health; Britannia Pharmaceuticals; H. Lundbeck A/S; Newcastle University; Eisai; University of Oxford; Wellcome Trust; Medical Research Council; International Parkinson and Movement Disorder Society; AbbVie; EVER Neuro Pharma; Ministero dell’Istruzione, dell’Università e della Ricerca; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Pfizer","keywords":"Medicine; Parkinson's disease; Open label; Neurology; Internal medicine; Pharmacology; Disease; Adverse effect; Psychiatry","score_opus":0.04677587415452242,"score_gpt":0.3153436746865626,"score_spread":0.2685678005320402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386189439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927374,0.0025423276,0.0000022918643,0.0017229884,0.0002500377,0.0018842628,0.0003628102,0.00013527088,0.00036257252],"genre_scores_gemma":[0.99470377,0.003207493,0.000022619686,0.0014107231,0.00008612197,0.00009084148,0.0002080125,0.00004823063,0.00022221121],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976553,0.00033693665,0.00041034378,0.0009569106,0.00019857321,0.00044197563],"domain_scores_gemma":[0.9985622,0.0004400585,0.000119430566,0.00047621666,0.000029180743,0.000372886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026397282,0.00033414326,0.0006492732,0.0001736842,0.00017758866,0.000059144062,0.00016280927,0.00012653075,0.000041410553],"category_scores_gemma":[0.000107466134,0.0002827671,0.000040416362,0.00022225465,0.00011256667,0.00008287465,0.00014383737,0.00026624315,0.00002022652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4088813,0.043533053,0.20717718,0.00002342603,0.0008519224,0.05668695,0.002364798,0.0000069333455,0.0035738524,0.00008851663,0.0004941822,0.27631786],"study_design_scores_gemma":[0.16725539,0.030758955,0.73166245,0.00004928688,0.0002688056,0.0001545967,0.000113269285,0.0006172501,0.00011371163,0.0009149735,0.06770342,0.00038790694],"about_ca_topic_score_codex":0.0003617626,"about_ca_topic_score_gemma":0.00018070964,"teacher_disagreement_score":0.5244853,"about_ca_system_score_codex":0.00001848816,"about_ca_system_score_gemma":0.000059068232,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W4387002251","doi":"10.1007/s40120-023-00540-2","title":"Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Medical Coding and Health Information","field":"Health Professions","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Eisai Incorporated; National Institute on Aging; National Institutes of Health; Eisai","keywords":"Veterans Affairs; Diagnosis code; Medicine; Cognitive impairment; Disease; Gerontology; Cohort; Psychiatry; Internal medicine","score_opus":0.3720699163122119,"score_gpt":0.48910764434621246,"score_spread":0.11703772803400053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387002251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807282,0.0003282555,0.00042746076,0.01656749,0.00032048605,0.0011005779,0.00042094523,0.000103386235,0.0000032049923],"genre_scores_gemma":[0.9875789,0.0008701719,0.000026255022,0.010679328,0.00011848656,0.00011519782,0.0005950264,0.000014428991,0.000002157722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656695,0.0019393933,0.0007768573,0.00021133566,0.0002154368,0.00029000425],"domain_scores_gemma":[0.9937347,0.0052559576,0.00047410536,0.00018868291,0.00016392772,0.00018261853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016225358,0.00012043389,0.0002584585,0.0001125668,0.0006988344,0.0000075816934,0.00009911284,0.0001754624,0.000032447584],"category_scores_gemma":[0.00015465738,0.000067985646,0.000033427204,0.00030182782,0.0001975239,0.000050550425,0.000021647382,0.0005070156,0.000019619716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009905737,0.000099945515,0.97508097,0.00043268813,0.00014538768,0.000012666483,0.008875796,0.00020551035,0.000006465957,0.00018729128,0.00033096198,0.0047166115],"study_design_scores_gemma":[0.0046364535,0.0011259315,0.95769775,0.0005402672,0.00011063697,9.829649e-7,0.0044155,0.030521836,0.00002759578,0.00016271154,0.00065058423,0.00010974175],"about_ca_topic_score_codex":0.000824179,"about_ca_topic_score_gemma":0.000055588363,"teacher_disagreement_score":0.030316325,"about_ca_system_score_codex":0.000009743151,"about_ca_system_score_gemma":0.0003567086,"threshold_uncertainty_score":0.537494},"labels":[],"label_agreement":null},{"id":"W4387478185","doi":"10.1007/s40120-023-00554-w","title":"Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"erratum","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; Selkirk College","funders":"","keywords":"Medicine; Open label; Parkinson's disease; Neurology; Physical medicine and rehabilitation; Internal medicine; Disease; Adverse effect; Psychiatry","score_opus":0.039757762395473364,"score_gpt":0.3080810154763792,"score_spread":0.2683232530809059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387478185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522249,0.01611594,0.0000037908867,0.0017492858,0.019834964,0.0046592243,0.0016368113,0.00028638713,0.0034886955],"genre_scores_gemma":[0.94368327,0.023711497,0.000015735159,0.0019730325,0.0010742171,0.00028251167,0.0022906046,0.00021952485,0.026749618],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957367,0.00061599445,0.00076824054,0.0018781072,0.00037384685,0.0006270682],"domain_scores_gemma":[0.99746853,0.000689944,0.0003767699,0.0008466615,0.000072238334,0.00054587447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031558916,0.0007903543,0.0015546349,0.00032313706,0.00029226128,0.00012742869,0.0002983712,0.0005807036,0.00007807866],"category_scores_gemma":[0.00024207502,0.00070079864,0.000097160795,0.0002690787,0.00018717672,0.000092451126,0.00024072069,0.0012532768,0.000024514062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46580884,0.055822156,0.019475147,0.00007519754,0.0023284873,0.08610061,0.0015833416,0.0000035114658,0.00012951063,0.000013997412,0.13963899,0.22902022],"study_design_scores_gemma":[0.111176424,0.038413387,0.14608778,0.0002586123,0.000786336,0.00035036122,0.00008206318,0.00045309076,0.000008597894,0.000268317,0.7014449,0.0006700924],"about_ca_topic_score_codex":0.0010829377,"about_ca_topic_score_gemma":0.0009985171,"teacher_disagreement_score":0.56180596,"about_ca_system_score_codex":0.00006271653,"about_ca_system_score_gemma":0.00025460497,"threshold_uncertainty_score":0.9995443},"labels":[],"label_agreement":null},{"id":"W4387691701","doi":"10.1007/s40120-023-00548-8","title":"Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Toronto","funders":"National Institute of Neurological Disorders and Stroke; Medical Research Council; National Institutes of Health; Motor Neurone Disease Association; Brain Research UK; National Institute on Aging; Barrow Neurological Foundation; Arizona Community Foundation","keywords":"C9orf72; Amyotrophic lateral sclerosis; Frontotemporal dementia; Medicine; Frontotemporal lobar degeneration; Neuroscience; Trinucleotide repeat expansion; Positron emission tomography; Disease; Bioinformatics; Dementia; Psychology; Genetics; Biology; Pathology; Gene; Allele","score_opus":0.07597706507016341,"score_gpt":0.3146109324541491,"score_spread":0.2386338673839857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387691701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9573633,0.0008768046,0.000004674409,0.040370088,0.00016991752,0.0009892224,0.000008209185,0.00007376022,0.00014404117],"genre_scores_gemma":[0.990313,0.0033489747,0.00002467058,0.0053734747,0.00017351592,0.00024272846,0.000027092618,0.000038004695,0.00045854432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813205,0.00022355888,0.00034498266,0.0005364714,0.00023669904,0.0005262661],"domain_scores_gemma":[0.99910325,0.00026753443,0.000084757135,0.00037006979,0.00004960157,0.00012477084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079864264,0.00021274554,0.0003737415,0.00016879638,0.00019747556,0.00003946213,0.00012743578,0.00021655939,0.00010412053],"category_scores_gemma":[0.00009263411,0.0001357152,0.000075867356,0.00022074764,0.00025573038,0.00007441195,0.000073433715,0.00044412748,0.000022746723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005481624,0.00020082154,0.9542559,0.000044063418,0.00026592036,0.00065103575,0.00037508947,0.000014359974,0.01775228,0.0008985724,0.0056862966,0.014374043],"study_design_scores_gemma":[0.0033880493,0.0018417226,0.98203003,0.000036411537,0.000019502962,0.00005660789,0.000010774671,0.0005405336,0.00026563858,0.002055781,0.009628993,0.00012597052],"about_ca_topic_score_codex":0.00014495132,"about_ca_topic_score_gemma":0.0000607784,"teacher_disagreement_score":0.03499661,"about_ca_system_score_codex":0.000011323057,"about_ca_system_score_gemma":0.000038947906,"threshold_uncertainty_score":0.55343056},"labels":[],"label_agreement":null},{"id":"W4389136728","doi":"10.1007/s40120-023-00566-6","title":"An Integrative Nomogram for Identifying Cognitive Impairment Using Seizure Type and Cerebral Small Vessel Disease Neuroimaging Markers in Patients with Late-Onset Epilepsy of Unknown Origin","year":2023,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroimaging; Epilepsy; Medicine; Neurology; Cognitive impairment; Neuroscience; Cognition; Disease; Nomogram; Pathology; Psychiatry; Internal medicine; Psychology","score_opus":0.03447406113874,"score_gpt":0.3342680577388482,"score_spread":0.2997939966001082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389136728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983093,0.00017848489,0.000025702155,0.00031396258,0.00005218383,0.0010303332,0.0000579448,0.00002515439,0.000006949197],"genre_scores_gemma":[0.99905145,0.0002892891,0.000088841254,0.00032622943,0.000014477955,0.000042022933,0.00015467437,0.000022071763,0.000010971165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990221,0.00014900125,0.00014092079,0.00032014906,0.0000945103,0.0002732786],"domain_scores_gemma":[0.9994081,0.00014635822,0.00005599413,0.0001071161,0.00011898401,0.00016341373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013670903,0.00015209574,0.00024345003,0.00015873065,0.00007830588,0.000014700322,0.000035299305,0.00004712539,0.000006514124],"category_scores_gemma":[0.00003766816,0.00010758147,0.000026033416,0.00026565843,0.00015637453,0.00007923902,0.000020083735,0.00018103066,5.058596e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020569846,0.0004068454,0.9716106,0.00005391807,0.00010836293,0.00011993344,0.00040178417,0.000007869709,0.00008717204,0.000012343686,0.0000074607656,0.0066138846],"study_design_scores_gemma":[0.00808975,0.0064602853,0.98238117,0.000086137356,0.00005194503,0.0000071910185,0.000100782556,0.0023868275,0.00008345691,0.00025058337,0.000020449452,0.000081439626],"about_ca_topic_score_codex":0.0000587453,"about_ca_topic_score_gemma":0.000032358315,"teacher_disagreement_score":0.012480097,"about_ca_system_score_codex":0.000009399322,"about_ca_system_score_gemma":0.000084978135,"threshold_uncertainty_score":0.43870452},"labels":[],"label_agreement":null},{"id":"W4390663037","doi":"10.1007/s40120-023-00570-w","title":"The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"F. Hoffmann-La Roche; Bristol-Myers Squibb","keywords":"Myostatin; Duchenne muscular dystrophy; Medicine; Muscular dystrophy; Internal medicine; Clinical endpoint; Placebo; Endocrinology; Clinical trial; Skeletal muscle; Pathology","score_opus":0.026435878287992737,"score_gpt":0.326808358016509,"score_spread":0.3003724797285162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390663037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986269,0.012117606,0.00046058124,0.00055905426,0.0002793676,0.00028275154,0.000010544638,0.0000056495405,0.000015467855],"genre_scores_gemma":[0.9876881,0.011685738,0.00016139165,0.00024799828,0.000096075324,0.000061144514,0.000027013755,0.0000112061125,0.00002132372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920654,0.00014178448,0.00023571716,0.00024649242,0.000033635923,0.00013583888],"domain_scores_gemma":[0.999416,0.00023970255,0.00005945098,0.00022640692,0.000032666423,0.000025790876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023410062,0.00010673908,0.00015085566,0.000013974717,0.00015699804,0.000005923433,0.00011034342,0.00012322763,0.0000048698685],"category_scores_gemma":[0.000020178722,0.000056276964,0.00010583842,0.000033267694,0.00031547534,0.0000021943813,0.000015429334,0.00006045608,4.1068e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048053567,0.0008374753,0.00522935,0.000038472444,0.0010764434,0.0000033668575,0.00089154916,0.00008259246,0.2856661,0.001918842,0.00033999293,0.69911045],"study_design_scores_gemma":[0.00395407,0.019572148,0.13242637,0.00000693694,0.00009291493,0.000016379146,0.00018007612,0.0005909198,0.112991825,0.002360932,0.7275468,0.00026061808],"about_ca_topic_score_codex":0.0000074694476,"about_ca_topic_score_gemma":0.00002696092,"teacher_disagreement_score":0.7272068,"about_ca_system_score_codex":8.425137e-7,"about_ca_system_score_gemma":0.000061639636,"threshold_uncertainty_score":0.2294908},"labels":[],"label_agreement":null},{"id":"W4390743174","doi":"10.1007/s40120-023-00565-7","title":"Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Greenwich Biosciences; EMD Serono; Genentech; Horizon Therapeutics; Mylan; TG Therapeutics; Biogen; Celgene; Sanofi Genzyme; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Jazz Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; Sanofi; MedDay Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Multiple sclerosis; Neurology; Clinical trial; Immunosuppression; Disease; Interferon beta; Interferon beta-1a; Glatiramer acetate; Internal medicine; Oncology; Pediatrics; Immunology; Psychiatry","score_opus":0.09876984893684974,"score_gpt":0.32260762669681203,"score_spread":0.22383777775996228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390743174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96683365,0.028558278,0.000062924686,0.0032551729,0.00020361759,0.0006693348,0.000046171415,0.000073791205,0.00029707348],"genre_scores_gemma":[0.9887558,0.010412435,0.00006722417,0.0004234886,0.00011776248,0.00008261344,0.0000068613467,0.00002550319,0.000108267704],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99907875,0.000077576035,0.0001835727,0.00033873192,0.00011754454,0.00020385231],"domain_scores_gemma":[0.998961,0.0006942979,0.00003216834,0.00016907565,0.00007728001,0.0000661931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018173885,0.00012333575,0.0003261043,0.00012472612,0.00005221457,0.0000133960875,0.00007048983,0.00009538038,0.000038561277],"category_scores_gemma":[0.0000884401,0.000100368365,0.00011805183,0.000085743784,0.00035902715,0.00004738864,0.000041301308,0.00023051424,0.00000452064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06496702,0.0012832303,0.05959417,0.00087491894,0.0030747957,0.00048552174,0.02051056,0.00000780179,0.37749195,0.0021360894,0.012442985,0.45713097],"study_design_scores_gemma":[0.025510605,0.067462064,0.6887106,0.0006852401,0.00020454948,0.00052743393,0.0032106042,0.006417342,0.03465126,0.0012482688,0.1704907,0.00088136614],"about_ca_topic_score_codex":0.000035489797,"about_ca_topic_score_gemma":0.0000075894136,"teacher_disagreement_score":0.6291164,"about_ca_system_score_codex":0.0000078408475,"about_ca_system_score_gemma":0.00005098341,"threshold_uncertainty_score":0.4092903},"labels":[],"label_agreement":null},{"id":"W4391964471","doi":"10.1007/s40120-024-00579-9","title":"Summary of Research: What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Merck KGaA","keywords":"Cognition; Multiple sclerosis; Medicine; Foundation (evidence); Neuropsychology; Quality of life (healthcare); Cognitive impairment; Gerontology; Activities of daily living; Independent living; Disease; Affect (linguistics); Psychology; Psychiatry; Nursing; Pathology","score_opus":0.07331094111534517,"score_gpt":0.35913218201356667,"score_spread":0.2858212408982215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391964471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566633,0.003362966,0.0000149172,0.03809166,0.000058907175,0.0016172556,0.00013203203,0.000011398311,0.00004757122],"genre_scores_gemma":[0.9697482,0.029202504,0.000006816515,0.0007280668,0.00007901374,0.0001360311,0.00003246322,0.00002523857,0.00004169067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822795,0.00069211243,0.00024756038,0.00026166157,0.00030712658,0.00026359982],"domain_scores_gemma":[0.99457943,0.0048054024,0.00008716222,0.0002619138,0.00020651935,0.000059567177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001290105,0.00013550633,0.00029432314,0.000103111895,0.0003050857,0.000023370418,0.00012836896,0.00003749686,0.00007661095],"category_scores_gemma":[0.00014575484,0.000057633475,0.00014641818,0.0002658073,0.00091645605,0.0001143698,0.00019290441,0.0002988968,0.0000012066791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023978973,0.0016994635,0.61553806,0.0009500068,0.0032334635,0.000012300859,0.074548714,0.000027948645,0.20826769,0.000052501375,0.015956644,0.05573426],"study_design_scores_gemma":[0.002829284,0.008825683,0.9774836,0.0012025087,0.00007537238,0.0000141653545,0.0024624714,0.001173005,0.0054101585,0.00002999435,0.00042536296,0.000068421614],"about_ca_topic_score_codex":0.0002466928,"about_ca_topic_score_gemma":0.00016793428,"teacher_disagreement_score":0.36194554,"about_ca_system_score_codex":0.00002041964,"about_ca_system_score_gemma":0.000054692922,"threshold_uncertainty_score":0.33767205},"labels":[],"label_agreement":null},{"id":"W4392960370","doi":"10.1007/s40120-024-00596-8","title":"Publisher Correction: Summary of Research: What Is the True Impact of Cognitive Impairment for People Living with Multiple Sclerosis? A Commentary of Symposium Discussions at the 2020 European Charcot Foundation","year":2024,"lang":"en","type":"erratum","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Foundation (evidence); Medicine; Cognitive impairment; Multiple sclerosis; Gerontology; Neurology; Cognition; Alternative medicine; Physical medicine and rehabilitation; Neuroscience; Psychology; Psychiatry; Pathology; Political science","score_opus":0.06265815489145371,"score_gpt":0.34320248225376687,"score_spread":0.28054432736231316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392960370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7636517,0.028946659,0.000022153154,0.17783977,0.01371919,0.012125732,0.00090390164,0.000077193145,0.0027136453],"genre_scores_gemma":[0.88296634,0.106144525,0.00000463755,0.0015869078,0.00079369894,0.00052489986,0.0005082634,0.00010867541,0.007362052],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99678224,0.0011987078,0.00046221717,0.0005162575,0.0006210439,0.00041952427],"domain_scores_gemma":[0.994014,0.004427548,0.00031715413,0.0005116553,0.0006303567,0.00009926502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017942702,0.00031363041,0.0006897628,0.00024018083,0.00049097574,0.00007185831,0.0002690923,0.00017196912,0.00015273037],"category_scores_gemma":[0.00037512687,0.00014106782,0.00031977062,0.0004741602,0.0014205084,0.00019283431,0.00043611447,0.0013005032,0.0000019262632],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006840966,0.0005823253,0.03645624,0.0004925511,0.0017298391,0.0000038167245,0.011233348,0.0000034876437,0.0011677104,0.0000020020764,0.9341001,0.0073876292],"study_design_scores_gemma":[0.005666649,0.020523164,0.93286854,0.0061166505,0.0004236447,0.000053664797,0.0054720626,0.00090395386,0.00035111821,0.000047941947,0.02729975,0.00027287612],"about_ca_topic_score_codex":0.00059852574,"about_ca_topic_score_gemma":0.0006987774,"teacher_disagreement_score":0.9068003,"about_ca_system_score_codex":0.000058330017,"about_ca_system_score_gemma":0.00019635972,"threshold_uncertainty_score":0.5752579},"labels":[],"label_agreement":null},{"id":"W4396922387","doi":"10.1007/s40120-024-00622-9","title":"Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Sleep and related disorders","field":"Psychology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Eisai Incorporated","keywords":"Insomnia; Medicine; Sleep onset; Alertness; Sleep disorder; Morning; Placebo; Sleep onset latency; Primary Insomnia; Epworth Sleepiness Scale; Excessive daytime sleepiness; Polysomnography; Physical therapy; Psychiatry; Internal medicine; Apnea","score_opus":0.006870321669033029,"score_gpt":0.25903289406426855,"score_spread":0.25216257239523554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396922387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561734,0.011671809,0.0000063933226,0.0003111201,0.00025672273,0.00015611612,0.0000032382934,0.000022075661,0.0019551679],"genre_scores_gemma":[0.99709135,0.0025602074,0.0000063900475,0.00025890087,0.000012617108,0.000008901,0.0000033966453,0.000015263126,0.00004296805],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993701,0.000088041525,0.00015242018,0.00020834002,0.000047730333,0.00013335644],"domain_scores_gemma":[0.99964887,0.00015269445,0.000032161075,0.00013942199,0.000007502831,0.000019327328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006373982,0.00008055324,0.00016292722,0.0001402516,0.000009362296,0.0000022387223,0.000069386966,0.00015905408,0.00014680884],"category_scores_gemma":[0.0000042930033,0.000060564016,0.000029500563,0.0002013866,0.00021142716,0.000018980241,0.000009064246,0.00023116103,0.000008013349],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016365198,0.001895036,0.21221052,0.000074133175,0.0009327976,0.00095186254,0.023207135,0.000110137196,0.00087782,0.016083196,0.00043150902,0.72686064],"study_design_scores_gemma":[0.010586927,0.0026963227,0.967281,0.000057107864,0.000029668132,0.000040069994,0.0001686317,0.0000559094,0.00006384525,0.0010034036,0.017877502,0.00013963124],"about_ca_topic_score_codex":0.00019713867,"about_ca_topic_score_gemma":0.00007055277,"teacher_disagreement_score":0.75507045,"about_ca_system_score_codex":7.4361367e-7,"about_ca_system_score_gemma":0.000010749936,"threshold_uncertainty_score":0.24697289},"labels":[],"label_agreement":null},{"id":"W4400950647","doi":"10.1007/s40120-024-00647-0","title":"Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Natalizumab; Medicine; Dosing; Crossover study; Clinical endpoint; Randomized controlled trial; Anesthesia; Internal medicine; Placebo","score_opus":0.06544853152701602,"score_gpt":0.32205249108967166,"score_spread":0.25660395956265564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400950647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930821,0.004278628,0.0000466924,0.0005612115,0.0007074301,0.001023007,0.00003652762,0.00010847527,0.00015594908],"genre_scores_gemma":[0.9984652,0.0007201874,0.000019213136,0.0005027091,0.0001059058,0.000049162958,0.000053605712,0.000026612144,0.000057448317],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990008,0.00005304654,0.00018780147,0.00041013063,0.00013552763,0.00021268493],"domain_scores_gemma":[0.99946374,0.00014031486,0.00004495503,0.0001851147,0.000054088476,0.000111766574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053221174,0.00017368967,0.00021560855,0.0000754189,0.000120210214,0.000030344481,0.000035342495,0.00012115598,0.00005253065],"category_scores_gemma":[0.000017006148,0.00011809925,0.000044166754,0.00009734286,0.00011971847,0.00005511937,0.000010545981,0.00020905079,0.000005123148],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4010312,0.01323847,0.0012839611,0.00017015096,0.0012077627,0.012174324,0.002845465,0.000022335036,0.007559082,0.0006126267,0.0008700765,0.5589846],"study_design_scores_gemma":[0.075503305,0.8125735,0.01127762,0.00032011353,0.0016819239,0.009685453,0.00046646633,0.003689656,0.0078090513,0.0006752631,0.07530423,0.001013432],"about_ca_topic_score_codex":0.000018388408,"about_ca_topic_score_gemma":0.00001902894,"teacher_disagreement_score":0.799335,"about_ca_system_score_codex":0.000008963107,"about_ca_system_score_gemma":0.00013763094,"threshold_uncertainty_score":0.48159477},"labels":[],"label_agreement":null},{"id":"W4402506270","doi":"10.1007/s40120-024-00656-z","title":"Advancements and Challenges in Exercise Training for Multiple Sclerosis: Comprehensive Review and Future Directions for Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Randomized controlled trial; Medicine; Neurology; Multiple sclerosis; Physical therapy; Physical medicine and rehabilitation; Alternative medicine; Internal medicine; Pathology; Psychiatry","score_opus":0.4063405494038279,"score_gpt":0.44346385427401935,"score_spread":0.03712330487019144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402506270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000271537,0.96471363,0.000003393886,0.0063415966,0.000343499,0.028394336,0.00012689267,0.000035191373,0.0000143048455],"genre_scores_gemma":[0.0000108598215,0.9734084,0.00014679653,0.0006360712,0.00036314418,0.025307309,0.00004201507,0.000054618493,0.000030778705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638706,0.0012789347,0.0011751684,0.0007044927,0.00011324147,0.00034112151],"domain_scores_gemma":[0.9884654,0.010739199,0.00038164767,0.00018652092,0.000120815625,0.00010636669],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002944055,0.00050282123,0.01251773,0.0003062338,0.0001509819,0.000022498087,0.00005950198,0.00030955838,0.0000073360766],"category_scores_gemma":[0.0020315337,0.00028277616,0.00084265403,0.00010660783,0.00026426735,0.000040304105,0.000046025016,0.0004250255,4.074865e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04196343,0.000053045092,8.760132e-7,0.04686085,0.0016957311,0.000002360236,0.00026592196,1.07490035e-8,0.0000022395745,0.000031927826,0.00012264583,0.90900093],"study_design_scores_gemma":[0.20736954,0.00045445078,0.000018254475,0.014729505,0.0044410652,0.000016829485,0.000042422475,0.00002152666,1.4089117e-7,0.000078590754,0.77268124,0.00014645584],"about_ca_topic_score_codex":0.0000024146982,"about_ca_topic_score_gemma":0.000008432435,"teacher_disagreement_score":0.9088545,"about_ca_system_score_codex":0.00000912577,"about_ca_system_score_gemma":0.00006477383,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W4402601342","doi":"10.1007/s40120-024-00661-2","title":"Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Neurology; Disease; Scale (ratio); Neuroscience; Internal medicine; Psychiatry; Biology","score_opus":0.05071219049739833,"score_gpt":0.38270741625987176,"score_spread":0.3319952257624734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402601342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97430223,0.010968213,0.0033563238,0.0098680565,0.00005252271,0.0013400714,0.00009056176,0.000016532416,0.0000055137157],"genre_scores_gemma":[0.9935243,0.001748742,0.0034141631,0.00044328452,0.000069002104,0.0007427997,0.0000217457,0.000015629907,0.000020340269],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99930876,0.000053471802,0.00018146471,0.00023085874,0.000082642204,0.0001428175],"domain_scores_gemma":[0.9992984,0.00036084017,0.000048043043,0.00012966404,0.000093721086,0.00006932569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010203812,0.000099169774,0.00019058038,0.00004877763,0.00018217326,0.000016937875,0.000063688196,0.000035312245,0.000005695409],"category_scores_gemma":[0.0000083617115,0.000057334393,0.000057407713,0.00006621269,0.00026847288,0.00003508233,0.000032913664,0.00008121788,4.723042e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004214628,0.0005118675,0.23394719,0.00067094463,0.0009194773,0.0000039653264,0.0024602462,0.000060843573,0.5044525,0.011161195,0.00020385865,0.24139327],"study_design_scores_gemma":[0.0010394691,0.000699497,0.98640466,0.000028453445,0.00006516007,0.0000056470894,0.000011253174,0.0067500444,0.0017198349,0.0011078629,0.0021124785,0.000055624783],"about_ca_topic_score_codex":0.0000020532664,"about_ca_topic_score_gemma":0.0000013255104,"teacher_disagreement_score":0.7524575,"about_ca_system_score_codex":0.0000056070444,"about_ca_system_score_gemma":0.00012708888,"threshold_uncertainty_score":0.23380287},"labels":[],"label_agreement":null},{"id":"W4404012161","doi":"10.1007/s40120-024-00676-9","title":"Quality of Life in Mild Cognitive Impairment and Mild Dementia Associated with Alzheimer’s Disease: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; TransCanada (Canada)","funders":"Eisai Incorporated","keywords":"Dementia; Medicine; Neurology; Disease; Alzheimer's disease; Cognitive impairment; Quality of life (healthcare); Cognition; Psychiatry; Gerontology; Neuroscience; Psychology; Internal medicine","score_opus":0.08967961699036008,"score_gpt":0.4049455078359748,"score_spread":0.31526589084561474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404012161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064342516,0.9867208,9.479055e-7,0.0004013985,0.000037940466,0.006200294,0.00010119122,0.00002492166,0.00007825266],"genre_scores_gemma":[0.009959863,0.98664755,0.0000015015619,0.002167051,0.000018924635,0.0009591457,0.0001554242,0.000042894353,0.00004764417],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960997,0.0016217525,0.00097402063,0.0005814878,0.00038522918,0.00033781643],"domain_scores_gemma":[0.9983878,0.00060431403,0.00041389788,0.00022668768,0.00012642331,0.00024087187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013222436,0.00043145413,0.003053424,0.00026102847,0.000044091663,0.00001686928,0.000089282395,0.00019231,0.00007412617],"category_scores_gemma":[0.00022544926,0.00026192513,0.00024988948,0.00037456417,0.0002624711,0.000037510115,0.00007481063,0.0005980543,0.000007814074],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011210605,0.00074781966,0.018430626,0.953027,0.0072971974,0.0001924731,0.00005563028,2.7776372e-9,1.5382933e-7,0.00004145321,0.00017343009,0.01891316],"study_design_scores_gemma":[0.0056950683,0.003944559,0.05904239,0.89596903,0.02987333,0.00006826498,0.000021482765,0.0000039619804,5.0014853e-7,0.00007079112,0.0048340918,0.00047650852],"about_ca_topic_score_codex":0.000014725874,"about_ca_topic_score_gemma":0.000013626258,"teacher_disagreement_score":0.057057943,"about_ca_system_score_codex":0.000011461562,"about_ca_system_score_gemma":0.00033762833,"threshold_uncertainty_score":0.9999833},"labels":[],"label_agreement":null},{"id":"W4404439795","doi":"10.1007/s40120-024-00681-y","title":"Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Otsuka Pharmaceutical Development and Commercialization","keywords":"Attention deficit hyperactivity disorder; Neurology; Medicine; Psychiatry; Attention deficit; Attention deficit disorder","score_opus":0.015402258024053928,"score_gpt":0.27759532142542614,"score_spread":0.2621930634013722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404439795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960038,0.0006482965,0.000009736823,0.002801282,0.000033926975,0.0004152322,0.000023983735,0.000013870528,0.00004988857],"genre_scores_gemma":[0.9984088,0.0010153962,0.0000064450123,0.00038495215,0.000012243158,0.00006539923,0.000070441536,0.000012573889,0.000023742392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921334,0.00014064937,0.00012937622,0.0002410624,0.00013868306,0.00013689119],"domain_scores_gemma":[0.9994297,0.00033933145,0.0000517514,0.00011717658,0.000042677315,0.0000193331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003193706,0.00014510508,0.00021057812,0.000070087546,0.00007242913,0.0000150588385,0.000029362678,0.000039477498,0.0000096246295],"category_scores_gemma":[0.000012042285,0.00008086915,0.000022565684,0.00014386934,0.00009672372,0.00007527715,0.000008049772,0.00013994104,2.1438899e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039626518,0.0004176175,0.9877228,0.000023011804,0.00010119201,0.00001205587,0.00075045595,0.00002707976,0.00022968973,0.00004663317,0.0000030678036,0.010270113],"study_design_scores_gemma":[0.0024689552,0.0017168805,0.99281967,0.00003543117,0.000048894468,0.000011099269,0.0013900829,0.0008408227,0.000019384172,0.000010748873,0.00055975275,0.00007829647],"about_ca_topic_score_codex":0.18109147,"about_ca_topic_score_gemma":0.12927192,"teacher_disagreement_score":0.051819544,"about_ca_system_score_codex":0.000013607728,"about_ca_system_score_gemma":0.000050491704,"threshold_uncertainty_score":0.8866166},"labels":[],"label_agreement":null},{"id":"W4405390476","doi":"10.1007/s40120-024-00680-z","title":"Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Memorial Hospital","funders":"Biogen","keywords":"Medicine; Discontinuation; Dimethyl fumarate; Adverse effect; Confidence interval; Internal medicine; Incidence (geometry); Multiple sclerosis; Rate ratio; Pediatrics; Surgery; Psychiatry","score_opus":0.033209622796934575,"score_gpt":0.3257044477275513,"score_spread":0.29249482493061674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405390476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766237,0.00096740737,0.0000049320574,0.00041449408,0.000025756899,0.000892328,0.000011966004,0.000007526618,0.000013229692],"genre_scores_gemma":[0.9980578,0.001809671,0.0000034855793,0.00007137726,0.000005298873,0.0000330251,0.0000071879213,0.000009447183,0.0000027243377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977598,0.0011547109,0.00028339817,0.0003099574,0.00032985574,0.00016224524],"domain_scores_gemma":[0.9974309,0.0021788646,0.00006873605,0.00018958996,0.00008469223,0.000047190697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001062536,0.00012937906,0.00055420486,0.00030349285,0.00003760615,0.0000056221756,0.000070132766,0.00008742566,0.000016681837],"category_scores_gemma":[0.000503196,0.000071329356,0.00004491852,0.00095410785,0.0003173269,0.000057761503,0.000074373565,0.00035411952,1.3263016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01980737,0.0013301144,0.9648772,0.00007995035,0.0010866841,0.000031752304,0.0006187733,0.00002650181,0.00044353632,0.0000036678139,2.9721411e-7,0.011694192],"study_design_scores_gemma":[0.010874437,0.0031687208,0.98441917,0.00014510597,0.00022936537,0.0000018349591,0.000024348165,0.0008571605,0.00022653914,0.0000011272417,0.0000033880908,0.00004881312],"about_ca_topic_score_codex":0.0003769946,"about_ca_topic_score_gemma":0.000798796,"teacher_disagreement_score":0.019542001,"about_ca_system_score_codex":0.000012348244,"about_ca_system_score_gemma":0.00003678269,"threshold_uncertainty_score":0.29087266},"labels":[],"label_agreement":null},{"id":"W4405583612","doi":"10.1007/s40120-024-00689-4","title":"Infarct Growth in Patients with Emergent Large Vessel Occlusion Stroke Transferred for Endovascular Thrombectomy","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Environmentally Friendly Materials and Occupational Health Research Institute, Anhui University of Science and Technology","keywords":"Medicine; Stroke (engine); Neurology; Cardiology; Internal medicine; Occlusion; Ischemic stroke; Ischemia","score_opus":0.007432533015911012,"score_gpt":0.23648056251260086,"score_spread":0.22904802949668984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405583612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932321,0.001373481,0.0010208613,0.0027524356,0.00019903362,0.00096744875,0.000025240208,0.00005608476,0.00037336993],"genre_scores_gemma":[0.99578226,0.0011518818,0.00008892601,0.0027093887,0.00005202864,0.00006724266,0.00005349279,0.000027562823,0.00006724101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991,0.00003532134,0.00014823627,0.0003299135,0.00013797056,0.000248555],"domain_scores_gemma":[0.9997206,0.000049359525,0.0000145224685,0.00013748893,0.000029603974,0.0000484234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012319136,0.00014744286,0.0002284909,0.00014036467,0.000043440705,0.000007647858,0.000054144806,0.00008833301,0.00006771211],"category_scores_gemma":[0.000007604988,0.00010539188,0.00006453271,0.00011946396,0.000042233696,0.000051010702,0.000021658021,0.00019735175,0.000002355406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01150062,0.0009600807,0.9587103,0.00031914655,0.0010308104,0.0002447877,0.0011835792,0.0000040684454,0.0043925056,0.0010665717,0.005435453,0.015152077],"study_design_scores_gemma":[0.01868595,0.004463068,0.81550646,0.000043619028,0.00011020743,0.00002082824,0.000016459313,0.00044379255,0.0025251694,0.000120729695,0.15787269,0.00019101368],"about_ca_topic_score_codex":0.000010160028,"about_ca_topic_score_gemma":0.0000052021314,"teacher_disagreement_score":0.15243724,"about_ca_system_score_codex":0.000008246244,"about_ca_system_score_gemma":0.000018861523,"threshold_uncertainty_score":0.42977563},"labels":[],"label_agreement":null},{"id":"W4405590901","doi":"10.1007/s40120-024-00695-6","title":"Incidence and Prevalence of Alzheimer’s Disease in Medicare Beneficiaries","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Eisai Incorporated","keywords":"Medicine; Incidence (geometry); Dementia; Epidemiology; Disease; Population; Medicare Part B; Neurology; Alzheimer's disease; Gerontology; Geriatrics; Population ageing; Diagnosis code; Demography; Pediatrics; Psychiatry; Internal medicine; Environmental health","score_opus":0.020603388954310808,"score_gpt":0.3271034797007168,"score_spread":0.306500090746406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405590901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9352798,0.060769264,0.00000528988,0.0035883298,0.00003766484,0.00017078874,0.000004882466,0.000012210274,0.00013175952],"genre_scores_gemma":[0.9785573,0.020630108,0.000004939285,0.0007321444,0.000019127097,0.000016681892,0.0000017285379,0.0000044659337,0.000033541797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994721,0.000054476764,0.0000899536,0.00017073247,0.000107602995,0.00010515026],"domain_scores_gemma":[0.9997352,0.00010171777,0.000009717794,0.000063670814,0.000021733124,0.000068013134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015254348,0.000054452175,0.00009977117,0.00008601946,0.000018826691,0.0000061980854,0.000025549021,0.000036429017,0.000116117975],"category_scores_gemma":[0.00003413038,0.00004095811,0.0000146909715,0.00007498272,0.00018540243,0.000043490894,0.000025909083,0.0001385369,0.0000013679257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005671919,0.00004774147,0.93176115,0.00016314317,0.00002787866,0.00019310394,0.00021929319,1.6473606e-7,0.0007800384,0.0006194151,0.00001688236,0.06560399],"study_design_scores_gemma":[0.00048462264,0.0006899032,0.9956173,0.00007233452,0.00003446858,0.00002264859,0.000009078478,0.00028509324,0.00062131643,0.0014213459,0.0007117399,0.000030156814],"about_ca_topic_score_codex":0.000016379956,"about_ca_topic_score_gemma":0.0000059605286,"teacher_disagreement_score":0.065573834,"about_ca_system_score_codex":8.809463e-7,"about_ca_system_score_gemma":0.000050836792,"threshold_uncertainty_score":0.16702233},"labels":[],"label_agreement":null},{"id":"W4406311084","doi":"10.1007/s40120-024-00708-4","title":"Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Spinocerebellar ataxia; Ataxia; Rating scale; Cohort; Medicine; Activities of daily living; Physical therapy; Prom; Convergent validity; Physical medicine and rehabilitation; Psychometrics; Psychology; Internal consistency; Internal medicine; Clinical psychology; Psychiatry; Developmental psychology","score_opus":0.030983778484564895,"score_gpt":0.21973197139967385,"score_spread":0.18874819291510894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406311084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805874,0.0006391986,0.000007634741,0.0005686873,0.00012763386,0.00045801574,0.0000034521147,0.000011113379,0.00012550106],"genre_scores_gemma":[0.9965689,0.0000736904,0.0000052326704,0.0032891433,0.000006831839,0.000024354878,1.5676248e-7,0.000008599753,0.000023071036],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998736,0.00036793755,0.00016873235,0.00033544158,0.00022335266,0.00016850342],"domain_scores_gemma":[0.9995542,0.000020000281,0.000073957504,0.000263153,0.000066582434,0.000022089494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009036922,0.00012580614,0.00014488549,0.000053624455,0.00013613014,0.0000127134745,0.00020390957,0.000039832645,0.0000047817434],"category_scores_gemma":[0.00010617594,0.00007470163,0.00002333549,0.00022547254,0.0002737841,0.000040379557,0.00006929122,0.00014106095,7.610626e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005259946,0.0001555507,0.7481753,0.000018650559,0.000004499991,5.707343e-7,0.00010084602,0.000072667506,0.24986613,0.000089506364,0.000018477675,0.0009717836],"study_design_scores_gemma":[0.00085667055,0.00019426353,0.494677,0.000018257564,0.0000033854672,3.6872424e-7,0.0000028989336,0.000023443376,0.50398344,0.00006528143,0.00013293338,0.000042050287],"about_ca_topic_score_codex":0.0000125112465,"about_ca_topic_score_gemma":0.000029992141,"teacher_disagreement_score":0.2541173,"about_ca_system_score_codex":0.0000046170403,"about_ca_system_score_gemma":0.00006030801,"threshold_uncertainty_score":0.3046244},"labels":[],"label_agreement":null},{"id":"W4407775486","doi":"10.1007/s40120-024-00697-4","title":"Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"UCB","keywords":"Observational study; Medicine; Neurology; Adjunctive treatment; Epilepsy; Pediatrics; Intensive care medicine; Internal medicine; Psychiatry","score_opus":0.025779321202230622,"score_gpt":0.31243263349886585,"score_spread":0.2866533122966352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407775486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569607,0.00019943801,9.239021e-7,0.00054644264,0.00002763392,0.0032923566,0.000008900571,0.000020602301,0.0002076287],"genre_scores_gemma":[0.9987925,0.00021351856,0.000008259378,0.00022081728,0.000008966974,0.0006702516,0.000025747133,0.000015026421,0.00004486635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982302,0.00061763386,0.00021063953,0.0004913662,0.00015532403,0.00029481502],"domain_scores_gemma":[0.99933356,0.00029659175,0.00004255294,0.00018365275,0.00007592946,0.00006768922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002092849,0.00020317499,0.00041071497,0.0003117365,0.00006599334,0.000009546113,0.000046211444,0.00007154044,0.0000058828373],"category_scores_gemma":[0.000092831826,0.00014194356,0.000022004113,0.0004862912,0.00007974907,0.0000646483,0.000029699324,0.00027663147,9.532014e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04318568,0.00567828,0.94832695,0.000027301867,0.00018603994,0.0006685448,0.0006889861,0.000050817678,0.000028132063,0.000037091188,0.0000019367276,0.0011202628],"study_design_scores_gemma":[0.040056396,0.012879696,0.94665277,0.00006306458,0.000015758109,0.000005525295,0.000033571592,0.000041992425,0.000072484196,0.000087867666,0.000010359415,0.00008051526],"about_ca_topic_score_codex":0.0005849934,"about_ca_topic_score_gemma":0.001852674,"teacher_disagreement_score":0.0072014164,"about_ca_system_score_codex":0.00010499169,"about_ca_system_score_gemma":0.00021666677,"threshold_uncertainty_score":0.578829},"labels":[],"label_agreement":null},{"id":"W4409119298","doi":"10.1007/s40120-025-00724-y","title":"Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Liraglutide; Exenatide; Medicine; Semaglutide; Neuroprotection; Glucagon-like peptide 1 receptor; Pharmacology; Internal medicine; Endocrinology; Diabetes mellitus; Receptor; Type 2 diabetes; Agonist","score_opus":0.02608192491742797,"score_gpt":0.30595950502951197,"score_spread":0.279877580112084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409119298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022215248,0.98995686,0.0000017084888,0.0011906319,0.0012466038,0.0036296058,0.000047335412,0.00015860026,0.0035465069],"genre_scores_gemma":[0.000058458187,0.9883707,0.000015517964,0.00539311,0.00023549303,0.0005825146,0.00029173915,0.00005839534,0.0049940557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720883,0.0005178819,0.0006427785,0.00085618306,0.0001972489,0.0005770658],"domain_scores_gemma":[0.9984049,0.00018875756,0.0005493468,0.00060075114,0.00006524118,0.00019097871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021014993,0.00072170683,0.0030259478,0.00020065812,0.00018555929,0.000029978259,0.00022158407,0.0004286148,0.00018872056],"category_scores_gemma":[0.00002952095,0.0005073357,0.00059999677,0.00031690125,0.00013783781,0.000046750305,0.000075945136,0.0005782234,0.000068348236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001703601,0.00019517778,0.000091507565,0.09399542,0.0013429322,0.00027085486,0.00008948665,4.5229758e-8,2.404077e-7,0.0002262603,0.025130674,0.87848705],"study_design_scores_gemma":[0.0011425589,0.0009924866,0.00023187458,0.04270662,0.0019776085,0.00008051835,0.000018875036,6.9128606e-7,4.973025e-7,0.0000057843586,0.95255613,0.00028632258],"about_ca_topic_score_codex":0.00001025132,"about_ca_topic_score_gemma":0.000008776497,"teacher_disagreement_score":0.9274255,"about_ca_system_score_codex":0.00005933426,"about_ca_system_score_gemma":0.0001743726,"threshold_uncertainty_score":0.9997378},"labels":[],"label_agreement":null},{"id":"W4410074912","doi":"10.1007/s40120-025-00756-4","title":"Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Biogen","keywords":"Medicine; Neurology; Disease; Alzheimer's disease; Neuroscience; Gerontology; Internal medicine; Psychiatry; Psychology","score_opus":0.07351256682237726,"score_gpt":0.38185914796161596,"score_spread":0.3083465811392387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410074912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935081,0.0003849845,5.371511e-7,0.0045588794,0.000030231568,0.0013457232,0.0000027210413,0.0000055153596,0.00016329956],"genre_scores_gemma":[0.9939612,0.0019572733,6.013353e-7,0.00388727,0.000010732247,0.00014539297,0.0000106251755,0.000005185359,0.000021716642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984481,0.000799467,0.0002299177,0.00017571822,0.00015793635,0.00018886903],"domain_scores_gemma":[0.9991124,0.0005620047,0.00006229864,0.0001722084,0.000057930356,0.000033136886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047505167,0.00010117485,0.00017427563,0.000280792,0.00008021273,0.000017206361,0.00009691094,0.000020980895,0.000015411862],"category_scores_gemma":[0.000055044457,0.0000537045,0.00002757412,0.0004983919,0.000091374386,0.000054303855,0.00002743347,0.00021898153,6.442522e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037373232,0.0012947078,0.9815034,0.000007664227,0.00008089428,0.000057603527,0.004341905,0.0000012148563,0.00003843999,0.000024073206,0.000004532989,0.008908205],"study_design_scores_gemma":[0.003918698,0.0043774606,0.9907958,0.00006535348,0.00005857067,5.406127e-7,0.00038845072,0.000073615396,0.000054874814,0.00008864811,0.00014446644,0.00003355554],"about_ca_topic_score_codex":0.0015606574,"about_ca_topic_score_gemma":0.0002847663,"teacher_disagreement_score":0.00929233,"about_ca_system_score_codex":0.000010188871,"about_ca_system_score_gemma":0.00008046863,"threshold_uncertainty_score":0.23592576},"labels":[],"label_agreement":null},{"id":"W4410081720","doi":"10.1007/s40120-025-00746-6","title":"Feasibility of Identifying Acute Nontraumatic Intracerebral Hemorrhage Events Using Diagnostic Coding Among Veterans with Mild Cognitive Impairment or Alzheimer’s Dementia","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Intracerebral and Subarachnoid Hemorrhage Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Eisai Incorporated; National Institute on Aging; National Institutes of Health; Eisai; U.S. Department of Veterans Affairs","keywords":"Medicine; Neurology; Dementia; Intracerebral hemorrhage; Cognitive impairment; Coding (social sciences); Behavioral neurology; Neurochemistry; Cognition; Disease; Psychiatry; Internal medicine; Subarachnoid hemorrhage","score_opus":0.06858072446765487,"score_gpt":0.36053657987703325,"score_spread":0.2919558554093784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410081720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466854,0.0019716376,0.0012002077,0.00052003114,0.00012644999,0.0013886708,0.000015823527,0.00003385811,0.000074768875],"genre_scores_gemma":[0.9978855,0.0004330932,0.000803088,0.0007361134,0.000035217512,0.00004640538,0.00001310056,0.000020432677,0.000027047463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983244,0.00022501306,0.00037761123,0.00041752603,0.0002297987,0.00042562783],"domain_scores_gemma":[0.99890715,0.00051941024,0.00011838263,0.00021489216,0.00013023378,0.00010995441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034652394,0.00023607137,0.0005022974,0.00018596956,0.00022475162,0.000019601755,0.00010237819,0.00015429806,0.00014930086],"category_scores_gemma":[0.000078271245,0.0001644977,0.00008499035,0.0002643609,0.00031594466,0.00013874978,0.000057530313,0.00046785866,0.0000021142107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012788153,0.00072393037,0.9490027,0.00042002494,0.0021762876,0.000726665,0.0008002728,0.0000052236783,0.0043329494,0.000046987527,0.000011271091,0.02896554],"study_design_scores_gemma":[0.01315334,0.0034143275,0.9490976,0.00044500746,0.0019369021,0.00047881223,0.0002672594,0.015769852,0.014890053,0.00028885418,0.000001584579,0.00025643702],"about_ca_topic_score_codex":0.00011575329,"about_ca_topic_score_gemma":0.00007549079,"teacher_disagreement_score":0.028709102,"about_ca_system_score_codex":0.000016075122,"about_ca_system_score_gemma":0.00012578814,"threshold_uncertainty_score":0.6708022},"labels":[],"label_agreement":null},{"id":"W4410279528","doi":"10.1007/s40120-025-00757-3","title":"The Modified Functional Status Questionnaire for Assessing Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"ACADIA Pharmaceuticals","keywords":"Psychosis; Medicine; Parkinson's disease; Neurology; Disease; Post hoc; Post-hoc analysis; Psychiatry; Physical medicine and rehabilitation; Internal medicine","score_opus":0.010497228238013136,"score_gpt":0.2592852638900164,"score_spread":0.24878803565200325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410279528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935964,0.0015017735,0.0019813569,0.0020790866,0.00006688407,0.00060519873,0.0000625222,0.00004911594,0.000057683304],"genre_scores_gemma":[0.99656,0.0005598731,0.00007169113,0.0021881848,0.000019512177,0.00029616535,0.00018172414,0.000016074748,0.00010679929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990306,0.00007698905,0.00012265946,0.00038669392,0.00013250629,0.00025056745],"domain_scores_gemma":[0.9992897,0.000081836275,0.0000704128,0.0002338418,0.00016918163,0.00015504149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050235176,0.00018768595,0.00023313786,0.00013939927,0.0004362614,0.000046799578,0.00003496322,0.000059410882,0.000009587275],"category_scores_gemma":[0.000011580633,0.00010175783,0.000082048275,0.00032451618,0.00011059112,0.00006992257,0.000007027813,0.00009227491,5.489353e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040129945,0.0005463584,0.9272849,0.000012362866,0.0016801327,0.000018920364,0.000017370246,0.00003953024,0.000009765757,0.00037254608,0.000038391107,0.029849805],"study_design_scores_gemma":[0.00840721,0.0018531939,0.979978,0.000019189623,0.0011226464,0.000001620727,0.0000073990423,0.00067282526,0.000010658294,0.00023688645,0.007606792,0.00008355622],"about_ca_topic_score_codex":0.00003775011,"about_ca_topic_score_gemma":0.00007195261,"teacher_disagreement_score":0.05269315,"about_ca_system_score_codex":0.000017039665,"about_ca_system_score_gemma":0.00008777541,"threshold_uncertainty_score":0.41495642},"labels":[],"label_agreement":null},{"id":"W4411321314","doi":"10.1007/s40120-025-00771-5","title":"Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson’s Disease","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada)","funders":"Allergan","keywords":"Parkinson's disease; Medicine; Neurology; Disease; Neuroscience; Internal medicine; Psychology; Psychiatry","score_opus":0.018395808193910224,"score_gpt":0.3132663788559958,"score_spread":0.29487057066208555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411321314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911627,0.0071341507,0.00014915399,0.00064862263,0.00004502039,0.0008273539,0.000007173853,0.000013941378,0.000011878554],"genre_scores_gemma":[0.99723554,0.0012972963,0.0008455346,0.00032407985,0.000009029639,0.00023305384,0.00003767751,0.000007428076,0.000010362088],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999371,0.00006881073,0.00012763792,0.00026065504,0.000052693926,0.00011920593],"domain_scores_gemma":[0.99961334,0.000110894485,0.000045647415,0.0000824838,0.000014818799,0.00013281923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006020953,0.00012669296,0.00021779414,0.00009832087,0.000090711495,0.000013052134,0.000014685142,0.000042821724,7.7404945e-7],"category_scores_gemma":[0.0000105821,0.000092507944,0.000023535518,0.000045122,0.00006407704,0.000043141325,0.00001507462,0.000033077762,8.200479e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036201293,0.0005639439,0.7256754,0.0001433298,0.00006444428,0.000060411607,0.00007976576,8.78482e-7,0.0013083888,0.00025210407,0.0000013759466,0.2682298],"study_design_scores_gemma":[0.006349964,0.00040361853,0.98164845,0.0001296337,0.00009036585,0.000002324328,0.000004015283,0.0003652567,0.005632814,0.0010965423,0.004217023,0.000059983166],"about_ca_topic_score_codex":0.0000027092688,"about_ca_topic_score_gemma":0.000002517481,"teacher_disagreement_score":0.26816985,"about_ca_system_score_codex":0.000011474226,"about_ca_system_score_gemma":0.000056175213,"threshold_uncertainty_score":0.37723646},"labels":[],"label_agreement":null},{"id":"W4411653218","doi":"10.1007/s40120-025-00758-2","title":"Correction: Are Glucagon-Like Peptide‑1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Penetrant (biochemical); Central nervous system; Neuroscience; Glucagon-like peptide-1; Neurology; Medicine; Chemistry; Endocrinology; Biology; Diabetes mellitus","score_opus":0.020649379626404476,"score_gpt":0.2959119807250109,"score_spread":0.27526260109860645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411653218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008408654,0.98501015,0.0000031356305,0.000998903,0.004543766,0.0032164985,0.000026600233,0.0001808588,0.005936019],"genre_scores_gemma":[0.00004931844,0.9826119,0.000010110388,0.0034791925,0.00034233046,0.0005796145,0.00029606844,0.000052119845,0.012579327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973691,0.000500534,0.0006111409,0.0008252543,0.00018891391,0.00050503906],"domain_scores_gemma":[0.9985626,0.0002251771,0.0004293651,0.00053392624,0.000075433534,0.00017354885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019293513,0.0006726201,0.0026798109,0.00019670006,0.00022335329,0.000031750715,0.00018044289,0.00041816133,0.00022632905],"category_scores_gemma":[0.00002955407,0.00048621013,0.0005585001,0.0003634046,0.00012729563,0.000050721075,0.00006126162,0.00062825304,0.00006485563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017811812,0.00017081578,0.00007146531,0.051662512,0.0010462593,0.00015703664,0.000090131456,8.6359556e-8,1.3721915e-7,0.00008916264,0.07209785,0.87443644],"study_design_scores_gemma":[0.0009964162,0.0012627784,0.00018833968,0.043365397,0.0018159659,0.0001539763,0.000026530219,0.0000022771123,5.7830084e-7,0.000002877344,0.95191205,0.00027282335],"about_ca_topic_score_codex":0.000014976273,"about_ca_topic_score_gemma":0.000012708485,"teacher_disagreement_score":0.8798142,"about_ca_system_score_codex":0.00007330871,"about_ca_system_score_gemma":0.0002050799,"threshold_uncertainty_score":0.99975896},"labels":[],"label_agreement":null},{"id":"W4411991434","doi":"10.1007/s40120-025-00790-2","title":"Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer’s Disease: A U.S. Cost Comparison Model","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Eisai","keywords":"Medicine; Neurology; Disease; Alzheimer's disease; Intensive care medicine; Internal medicine; Psychiatry","score_opus":0.03553979778329394,"score_gpt":0.34027079465225585,"score_spread":0.3047309968689619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411991434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95141846,0.046616565,0.000018301163,0.00082878204,0.000054123488,0.0005841887,0.000022524246,0.000018362518,0.00043870596],"genre_scores_gemma":[0.9959504,0.003605493,0.000014191884,0.00035253644,0.000009794732,0.000033037515,0.000015548552,0.000010207427,0.000008762618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990432,0.000073141826,0.00018068202,0.00028952686,0.00013575109,0.00027767057],"domain_scores_gemma":[0.9994318,0.00014336336,0.000040507377,0.00016460671,0.000040440813,0.00017927481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065983964,0.0001425445,0.0003201029,0.00011420117,0.000073859366,0.000008658536,0.00005823488,0.000095204545,0.000008466137],"category_scores_gemma":[0.000016403272,0.00012166755,0.00004734734,0.00013907164,0.00032966322,0.00002951985,0.0000331001,0.00022364073,0.0000018238024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11844796,0.005484444,0.74469596,0.00011656024,0.005968065,0.0023010995,0.0012015402,0.00022593135,0.0006055708,0.0027191204,0.00026774942,0.117965996],"study_design_scores_gemma":[0.043884672,0.013680442,0.8731122,0.000101448604,0.0012564294,0.00013985988,0.00008588106,0.06425794,0.0009080324,0.0018829835,0.0002740076,0.00041609132],"about_ca_topic_score_codex":0.000077608536,"about_ca_topic_score_gemma":0.000020353084,"teacher_disagreement_score":0.12841624,"about_ca_system_score_codex":0.000012411518,"about_ca_system_score_gemma":0.00020356716,"threshold_uncertainty_score":0.49614587},"labels":[],"label_agreement":null},{"id":"W4412042106","doi":"10.1007/s40120-025-00782-2","title":"Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study","year":2025,"lang":"en","type":"editorial","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Merck","keywords":"Cladribine; Multiple sclerosis; Medicine; Neurology; Biomarker; Internal medicine; Oncology; Pharmacology; Immunology; Psychiatry","score_opus":0.04952971653575495,"score_gpt":0.3127057375482895,"score_spread":0.26317602101253457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412042106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816154,0.0013350458,7.8599334e-7,0.0011533898,0.011448113,0.0030420711,0.00058882067,0.00003374467,0.0007826344],"genre_scores_gemma":[0.97079,0.01982198,0.00006211926,0.000053052965,0.007792388,0.00022787238,0.00024053403,0.00009133035,0.00092070823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950821,0.0014147866,0.0007035201,0.0008895349,0.001297773,0.0006122772],"domain_scores_gemma":[0.9929461,0.004648139,0.00033886905,0.0010335965,0.0009427311,0.000090595415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017976929,0.0004230737,0.0012541759,0.0007282068,0.00021943713,0.000018720182,0.00039737587,0.00064691145,0.00000996512],"category_scores_gemma":[0.0021204895,0.00024300428,0.000090064656,0.0016731252,0.0012610808,0.000058888534,0.00031592717,0.002277864,3.234987e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09861095,0.003311485,0.83093196,0.00050542864,0.0015151154,0.00010039536,0.0008363344,0.000011179692,0.0022821152,0.0000049471832,0.060380697,0.0015094021],"study_design_scores_gemma":[0.06761585,0.020917611,0.89658904,0.0024659904,0.00034934422,0.0000090549975,0.0007520296,0.0003883384,0.0007306547,0.000011777072,0.0098258145,0.00034451563],"about_ca_topic_score_codex":0.0056293174,"about_ca_topic_score_gemma":0.017797248,"teacher_disagreement_score":0.065657064,"about_ca_system_score_codex":0.00006787071,"about_ca_system_score_gemma":0.00053501205,"threshold_uncertainty_score":0.9931282},"labels":[],"label_agreement":null},{"id":"W4412370560","doi":"10.1007/s40120-025-00784-0","title":"Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"EMD Serono; Idorsia Pharmaceuticals; Schweizerische Multiple Sklerose Gesellschaft; Ministry of Health, Labour and Welfare; Fondazione Cariplo; Multiple Sclerosis Society; Shionogi; Argenx; Atara Biotherapeutics; Genentech; Amicus Therapeutics; Novartis; Celgene; Ministry of Education, Culture, Sports, Science and Technology; BioCryst; Sanofi; GW Pharmaceuticals; TG Therapeutics; Samsung; Bristol-Myers Squibb; CSL Behring; Pfizer; Biogen; F. Hoffmann-La Roche; Greenwich Biosciences; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi Genzyme; Patient-Centered Outcomes Research Institute","keywords":"Medicine; Ofatumumab; Multiple sclerosis; Neurology; Natalizumab; Internal medicine; Dermatology; Immunology; Psychiatry; Rituximab; Lymphoma","score_opus":0.022000231176926028,"score_gpt":0.2685536937391004,"score_spread":0.24655346256217434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412370560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571484,0.0004122761,0.000011983388,0.0028607785,0.00003550693,0.00057670043,0.0000052058504,0.000027814507,0.00035491743],"genre_scores_gemma":[0.9958814,0.0023661677,0.00015631261,0.0014489205,0.000007960788,0.000016367065,0.0000054997217,0.000013339765,0.00010404634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990445,0.00009835608,0.00014671456,0.00032409703,0.00014074695,0.00024558292],"domain_scores_gemma":[0.99925566,0.00040909759,0.000035390316,0.00018298553,0.000058952653,0.00005791247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011260005,0.00015071576,0.00035131618,0.00015054081,0.0001397804,0.000011446532,0.000045611072,0.000080134254,0.000011429408],"category_scores_gemma":[0.00012161592,0.000093102884,0.00001873425,0.00017504483,0.00030101373,0.000050797404,0.000050230185,0.00031637022,0.0000010194501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014587469,0.00023209545,0.9600598,0.000016302683,0.000115690294,0.000004954401,0.00025287815,0.0000050429935,0.0001365328,0.00003337876,0.000033781653,0.02452205],"study_design_scores_gemma":[0.027585573,0.0016234481,0.9696684,0.00008062757,0.000013351417,0.000001067455,0.000022598548,0.000056299086,0.000047061993,0.000009893219,0.0008171641,0.00007455365],"about_ca_topic_score_codex":0.000060677805,"about_ca_topic_score_gemma":0.000085279135,"teacher_disagreement_score":0.024447495,"about_ca_system_score_codex":0.000009838468,"about_ca_system_score_gemma":0.00002675078,"threshold_uncertainty_score":0.37966254},"labels":[],"label_agreement":null},{"id":"W4413110291","doi":"10.1007/s40120-025-00810-1","title":"Advances in Ischemic Stroke Treatment: Current and Future Therapies","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Journal of Administrative Sciences","funders":"","keywords":"Medicine; Neurorehabilitation; Stroke (engine); Neurology; Collateral circulation; Thrombolysis; Neuroplasticity; Blood pressure; Intensive care medicine; Cardiology; Cerebral blood flow; Internal medicine; Physical medicine and rehabilitation; Rehabilitation; Physical therapy; Myocardial infarction","score_opus":0.0190720796592383,"score_gpt":0.32794195928013925,"score_spread":0.30886987962090096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413110291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000471861,0.9910476,0.0000017130516,0.00073545775,0.00038071797,0.0009198093,0.000023710383,0.000033166172,0.006385967],"genre_scores_gemma":[0.000025363288,0.9984033,0.00002031613,0.0005338431,0.00036066916,0.00019799417,0.00004528841,0.00002246472,0.0003907559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988295,0.000101123194,0.00027363698,0.00049708027,0.00007222,0.00022643116],"domain_scores_gemma":[0.99940336,0.00016035723,0.00011407534,0.0002625962,0.00001005038,0.00004958413],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000061224164,0.0003961817,0.0012357949,0.00024214474,0.000038675113,0.000008951482,0.00008043951,0.00027336358,0.000031694923],"category_scores_gemma":[0.000004111754,0.0002597045,0.00013537535,0.00012548297,0.00011765059,0.000042164047,0.000045630015,0.00044689578,0.0000024246538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014635798,0.000081927144,0.00044742003,0.0027846897,0.00014471471,0.0000364192,0.00006144438,6.6489667e-9,0.0000012099987,0.000046624806,0.00050680886,0.9957424],"study_design_scores_gemma":[0.0015718177,0.0005392767,0.00008165874,0.0008840964,0.00026374345,0.00007417257,0.000009589839,5.6413916e-7,0.0000022188071,0.000013253299,0.9964245,0.00013513533],"about_ca_topic_score_codex":0.0000021279902,"about_ca_topic_score_gemma":0.0000028328668,"teacher_disagreement_score":0.9959177,"about_ca_system_score_codex":0.000016713817,"about_ca_system_score_gemma":0.00006520561,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W4413137480","doi":"10.1007/s40120-025-00802-1","title":"Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Biotech","keywords":"Medicine; Medicaid; Depression (economics); Emergency department; Emergency medicine; Anxiety; Neurosurgery; Psychiatry; Health care","score_opus":0.020134218856363455,"score_gpt":0.2856034381202897,"score_spread":0.26546921926392625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413137480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916001,0.0026237539,0.000009851916,0.003474429,0.0000749634,0.00040950195,0.000010539249,0.000060883878,0.0017359524],"genre_scores_gemma":[0.9971747,0.0012479759,0.00007824789,0.0012336841,0.000024803896,0.00003225275,0.00003234703,0.000011819332,0.00016421707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918956,0.00008249996,0.0001652698,0.00028045138,0.0001326396,0.00014956451],"domain_scores_gemma":[0.99939233,0.00020142524,0.000078520105,0.0002388494,0.000037710808,0.000051170024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047231737,0.00017620737,0.0003373734,0.00014117909,0.00007719789,0.0000043588398,0.000043491,0.00014593276,0.000041686813],"category_scores_gemma":[0.000023504677,0.00009782507,0.000035394936,0.000106989595,0.0001344893,0.000028558401,0.00001105343,0.00012425077,0.0000012496639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09333551,0.0034815413,0.5868941,0.000071246584,0.0007728105,0.000546175,0.0003192077,0.000013466662,0.16216148,0.0019770155,0.00024588997,0.15018155],"study_design_scores_gemma":[0.014484856,0.01945829,0.7169523,0.0001874456,0.00014980393,0.00004161953,0.0000149427315,0.000028413233,0.244891,0.00029865297,0.0033933672,0.000099279736],"about_ca_topic_score_codex":0.000019494497,"about_ca_topic_score_gemma":0.0000146580705,"teacher_disagreement_score":0.15008226,"about_ca_system_score_codex":0.000007204221,"about_ca_system_score_gemma":0.00006215272,"threshold_uncertainty_score":0.39891905},"labels":[],"label_agreement":null},{"id":"W4413767126","doi":"10.1007/s40120-025-00815-w","title":"Global Societal Burden of Alzheimer’s Disease by Severity: a Targeted Literature Review","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Neurology; Disease; Alzheimer's disease; Burden of disease; Intensive care medicine; Psychiatry; Internal medicine","score_opus":0.022737650105928126,"score_gpt":0.37075194544064594,"score_spread":0.34801429533471784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413767126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000066458706,0.99495715,0.0000019442439,0.0020260785,0.00009869498,0.0016717013,0.0004428604,0.000025517624,0.0007095684],"genre_scores_gemma":[0.00004837049,0.993483,0.000005424439,0.0049965694,0.00008051978,0.00014633336,0.0007327416,0.000015381684,0.00049164996],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821836,0.00044865563,0.00037044965,0.00045938045,0.00022808574,0.00027508853],"domain_scores_gemma":[0.99919003,0.000085412015,0.00014708232,0.00027920076,0.0001194473,0.00017882246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020728214,0.0003273194,0.001477521,0.000070136586,0.000053159423,0.000012686195,0.00013145785,0.0002905562,0.00025336584],"category_scores_gemma":[0.000055633787,0.0002310506,0.00049078563,0.00043251744,0.00018400619,0.00003394953,0.00007955599,0.0004752587,0.0000055610953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022368155,0.00014936033,0.0003045395,0.03925023,0.0007619148,0.0001557795,0.000007527997,1.3328709e-9,6.6869626e-7,0.000024655048,0.02275296,0.9363687],"study_design_scores_gemma":[0.00080238044,0.000571856,0.000433728,0.022277553,0.0020174053,0.000105799096,6.7213966e-7,8.3251575e-7,5.836973e-7,0.00010621955,0.9735469,0.00013606444],"about_ca_topic_score_codex":0.000003902512,"about_ca_topic_score_gemma":1.3223402e-7,"teacher_disagreement_score":0.9507939,"about_ca_system_score_codex":0.000005392609,"about_ca_system_score_gemma":0.00037913801,"threshold_uncertainty_score":0.942197},"labels":[],"label_agreement":null},{"id":"W4414031817","doi":"10.1007/s40120-025-00824-9","title":"Investigation of Sensory and Neuropsychological Parameters in Migraine Sufferers: A Cross-Sectional Study with Negative Findings","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cross-sectional study; Neurology; Medicine; Neuropsychology; Migraine; Clinical psychology; Psychiatry; Audiology; Physical medicine and rehabilitation; Cognition; Pathology","score_opus":0.04890833893272112,"score_gpt":0.33165853693149305,"score_spread":0.28275019799877193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414031817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997126,0.00024886907,0.0000030074348,0.0020636844,0.000013331125,0.00035897802,0.000001594184,0.000011824724,0.00017275182],"genre_scores_gemma":[0.9963285,0.00025947054,0.000045788038,0.003209723,0.000009354749,0.000019362009,0.0000013033996,0.000003894102,0.00012260312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993259,0.00011944138,0.00015788946,0.00023815241,0.000060066664,0.00009860531],"domain_scores_gemma":[0.99955386,0.0002760864,0.00003208884,0.000073725496,0.00003767253,0.000026590196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001517601,0.00009259311,0.00022017588,0.00013030885,0.00005147969,0.0000051674647,0.000020453665,0.00007035355,0.000005285562],"category_scores_gemma":[0.00006604492,0.000063785374,0.000018510365,0.00014960994,0.00042330124,0.0000243964,0.000014066865,0.00023330418,1.7790862e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004486007,0.000101558,0.9916002,0.000013154142,0.00006861219,0.00003073981,0.0014580922,0.0000012752944,0.0019693214,0.00009162287,0.000046192767,0.000133236],"study_design_scores_gemma":[0.0038663705,0.004846003,0.98991686,0.00000770041,0.000012353603,0.000037574464,0.00014848122,0.000017319753,0.00035277757,0.0007031074,0.000051133367,0.000040308718],"about_ca_topic_score_codex":0.000087728644,"about_ca_topic_score_gemma":0.000087284716,"teacher_disagreement_score":0.004744445,"about_ca_system_score_codex":0.0000021428184,"about_ca_system_score_gemma":0.000015614562,"threshold_uncertainty_score":0.26010922},"labels":[],"label_agreement":null},{"id":"W4414371995","doi":"10.1007/s40120-025-00822-x","title":"Testing the Clinical Dementia Rating Sum of Boxes as an Outcome for Dementia with Lewy Bodies Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute on Aging","keywords":"Dementia with Lewy bodies; Clinical trial; Dementia; Outcome (game theory); Neurology; Clinical neurology; Clinical Dementia Rating; Drug trial","score_opus":0.264615632011641,"score_gpt":0.5241470820583223,"score_spread":0.25953145004668127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414371995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899717,0.0013740585,0.0006087667,0.005716242,0.00022442684,0.0012664284,0.0000044326284,0.000026698437,0.00080722803],"genre_scores_gemma":[0.99133897,0.00050655485,0.0005765241,0.0071742698,0.00016926532,0.00009797215,0.0000083066625,0.000012363931,0.000115765746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967053,0.0014683316,0.0010272318,0.00036369247,0.00015941155,0.0002760282],"domain_scores_gemma":[0.99348927,0.0056851297,0.0002795234,0.00023565456,0.00023199884,0.00007844838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007857854,0.00014421594,0.000660309,0.000075001204,0.00021359234,0.000026640007,0.0001269449,0.00013227787,0.000054965007],"category_scores_gemma":[0.00263069,0.00007989015,0.0001603368,0.00009803792,0.00050432177,0.00005806611,0.000054041233,0.0003645973,0.0000013742056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050501754,0.00037425978,0.894063,0.0000326855,0.00091635314,0.0000071832696,0.000043987475,2.2811102e-7,0.00086891407,0.00043855,0.00016236414,0.09804228],"study_design_scores_gemma":[0.009059949,0.011496239,0.9709428,0.000027695438,0.0005972266,0.00001392753,0.0001059011,0.00016436634,0.0008222714,0.0017405305,0.0049563353,0.00007274869],"about_ca_topic_score_codex":0.000018834655,"about_ca_topic_score_gemma":0.000019168127,"teacher_disagreement_score":0.09796953,"about_ca_system_score_codex":0.0000012637025,"about_ca_system_score_gemma":0.00014761723,"threshold_uncertainty_score":0.32578257},"labels":[],"label_agreement":null},{"id":"W4414760533","doi":"10.1007/s40120-025-00836-5","title":"Safety and Effectiveness of Direct Oral Anticoagulants in Combination with Antiseizure Medications: Protocol for a Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"review","venue":"Neurology and Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protocol (science); Neurology; MEDLINE; Stroke (engine); Dabigatran","score_opus":0.10959240661430604,"score_gpt":0.4410277105149581,"score_spread":0.33143530390065207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414760533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000039447345,0.8421702,0.00013336477,0.0003738859,0.0000050631825,0.15726611,0.000015910595,0.000008891068,0.000022671495],"genre_scores_gemma":[0.0000625179,0.9695595,0.000039332554,0.00020370063,0.0000047627113,0.03000874,0.000048079193,0.000009576063,0.000063812986],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9980781,0.00093030324,0.00053161924,0.00028886946,0.00008990208,0.00008122341],"domain_scores_gemma":[0.997886,0.0014494046,0.00038888492,0.00019099707,0.000059757895,0.00002497851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010924073,0.00020813607,0.0052282517,0.0003312385,0.000037958845,0.000006405404,0.000041209765,0.00013181353,0.0000083052155],"category_scores_gemma":[0.00013268532,0.0001127355,0.00027867942,0.00046668423,0.00007580925,0.000031125473,0.000018494404,0.00009152502,7.9501675e-8],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004263055,0.000022099219,0.001472601,0.9627075,0.030711541,0.000003139401,0.0000074862014,1.7393866e-7,6.961324e-8,0.00038970885,0.0000027564945,0.0042565726],"study_design_scores_gemma":[0.005658318,0.0012868495,0.0057926243,0.055342786,0.9063158,0.00003589665,0.0000015609696,0.000029611603,7.44269e-7,0.00013525269,0.025163867,0.00023668974],"about_ca_topic_score_codex":0.0000046490404,"about_ca_topic_score_gemma":0.0000045252564,"teacher_disagreement_score":0.9073648,"about_ca_system_score_codex":0.0000037249604,"about_ca_system_score_gemma":0.000041643718,"threshold_uncertainty_score":0.459722},"labels":[],"label_agreement":null},{"id":"W4414896846","doi":"10.1007/s40120-025-00838-3","title":"The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment","year":2025,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre for Addiction and Mental Health","funders":"Allergan; HLS Therapeutics; Idorsia Pharmaceuticals; H. Lundbeck A/S; Mitsubishi Tanabe Pharma Corporation; Mylan; Astellas Pharma; Eisai; University of Oxford; National Health and Medical Research Council; University of Cambridge; Canadian Institutes of Health Research; Sunovion; Servier; Seqirus; Fondation Brain Canada; Bristol-Myers Squibb; Indivior; Teva Pharmaceutical Industries","keywords":"MEDLINE; Alternative medicine; Panel discussion; Expert opinion; Health professionals","score_opus":0.06910784830085255,"score_gpt":0.3360386661725365,"score_spread":0.266930817871684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414896846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98479587,0.0009890004,0.0003561599,0.012598832,0.000046762663,0.001140022,0.000047659567,0.000014126741,0.000011588049],"genre_scores_gemma":[0.994032,0.0017926766,0.0033221755,0.0003786693,0.000023794288,0.00032811626,0.000023377137,0.00001175623,0.000087420245],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99930465,0.00005814482,0.00015383892,0.00019828782,0.000041177107,0.00024392732],"domain_scores_gemma":[0.9976124,0.0020606483,0.00006614648,0.00013064205,0.00006736689,0.00006280268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001430172,0.00011114785,0.00021977736,0.000066732406,0.00055056246,0.000028169308,0.000024751873,0.00004381378,0.000004820163],"category_scores_gemma":[0.0001238566,0.000065367574,0.00004205672,0.00007402847,0.00010631771,0.000028650908,0.000016622764,0.00006842348,3.6147764e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09759267,0.0001535074,0.32314503,0.00007904955,0.0013825216,0.000010732466,0.00050853105,0.0000061223423,0.0011267349,0.0043387725,0.00038464772,0.5712717],"study_design_scores_gemma":[0.20605591,0.047505375,0.4925797,0.00030902968,0.0016209641,0.00060144597,0.0025828653,0.008923738,0.04005986,0.009259805,0.18974006,0.00076122326],"about_ca_topic_score_codex":0.0001235172,"about_ca_topic_score_gemma":0.0010502597,"teacher_disagreement_score":0.57051045,"about_ca_system_score_codex":0.000010721253,"about_ca_system_score_gemma":0.00014413809,"threshold_uncertainty_score":0.42345372},"labels":[],"label_agreement":null}]}